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Abstract 
 
 
Molecular imaging techniques have revolutionised our understanding of disease 
states and the underlying processes causing their occurrence. Such a feat would not 
have been accomplished without the utilisation of the imaging probes central to the 
field of molecular imaging. The work undertaken in this thesis describes the synthesis 
and biological evaluation of lipidic contrast agent probes, designed for effective 
cellular entry and solid tumour imaging.  
 
A gadolinium (Gd) based paramagnetic lipid (Gd.DOTA.DSA) was synthesised and 
liposome formulations containing this lipid were optimised for maximum cellular 
labelling. MRI signal enhancing properties of bimodal paramagnetic-fluorescent 
liposomes utilising Gd.DOTA.DSA was shown both in vitro and in vivo. Tumour MRI 
results revealed these liposomes to benefit from a prolonged in vivo circulation time 
and excellent tumour accumulation properties as co-validated by both MRI and 
fluorescence microscopy of tumour sections. Here, the enhanced permeation and 
retention (EPR) effect of tumour tissue was exploited, whereby nanoparticles such as 
the paramagnetic liposomes described, are able to accumulate in tumour tissue due 
to leaky endothelial layers of damaged blood vessels.  
 
A further bimodal fluorescent and paramagnetic lipid (Gd.DOTA.Rhoda.DSA) was 
designed and synthesised and was shown to label cancer cells in vitro and effectively 
enhance tumour MRI signal in vivo. These results were also analysed by MRI and 
fluorescence modalities.  
 
Work towards a trimodal fluorescent, 1H and 19F MRI agent was undertaken and 
prospective routes for its final synthesis purposed.  
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1.1 Biological Imaging  
 
In 1665 physicist Robert Hooke looked at a sliver of cork through a microscope lens 
and noticed pore-like structures. It was from this observation that the idea of a cellular 
unit was envisaged. Since then tremendous discoveries have been made through the 
lens of a microscope and microscopy itself has become the definitive tool in aiding 
researchers “see” biological processes at the cellular and molecular level. Biological 
imaging encompasses the visualisation and detection of complex biomolecular 
assemblies, at all levels of biology including cells, tissues and organs. This “seeing” 
or “sensing” is realised with various imaging techniques which exploit the 
fluorescence, acoustic wave, radioactive and paramagnetic phenomenon.  
 
Perhaps the most important application of biological imaging has arisen due to the 
need to image aberrant biology where and when it occurs. The study of disease 
states and the need for effective diagnosis and treatment has led to the 
establishment of well defined biological imaging techniques. As well as the ability to 
image anatomical detail, it is now possible to extend biological imaging to the 
“molecular” or “cellular” levels where molecules and sub-cellular components can be 
studied and pictured in real-time. Advancement in terms of both spatial and temporal 
resolution aids in the visualisation and detection of disease, and helps treatment 
efficacy, these developments are certain to play an important role within 
“theranostics”. Theranostics describes the use of diagnostic testing to diagnose 
disease, identify the correct treatment protocol and in addition, monitor patient 
response to therapy. Theranostics is set to create unique opportunities which will 
bring together both the pharmaceutical and diagnostic industries and will offer a more 
holistic approach where disease detection, diagnosis and treatment may be achieved 
concurrently.  
 
1.1.1 Molecular Imaging  
 
Molecular imaging has been defined by the Commission on Molecular Imaging of the 
American College of Radiology as: “The spatially localized and/or temporally resolved 
sensing of molecular and cellular processes in vivo”.1
This multidisciplinary field implements the visual portrayal, characterisation and 
quantification of complex biological processes at the molecular level. This “sensing” 
of molecular and cellular processes is realised by imaging modalities which allow the 
visualisation of the signal transmission from a tagged component within a targeted 
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area, for example a fluorescent probe inside a cell. As such, molecular imaging 
modalities are designed to detect signals from a range of relevant chemical entities 
termed probes. These can be radiopharmaceuticals, incorporating radionuclides 
which are used in nuclear imaging techniques such as positron emission tomography 
(PET) or single photon emission computed tomography (SPECT), they can also be 
paramagnetic contrast agents utilised in magnetic resonance imaging (MRI) or 
fluorescent agents used in optical imaging.  
 
Molecular imaging aided by probes and the very techniques dedicated to it, has 
played a vital role in the progression of the study of gross anatomy to a more 
molecular approach, downscaling our attention to metabolic and physiological 
processes. For most part, molecular imaging has been applied to the study of 
molecular and cell biology of gene expression, since the sequencing of the human 
genome and other genomes, has made available a large amount of deoxyribonucleic 
acid (DNA) sequence data. As such, the imaging of reporter gene expression has 
been widespread in molecular imaging.2 Nevertheless, the imaging of specific 
molecules involved in disease pathways in living systems has also been studied. 
 
In summary, molecular imaging is a multidisciplinary research field which is 
concerned with the development of novel probes, reagents and techniques to image 
specific biological pathways both in vitro and in vivo with an emphasis on the imaging 
of key components of disease manifestations and processes. Probes designed and 
synthesised in this project have been applied to the labelling of cells in vitro and the 
imaging of tumours in vivo. This has been made possible through the imaging of such 
particles by MRI and fluorescence microscopy. 
 
1.1.2 Targets for Molecular Imaging 
 
Any biological component or system that can attract and retain an exogenous probe, 
imaging agent, or ligand, through either covalent or non-covalent molecular 
interactions can act as a target in molecular imaging. Imaging targets may involve 
cells, organelles, proteins, organ systems, or the whole organism. Advances within 
molecular imaging have been made possible as a result of the close interface of 
biology and chemistry, whereby custom-made molecules have been designed and 
synthesised for specific biological target-recognition processes. The diagram in 
Figure 1 represents some cellular targets for which specific probes may be designed 
and probe-target interactions studied through molecular imaging.  
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Figure 1. Example of targets for molecular imaging. 
 
 
Molecular imaging techniques have been mostly applied to the imaging of processes 
that are relevant in vivo; and are mainly; the imaging of gene expression (see 1.1.3) 
and molecular markers (1.1.4); where disease states can be identified, the 
progression or regression of cancer (1.1.5), drug treatment (1.1.6) and cell tracking 
where graft treatments like stem cell therapy can be visualised (1.1.7).   
 
1.1.3 Molecular Imaging of Gene Expression 
 
Molecular imaging techniques have been utilised to monitor gene expression using 
MRI, optical imaging, and nuclear imaging with PET and SPECT.3  Studying gene 
expression has been valuable in assessing the role of particular genes in organisms 
and has helped shed light on the complex interplay of gene expression processes, 
and the link with their expression products, such as enzymes and cell receptors.4-7 
The imaging of reporter gene expression has proved valuable in gene therapy where, 
by coupling the reporter gene to a therapeutic gene, the level of expression of the 
therapeutic gene is also established and quantitated.8-11  
 
Gene therapy aims to cure disease using the correct version of the functional gene 
that has become mutated or is absent within the host. Another level at which imaging 
probes may play a role is their interaction with the products of gene expression.12 For 
example, specific genes can encode products such as intracellular enzymes, cell 
surface receptors or peptides that exogenous imaging probes can interact with, 
thereby allowing for a unique signature resulting from their interaction. 
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The herpes simplex virus thymidine kinase (HSV1-tk) reporter gene which is the gene 
that produces the thymidine kinase enzyme has been widely used in gene expression 
studies.13-16 This enzyme has broad substrate specificity and once produced a range 
of radiolabelled ligands can be used as the enzyme’s substrate. These probes can be 
transported across the cell membrane via an active transport mechanism. Once 
inside the cell the radiolabelled substrates are phosphorylated by the viral enzyme 
(thymidine kinase, which is not naturally expressed from the host) and become 
trapped in the cell as signalled by the cell’s acquired radioactivity.17 This system has 
been studied in PET imaging most extensively and utilised in cancer therapy.18 For 
instance, the radiolabelled tracer; 5,[131I-2’-fluoro-1-β-D-arabinofuranosyl-uracil (FIAU) 
is administered and crosses the cell membrane by diffusion and facilitated transport 
(thymidine kinase transporters). It is then phosphorylated by the HSV1-tk enzyme 
from FIAU to FIAU monophosphate (FIAU-MP) which cannot escape cell membranes 
and hence accumulates inside the cells. Therefore, FIAU’s inherent radioactivity 
accumulates in cancer cells.19 This type of approach enables the monitoring of 
cancer gene therapy in patients.  
 
The transferrin receptor (Tf-R) is also an attractive target for molecular imaging since 
it is over-expressed in various tumour cells and as such has been a target for drug 
transport.20 Tf-R has also been used as a potential transporter for accumulation of 
probes in cells. Weissleder et al. have demonstrated the triggerable enhancement of 
signal from a sample by deliberately over-expressing the Tf-R in mice and then 
administering transferrin bound iron probe particles (Tf-MIONS, see Figure 2).21,22 
This type of biological signal amplification is a good means of studying the interaction 
of contrast agents attached to target receptors and also provides for a reliable 
method of quantitating gene expression, itself a challenging area in genetic therapy. 
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Figure 2. This diagram illustrates the use of MRI to visualise gene expression, receptor over-
expression, and the use of paramagnetic probes. ETR = engineered transferrin receptor, hTfR 
= human transferrin receptor, mRNA = messenger RNA, Tf-MION = transferrin-
monocrystalline iron oxide nanoparticles, UTR = untranslated region.22 
 
 
In MRI, contrast agents are often used to further enhance images, commonly 
gadolinium (Gd) is incorporated in MRI contrast agents since it is highly paramagnetic 
and capable of perturbing many water hydrogen nuclei. This in turn leads to a signal 
enhancement and subsequent localisation of the contrast agent (refer to section 1.5 
for more detail). One of the most elegant uses of molecular imaging for studying 
gene-expression is the use of “smart” activatable molecular probes in MRI. Here high 
affinity crowded chelators have been attached to Gd, acting like a “cap” and 
preventing water molecules from making contact, thus suppressing the MRI signal at 
first (Figure 3). However, upon cleavage of the probe by a galactosidase enzyme 
(the expression of which is induced), access by water molecules to the Gd is restored 
as indicated by an increase in image brightness.23,24 
 
 
 
            a     b 
 
Figure 3. The enzymatic cleavage of a macromolecular Gd contrast agent, the enzyme here 
is β-galactosidase which is a product of gene expression. In state a there is no MR signal, in 
state b, upon cleavage of the sugar moiety, the MR signal appears.23 
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In the same study, experiments in Xenopus embryo models showed areas of intense 
MR signal which correlated with the regions expressing β-galactosidase, 
demonstrating the ability of MRI to detect gene expression in vivo.  
 
Various molecular imaging methods and probes have been applied to the study of 
gene expression as described above.25-28 However, an ideal in vivo gene expression 
system must be minimally invasive and clinically translatable. Much effort is currently 
dedicated to designing reporter systems bearing such qualities. In addition, 
multimodality imaging is also increasing in popularity for studying gene expression, 
where the partnership of PET, MRI or optical imaging techniques could be used to 
develop a single reporter construct with a gene product that can be analysed by 
scintillography, fluorescence, bioluminescence, and nuclear or magnetic resonance 
imaging technologies.29 Here, the use of two signatures, such as fluorescence and 
MRI on the same probe is commonly referred to as bimodal or multimodal systems.  
 
Molecular imaging of gene delivery and expression is set to be of great value in the 
spatial and temporal analysis of gene therapy in patients and can help shed light on 
many aspects of gene therapy. These can include information on whether the genes 
have been delivered to the target site, the kinetics of gene expression and the 
correlation of this data with the actual therapy observed.30 
 
1.1.4 Molecular Imaging of Molecular Markers  
 
Specificity has become an important mark of recent classes of therapeutics. Paul 
Ehrlich’s notion of the “magic bullet” is of continuing relevance within the field of 
molecular imaging today, with molecular markers fitting this description well.30 
Molecular markers are chemical entities which are capable of specifically binding to 
targets of interest; their role can be relevant only to an imaging platform, or may 
extend to one of concurrent imaging and therapy, achieved through an additional 
attachment of a diagnostic or therapeutic moiety (theranostics). A common 
requirement for these agents is that they posses a targeting component which signals 
their localisation and a component that enables their detection by namely, MRI, 
optical or nuclear imaging (optical imaging techniques are mainly fluorescence or 
bioluminescence based, and nuclear imaging is a collective term for techniques such 
as PET or SPECT that image radionuclides). The molecular interactions responsible 
for localisation of the agent can be its binding to the targeted molecule, its local 
accumulation by means of molecular or cellular activity of the target, or its 
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modification to a detectable form through enzymatic activity of the target under 
investigation. 
 
An effective demonstration of molecular imaging using molecular markers is realised 
with the targeted contrast agent prepared by Poduslo et al. for in vivo targeting of 
amyloid plaques in Alzheimer’s disease.31 A derivative of human amyloid-β (Aβ) 
peptide was designed, synthesised, and covalently attached to an MRI contrast 
agent. This novel molecular marker was shown to selectively target individual amyloid 
plaques in the brain of Alzheimer’s disease transgenic mice. This engineered 
molecular maker was able to cross the blood-brain barrier due to the inclusion of 
Asp/Glu amino acids in the peptide sequence. This type of system is envisaged to 
enable the in vivo MR imaging of even single amyloid plaques within the brains of 
Alzheimer’s sufferers, and may be used to diagnose the disease at an onset stage, 
contributing to the assessment of anti-amyloid therapies that currently exist. 
 
Apoptosis (programmed cell death) is an area that has attracted a multitude of 
molecular markers designed to target the main apoptosis marker, annexin V. 
Unbalanced regulation of apoptosis is in fact a major cause of disease onset, 
applicable to cardiovascular, cancer and neurodegenerative diseases.32 Once cells 
enter apoptosis, the composition of phospholipids in their cell membranes changes. 
The start of apoptosis is marked by the expression of phosphatidylserine (PS). This 
lipid is presented on the outside of the cell membrane and therefore annexin V is 
capable of binding to PS during apoptosis.33  
Annexin V has also been radiolabelled using 99mTc, 18F, as well as with various 
radioactive isotopes of Iodine (for example 124I), and imaged using PET.33,34,35 As a 
result, radioactively tagged annexin is a useful marker for assessing the efficacy of 
cancer treatments, given that many cancer therapies lead to eventual cell death by 
apoptosis. 
 
Molecular markers in the form of antibodies have also been coupled to contrast 
agents and their potential as immunocontrast agents demonstrated. Muller et al. have 
shown the effectiveness of immunocontrast agents for MR imaging of human 
colorectal carcinoma (LS 174T) grafted in nude mice.36 Their results showed tumour 
uptake of the Gd-labelled immunoconjugates of up to 20% compared to control mice 
as evaluated by MRI. 
 
 
  30
A large number of molecular markers have been developed to date. Each has been 
successful in addressing the visualisation or marking of a particular disease state or 
condition. The aforementioned examples are merely a small selection from the entire 
plethora of developed molecular markers for molecular imaging. Molecular marker 
development is a proliferating field that continues to flourish and generate more 
uniquely targeted imaging agents, with the eventual goal of facile clinical translation, 
disease detection, and diagnosis. 
 
1.1.5 Molecular Imaging of Cancer 
 
Molecular imaging technologies can be used to study both the structure and function 
of processes associated with cancer. Computer tomography (CT), MRI, and 
ultrasonography (US) are standard imaging techniques used in oncological imaging. 
Serial imaging using these techniques can reveal morphological features of lesions 
and changes over time.37 These techniques, in addition to PET, SPECT and optical 
imaging have been used to image perfusion in order to improve detection and 
characterisation of tumours, and to monitor therapeutic response. Perfusion can be 
defined as the blood flow through a tissue of interest per unit volume.  
 
MRI has been applied to the study of tumour perfusion through the use of dynamic 
contrast-enhanced MRI (DCE-MRI). DCE-MRI is a fast imaging technique which 
allows for images to be acquired prior, during and after intravenous administration of 
Gd contrast agents. This type of imaging has made possible the assessment of 
tumour microvascularity, microvessel density, metastatic tendency, and tumour 
recurrence information.38 At present CT imaging is the most frequently used imaging 
tool for the clinical analysis of structural features of cancer.37 Another interesting area 
of cancer imaging is diffusion imaging, whereby the diffusion of water molecules can 
be quantitatively measured with diffusion-weighted MRI (DW-MRI). This technique 
yields information about tissue structure and water content and hence can be used to 
estimate tumour cellularity and to detect early therapeutic effects.39 It is believed that 
an increase in tumour cellularity leads to a restricted motion of water molecules by 
diffusion because of the reduction in the extracellular area, which, under normal 
conditions allows water diffusion more readily. 
 
A significant area in cancer imaging is the imaging of angiogenesis, the process of 
new blood vessel formation. Angiogenesis has been the targeting component of 
many therapeutic approaches, in particular the targeting of αvβ3 integrins which are 
presented on activated endothelial cells that are undergoing angiogenesis.40 The 
  31
molecular imaging of receptors that are over-expressed in various cancers is also 
contributing to the development of cancer therapeutics. For instance, the HER-2/neu 
receptor is over-expressed in numerous cancers, and antibodies targeted against this 
receptor have been investigated for anticancer therapy in clinical trials.41  
               
1.1.6 Molecular Imaging in Drug Discovery and Development 
 
The drug discovery and development process requires substantial time and 
resources since only a handful of compounds from thousands of candidates actually 
make it through to even a pre-clinical testing stage.42 As such, drug discovery can 
benefit from an extensive application of molecular imaging for both pre-clinical small 
animal and human studies, aiding the acceleration of the drug development process. 
Molecular imaging techniques such as ultrasound, micro-computed tomography 
(micro-CT), MRI, PET, SPECT, bioluminescence (BLI) and near infrared fluorescence 
imaging (NIRF) have been used in drug research and discovery. However, the 
nuclear imaging techniques, PET and SPECT have had foremost use due to their 
excellent sensitivities. PET and SPECT both use radionuclides, where the isotopes 
used are unstable and decay by emitting radiation to achieve a stable non-radioactive 
state, this radiation is then detected and translated into an image. These techniques 
posses the level of sensitivity that is required to study and monitor drug distribution, 
pharmacokinetics and pharmacodynamics. In PET imaging many drugs can be 
labelled with 11C or with 18F and since only a single radioisotope atom is required per 
molecule for an effective signal, labelling of the drug, only minimally affects its overall 
physicochemical properties. For example, Fluconazole which is a fluorine containing 
anti-fungal agent has been successfully labelled and its kinetics and biodistribution 
studied quantitatively in various tissues, including its distribution in the human brain.43 
 
With respect to molecular imaging agents, fluorodeoxyglucose (18F-FDG) has been 
most extensively studied clinically, where it is a marker of glucose transport 
expression in metabolism. To this end, the use of PET in clinical imaging has become 
pivotal. As well as its use in imaging brain function, 18F-FDG has been shown to be 
an excellent tumour detection marker since most tumours have a higher metabolic 
rate for glucose than normal tissues. Additionally, 18F-FDG uptake can be correlated 
with the type and aggressiveness level of certain tumours.44  
 
Radioimmunotherapy is another area where the “magic bullet” concept has been 
applied using nuclear imaging; this involves the targeting of an antigen expressed on 
a tumour cell by a specific antibody that binds to the antigen. The antibody is usually 
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labelled by a γ emitter (for example, 111In or 99mTc) for labelling or a β emitter (for 
example, 131I or 90Y) which can be used for cancer treatment.45 In most of these 
studies, the γ emitting agent is administered initially to establish the antibody 
targeting efficacy (dosimetry) and successive therapy is achieved by administering 
the β emitter.  
 
In recent years the development of biomarkers has led to the pharmaceutical 
industry’s avid use of molecular imaging techniques. The term biomarker or biological 
marker is defined by the Food and Drug Administration (FDA) as “a characteristic that 
is objectively measured and evaluated as an indicator of normal biologic processes, 
pathogenic processes, or pharmacologic responses to therapeutic intervention”.46 
The appropriate tagging of biomarkers allows for their detection and localisation in 
relevant biological models and aids in the prioritisation of drug discovery resources 
providing early proof-of-concept studies for novel therapeutic targets. Biomarker 
research has been applied to the identification of plaques vulnerable to rupture in the 
primary prevention efforts for coronary heart disease where MRI has been used to 
study heart function and structure, and to assess plaque composition.47 In addition to 
cardiology biomarker imaging, molecular imaging has also been used to study 
imaging-based biomarkers for neurodegenerative diseases such as Alzheimer’s 
disease, these comprise  the use of magnetic resonance spectroscopy (MRS), FDG-
PET, SPECT and volumetric MRI of the whole brain for studying amyloid plaques.48,49  
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1.2 Cellular Imaging  
 
Cellular imaging by optical methods such as fluorescence microscopy is routine 
procedure in many biological laboratories. Fluorescence microscopy has 
revolutionized our understanding of biological processes in single living cells. Using 
fluorescence microscopy the movement of cellular components such as proteins, 
nucleic acids and sub-cellular structures have been studied and analysed. Cell 
imaging however, has moved beyond the use of staining protocols and histological 
analysis in order to visualise cellular components of interest. The ability to study cells 
has been assisted by the appropriate use of pertinent imaging techniques. Cellular 
imaging is a collective term for the visualisation of any type of cell and has been 
defined as “the visualization of specific cells in an intact animal”.50 Molecular imaging 
aims to visualise molecules and can be specific, whereas cellular imaging concerns 
the imaging of entire cells.51 Nonetheless, both molecular and cellular imaging 
involves the use of molecular probes. 
 
Cellular imaging is an important area which has facilitated the study of cell behaviour 
in living animals; for example, the fate of stem cells has been tracked and monitored 
in a serial manner over time. The labelling of cell populations serves to shed light on 
the in vivo behaviour of therapeutic transplanted cells, for example, their tracking, 
viability, ability to differentiate and their chromosomal stability. The labelling of cells of 
interest is usually achieved through the use of molecular probes or nanoparticles 
which are capable of effective cellular entry. Perhaps due to the stability and 
customisable nature of the type of probes and contrast agents used in MRI, the use 
of paramagnetic contrast agents for the labelling and tracking of various cells in vivo 
has gained popularity in comparison to fluorescent or nuclear imaging techniques. 
Fluorescent labelling is often depth restricted and imaging with PET or SPECT is 
limited due to short lived radioisotopes, and a poor spatial resolution. In keeping with 
this general trend and the use of MR imaging in this project, the following discussions 
will mainly focus on the use of MRI compatible cell labelling techniques. 
 
MRI is capable of producing three dimensional images of tissues containing water 
with a high degree of spatial resolution. In MRI contrast agents are used to further 
improve the quality of an image. These agents consist of molecules which 
incorporate a paramagnetic metal ion, most commonly Gd or Iron (Fe). Image 
improvement arises due the effect of the enhancement of longitudinal (T1) or 
transverse (T2) relaxation times of the surrounding bulk water protons by the 
coordinated metal ion. Contrast agents incorporating Gd increase both 1/T1 and 1/T2 
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but are generally used in T1-weighted imaging where their 1/T1 effect is greater in 
tissue than their 1/T2 enhancement. Fe containing agents, on the other hand, lead to 
more substantial increases in 1/T2 and are therefore visualised with T2-weighted 
images (see section 1.5 for a more detailed discussion on MRI).52 
 
1.2.1 Cellular Labelling and MRI 
 
Magnetically labelling cell populations can help our understanding of pathogenic 
processes considerably, since labelled cells can be studied both under normal and 
atypical states. The future vision of clinical cell therapy is a promising one, since stem 
cells, or corrected specialist immune cells can be transferred to patients and their 
outcomes imaged by MRI, a pre-existing non-invasive clinical imaging modality. For 
cell populations to be imaged by MRI they must be distinguishable from natural 
background noise signal. The markers that are to be used for their labelling should be 
able to produce significant enhancement of either T1 (positive, bright) or T2 (negative, 
dark) relaxation. The ideal cellular label as addressed by Frangioni et al. should 
posses the following characteristics: a strong signalling effect, a biocompatible 
nature, non-interference with cellular genetics, ideally detect single cells, have 
minimal dilution effect due to cell division, remain retained only in the targeted cell 
population, and finally, have the ability for temporal imaging over long periods of 
time.53  
 
The traditional cell labelling agents of choice for MRI have been paramagnetic Fe or 
Gd based agents. Cells of interest can be labelled with these agents in vitro or ex-
vivo and then subsequently re-implanted into specific sites in vivo.  
 
There are various mechanisms through which cellular labelling agents have been 
able to enter cells. These mechanisms can be specific or non-specific. In 
macrophages (white blood cells) have been shown to continuously and non-
specifically phagocytose large labelling particles, this has been useful in the 
visualisation of local inflammation.54 The various cell internalisation mechanisms are 
shown in Figure 4. 
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Figure 4. Cell entry mechanisms. The size of particles is shown for the various uptake 
mechanisms of macromolecules and particles into cells. 
 
 
There are a number of pathways that particles can use to enter mammalian cells, 
these all fall under the general expression “endocytosis”.55 Endocytosis may include 
any of the following cell ingesting processes; phagocytosis, pinocytosis, clathrin-
mediated endocytosis, caveolin-mediated endocytosis, and clathrin and caveolin 
independent endocytosis.50 Phagocytosis is the uptake of large particles by cells and 
most phagocytic cells of the immune system use phagocytosis to internalise foreign 
bodies. These cells include neutrophils, monocytes, macrophages, and microglia. 
Non-phagocytic cells internalise particles using pinocytosis or fluid phase uptake and 
it is generally considered that any non-specific internalisation into cells is due to this 
mechanism. 50 
 
1.2.2 Iron Based MR Cellular Labelling Agents 
 
Iron containing contrast agents have been more widely used in cellular labelling due 
to their biocompatible nature and strong effects on T2* relaxation (a variation of T2 
relaxation). These Fe agents are used as part of superparamagnetic iron oxide 
nanoparticles. Contrast agents made of superparamagnetic iron oxides usually 
consist of a monocrystalline (MION) or polycrystalline magnetite (iron oxide) core, 
embedded within a polymer coating, such as dextran, carboxydextran, citrate or 
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polyethylene glycol (PEG) for effective cellular entry, solubility and immune system 
shielding respectively.56 A variation in size of these iron oxide nanoparticles produces 
ultrasmall superparamagnetic iron oxide particles (USPIO), superparamagnetic iron 
oxide (SPIO) and micron metre sized iron oxide particles (MPIO). USPIOs, which are 
small enough in size to permeate the cellular capillary wall have been investigated in 
clinical trials for the MR imaging of lymph and liver tumours.57,58 These agents 
generate strong T2 and T2* MR signal changes and have also been used in the 
imaging of plaques, since they are ingested by macrophages through 
phagocytosis.59,60 SPIO particles have been shown to be taken up by various cells, 
including T lymphocytes, dendritic cells, monocytes, cancer and stem cells.61 
 
The choice of polymer coating of the iron nanoparticles has been shown to be a 
determining factor for the route of cellular uptake. For example, Fleige et al. have 
shown particles coated with citrate, to enter macrophages via phagocytosis, whereas 
dextran-coated iron oxide particles were shown to be taken up by macrophages 
through pinocytosis.62 Dextran-coated SPIOs were first introduced for hepatic 
imaging, where following intravenous injection, the particles are rapidly taken up by 
liver Kupffer cells, which appear hypointense (dark) in MR images.63  
 
SPIO particles have been further functionalised to increase their cellular uptake ability 
by the incorporation of transfection agents or small peptides such as the 
transactivator (Tat) peptide of HIV which has been directly attached to iron oxide 
nanoparticles.64 A high loading of these particles into cells was also achieved with 
Tat-derivatised cross-linked superparamagnetic iron oxide (Tat-CLIO) particles, 
where the in vivo tracking of haematopoietic and neural progenitor cells to the bone 
marrow of mice was successfully imaged.64   
 
A strategy of increasing cellular uptake of particles is their surface functionalisation 
with a targeting ligand which can lead to the effective uptake of target cells via 
receptor-mediated (clathrin mediated) endocytosis. Various moieties have been used 
for cell surface targeting including, monoclonal antibodies, transferrin, albumin, 
insulin and growth factors such as vascular endothelial growth factor (VEGF).65 It is 
postulated that since the receptors for these ligands are frequently over-expressed on 
the surface of cancer cells, they preferentially target cancer cell surfaces.66 Suzuki et 
al. have recently tested various methods of labelling embryonic stem cells with iron 
oxide particles and have concluded that the use of protamine sulphate in the 
preparation of these particles significantly increased their intracellular uptake in 
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vitro.67 Protamine sulphate is a small naturally occurring polycationic peptide which is 
an antidote to heparin anticoagulation, and also an efficient cell transfecting agent.68 
 
The ability to label single cells by MRI is an exciting avenue and would be an ideal 
validation of cell labelling and localisation of molecular probes.  Recently Zhang et al. 
have imaged single labelled living human umbilical vein endothelial cells (HUVEC) 
with iron oxide particles in vitro.69 Uptake of SPIOs was confirmed with Prussian blue 
staining, electron microscopy and MACS (magnetically activated cell sorter) sorting 
after a 24 h incubation period (Figure 5). This study demonstrates the utility of 
cellular labelling in endothelial cell transplantation. 
 
 
 
 
 
Figure 5. a: An electron-microscope image of a single labelled HUVEC (x 5600, bar: 10 μm). 
b: A Prussian blue stained HUVEC cell (x 5600, bar: 10 μm). c-d: Bright field and fluorescent 
images of different HUVEC cells 24 h post labelling and e-f: Corresponding MR images of c 
and d respectively.69 
 
More recently, the in vivo detection of single primary mouse hepatocytes was 
demonstrated by Shapiro et al.70 These cells were double labelled with green 
fluorescent iron oxide particles of 1.63 µm and a red fluorescent endosomal labelling 
dye. Upon labelling they were then injected into the spleens of mice and their 
common migration from the spleen to the liver was observed as expected, one month 
after administration. This result was also co-validated with histological observations 
and controls, in order to verify the dark contrast regions in the liver, to be that of 
disperse single cells. This study exhibits the viability of detecting single-cells in vivo 
by MRI and may be advantageous in the assessment of donor hepatocytes for 
patients with damaged livers requiring transplantation. 
 
Cell labelling using superparamagnetic agents has been widely practiced.71 However, 
there are a number of limitations that should be taken into account, such as the loss 
a b c 
d 
e
f 
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of Fe content once labelled cells divide (valid for any cell labelling agent in general), 
and the fact that cells use Fe storage proteins such as apoferritin further complicates 
signal measurement.72 
 
1.2.3 Gadolinium Based Cell Labelling Agents 
 
From examples presented in the previous section, it can be concluded that labelling 
cells with various superparamagnetic iron core particles can be readily accomplished. 
These agents exhibit a high susceptibility effect in magnetic fields and can therefore 
produce very strong negative contrast enhancement in MR imaging, as demonstrated 
by their ability to image single cells both in vitro and in vivo. However, the high 
sensitivity and susceptibility effect of superparamagnetic iron oxide nanoparticles is 
not always advantageous as the observed signal is in fact a hyposignal (dark) and 
this can make the precise localisation of iron contrast agents difficult.73 The 
hypersensitivity (or susceptibility) of superparamagnetic contrast agents also affects 
spatial resolution and leads to poor image quality (see Figure 5, f). Therefore, the 
need to explore Gd based cell labelling agents has arisen given that Gd based 
agents do not suffer from any susceptibility issues, and image enhancement is purely 
a consequence of the metal ion’s effect on MR relaxation properties. 
 
Sitharaman and colleagues have recently developed gadofullerenes as magnetic 
labels for cellular MR imaging by investigating the use of anionic 
{Gd@C60[@C(COOH)2]10} gadofullerene complexes.74 Inductively-Coupled Plasma 
Atomic Emission (ICP-AE) spectroscopy and T1 relaxation measurements were used 
to assess the cellular uptake efficiency and internalisation of gadofullerene on both 
NIH 3T3 (mouse embryonic fibroblast) cells and marrow stromal cells. A cell labelling 
efficiency of up to 100% for both cell types was reported, and it was calculated that a 
total of 1011 Gd3+ ions were taken up per single cell. The non-specific uptake and the 
high labelling efficiency of these gadofullerenes can be useful in detecting any type of 
labelled cell by MRI in vivo. 
 
Recently a newly synthesised contrast agent system, Biotin-BSA-Gd-DTPA-FAM was 
used to track tumour-associated stroma by fluorescence and MR imaging.75 Here, 
Granot et al. have demonstrated the administration of the multimodal triple-labelled 
albumin-based contrast agent, Biotin-BSA-Gd-DTPA-FAM which was internalised into 
tumour associated myofibroblasts, where it appeared to be localised in intracellular 
granules. This was established both ex vivo by incubation of cells with the contrast 
material, and in vivo by intravenous administration of the contrast material to tumour-
  39
bearing mice.  Ex vivo incubation of human fibroblasts derived from skin, normal 
breast, and breast tumour tissues with the fluorescent-conjugated contrast material 
confirmed the uptake of biotin-BSA-Gd-DTPA-FAM into cytoplasmic granules. The 
retention of labels in cultured fibroblast cells was demonstrated for up to 2 weeks and 
derivation of the effective relaxivity of the contrast material showed increased visibility 
of Gd during the first four cell cycles. Interestingly, it was concluded that, the relaxivity 
of the contrast material increases with cell proliferation.71 
 
Previously in our group, we have demonstrated the use of paramagnetic Gd 
liposomal particles in the efficient cell labelling of three cell lines. Liposomes are 
composed of lipids that self-assemble in aqueous media to form round-bilayer 
membranes with an aqueous core. Oliver et al. have described the development and 
in vitro analysis of MAGfect, a novel liposome formulation containing a lipidic based 
Gd contrast agent for the labelling and MR visualisation of cells.76 MRI analysis of 
cells labelled with MAGfect showed them to be highly MR active, capable of reducing 
T1 relaxation to < 50% in comparison to control unlabelled cells. In addition, MAGfect 
was also found to be an effective vehicle for pDNA transfection of cells which 
demonstrated the additional gene delivery function of this molecular imaging agent.  
 
1.2.4 Fluorine Based Cellular Labelling Agents 
 
Recently, MR imaging of labelled immunotherapeutic cells has been achieved 
through the use of 19F perfluoropolyether (PFPE) agents. Since background 19F signal 
in living systems is extremely low, the detected 19F signal is consequently only due to 
labelled cells. Ahrens and colleagues have demonstrated the labelling efficiency of 
these agents with dendritic cells.77 These cells have been under investigation for 
cancer therapy and immunological diseases. Using both 19F spectroscopy and 1H MR 
imaging they have successfully demonstrated internalisation and quantification of the 
PFPE emulsions into cells in vitro and have also shown effective liver signal 
enhancement in mice in vivo. More recently, they have labelled diabetogenic T cells 
and shown their homing to the pancreas 48 hours post administration in type 1 
diabetic mice.78 
 
Fluorine spectroscopy has also been used to monitor fluorinated drugs and their 
effect on metabolism. Klomp et al. have shown that by using a tuneable 
radiofrequency coil, 1H MR imaging and 19F metabolite spectroscopy can be achieved 
simultaneously in order to detect 19F drug metabolites in the human liver.79 Using 19F 
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spectroscopy they were able to quantitate tissue metabolite concentrations of the 
chemotherapeutic drug, capecitabine.  
 
Lanza et al. have demonstrated the use of nanoparticle emulsions of perfluoro-15-
crown-5-ethers (CE), as well as particles consisting of perfluoroctylbromide cores 
(PFOB), and have targeted these agents to fibrin clots in vitro.80 These agents were 
further functionalised with biotin for targeting to avidin incubated clots, and also 
contained Gd (CE particles). These particles which were on average around 250 nm, 
were estimated to contain approximately 100,000 Gd3+ ions per CE particle and the 
PFOB particles were estimated to have a 100 M concentration of 19F. Gadolinium 
diethylene-triamine-pentaacetic acid-bis-oleate (Gd-DTPA-BOA) was also 
incorporated in a 30 mol% ratio in the CE emulsions.  
Both T1-weighted images and 19F spectroscopy were obtained of the fibrin clots and 
signals from both CE and PFOB agents were easily distinguished, allowing for the 
acquisition of 19F MRI of the fluorine particles bound to fibrin clots. In a more clinically 
relevant experiment, both 1H and 19F images were obtained, with 19F images 
revealing “hot spots” of bound nanoparticles in carotid artery specimens from 
symptomatic patients. This elegant study demonstrated the synergistic utility of both 
proton and fluorine MRI in clinical imaging at 1.5 Tesla (T). The utility of 19F MRI in 
conjunction with 1H MRI was also supported by work carried out by Higuchi et al. in 
their imaging of amyloid β plaques in vivo.81 They were able to label brain plaques 
using a 19F amyloidophilic contrast agent in mice.  
 
1.2.5 Manganese Based Cellular Imaging agents 
 
Manganese-enhanced MRI (MEMRI) has recently been established as a technique to 
image the movement of Mn2+ ions in the body, and is particularly applied to the 
imaging of active brain regions.82 Manganese chloride (MnCl2) is an effective MRI T1 
relaxation agent, and once injected into the body, produces Mn2+ ions, which are able 
to enter cells via voltage gated calcium channels. This movement of Mn2+ ions along 
neuronal pathways allows for the imaging of active brain regions.  
 
Manganese has also been used in cardiac imaging, since heart muscle tissue also 
contains active voltage-gated calcium channels which can exchange Ca2+ for Mn2+.83 
Aoki et al. have successfully shown the labelling of lymphocytes using MnCl2.84 Van 
der Linden et al. have also used MnCl2 in their extensive studies of the neuronal 
activity of the song bird vocal control system.85,86 
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1.2.6 Stem Cell Imaging With MRI 
 
The use of MRI in imaging cells and their biodistribution has been valuable in the 
monitoring of effective therapies for the treatment of cancer and conditions such as 
strokes. Undoubtedly, stem cell therapy presents the most distinguished use of 
cellular imaging to date; an elegant study by Kraitchman et al. has demonstrated the 
feasibility of MRI in this field.87 Paramagnetically labelled stem cells were used to 
study mesenchymal stem cell (MSC) migration in myocardial infarcts in vivo. The 
stem cells were magnetically labelled with iron containing ferumoxides (Feridex) and 
imaged. This study demonstrated that local transplantation of labelled stem cells 
shows great promise in the treatment of many cardiovascular diseases. This recent 
ability to label stem cells with paramagnetic MRI visible contrast agents enables 
serial tracking in vivo with a high spatial resolution, avoiding the need to use post-
mortem examinations (in animals) to determine the fate of migrating cells, and their 
number and location. MRI presents a non-invasive modality for the imaging of stem 
cell grafts. MRI cell tracking has found a range of applications in monitoring 
transplantation of stem cells and cell-based therapies.88-92 The labelling of stem cells 
with iron oxide particles has had prevalence since they can be loaded in high 
amounts into cells and have excellent sensitivity.93-95   
 
An area which has received most interest in the use of stem cell labelling and cell 
therapy, due to its limited regenerative capacity, is the central nervous system.96-99 
Modo et al. have labelled neuronal stem cells with a dual modality contrast agent that 
is both magnetically and fluorescently labelled, known as GRID (Gadolinium 
rhodamine dextran).100 The cells were labelled in vitro and re-implanted into the 
brains of ischemia-damaged rats. MRI and fluorescence microscopy was used to co-
validate in vivo MR imaging and histology observations. This study demonstrates the 
utility of bimodal imaging approaches for stem cell tracking and monitoring.  
 
Bos et al. have studied the labelling and tracking of stem cells to the liver.101 Rat 
MSC’s were isolated from the bone marrow and labelled with SPIOs using a 
dendrimer polymer as the transfection agent.  Cell labelling persisted up to 12 days 
and the labelled cells were shown to distribute throughout the liver. The MSCs were 
loaded, labelled with clinically approved SPIOs ex vivo, which were internalised by 
endocytosis in macrophages and the particles were injected intraportally into the liver. 
This work clearly demonstrates successful tracking of labelled MSCs with MRI. Most 
recently the ability to label MSCs without a transfection agent was demonstrated by 
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Hsiao et al., who have used SPIOs coated with carboxydextran to label these cells 
and detect them with clinical 1.5 T scanners at the single cell level.102  
 
1.2.7 Cellular Labelling with Other Imaging Modalities 
 
PET and SPECT techniques have also been employed in the imaging of cells, Adonai 
et al. have used copper-64-pyruvaldehyde-bis(N4-methylthiosemicarbazone) (64Cu-
PTSM) to radiolabel cells ex vivo for in vivo PET imaging studies of cell trafficking in 
mice.103 They showed that labelling efficiency was directly proportional to 64Cu-PTSM 
concentration and influenced negatively by serum, and that the liver was the principal 
organ of tracer localisation after tail-vein administration of 64Cu-PTSM. However due 
to the limited t1/2 of 64Cu (12.7 h) experiments requiring longer time spans are not 
possible using this type of labelling. 
 
Bioluminescence imaging of lymphocyte trafficking in vivo has been achieved by 
Hardy et al., with the specific labelling of effector lymphocytes in vitro permitting 
localisation of these cells in animals by BLI.104 Optical imaging is promising here, 
because of the ability of luciferases to emit light without external excitation and 
therefore, they can act as useful genetic tags. The disadvantage of this method is 
that an inherent genetic modification is necessary and the technique cannot be viable 
for clinical use in the long term. BLI also has depth detection limits and is therefore 
restricted to small animal studies. 
 
Cellular MRI has benefited from a broad range of applications in biology and the 
concept of pre-labelling and re-implantation of cells followed by in vivo imaging has 
started in human subjects.105 However, research is continuing to further optimise and 
make safe methods of cellular labelling which can become easily translatable to the 
clinic. 
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1.3 Tumour Imaging  
 
Solid tumour imaging based on small animal models of cancer has helped our 
understanding of human cancer significantly. Appropriately established models are 
able to accurately shed light on tumour characteristics such as angiogenesis, stromal 
interaction, and hormone dependence.106 Both molecular and cellular imaging 
techniques play an important role in analysing and studying the effects of therapy on 
tumour size, growth and apoptosis. This has also eliminated the need for invasive 
methods and post-mortem analysis. Imaging techniques such as MRI, PET and 
SPECT can all aid in the assessment of tumour physiology at both the molecular and 
cellular level, and information can be received dynamically. MRI has many 
advantages here, since both anatomical and functional information can be obtained 
systematically and dynamically over any given period of time. 
 
1.3.1 Angiogenesis Imaging 
 
Angiogenesis can be described as the growth of new blood vessels. This process 
involves the complex interplay of a range of specialised cells, growth factors, 
signalling molecules and regulatory elements. Molecular imaging of angiogenesis has 
been achieved through the use of non-invasive MRI and functional MRI (fMRI). The 
imaging of endothelial cell markers in angiogenesis has led to a critical understanding 
of angiogenic processes, an outcome which would have undoubtedly proved complex 
without the use of targeted contrast agents. Vascular endothelial growth factor 
receptors (VEGFR) that are tyrosine kinase endothelial cell-specific receptors are 
clinically relevant, since VEGF is known to be a predominant proangiogenic factor.107 
Once VEGF binds to various VEGFRs, a phosphorylation cascade is initiated which 
activates downstream receptor pathways leading to endothelial cell proliferation and 
angiogenesis. Various adhesion molecules have been shown to target efficiently to 
endothelial receptors which are themselves involved in VEGF activity. These include 
αVβ3, the integrin binding site for the arginine-glycine-aspartic cyclic tripeptide 
sequence (RGD) and E-selectin.108 
 
Recently Mulder et al. have imaged angiogenesis by detecting the over-expression of 
αvβ3 integrins in tumour bearing mice using a combination of MRI and fluorescence 
microscopy.109 They prepared paramagnetic and fluorescent liposomes, surface 
modified with the cyclic RGD amino acid sequence. These RGD functionalised 
liposomes were shown to target the vessel walls of cancer cells both in vitro and in 
vivo. Fluorescence microscopy revealed that both the control non-paramagnetic and 
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paramagnetic RGD liposomes targeted the vessel wall. The use of fluorescence 
microscopy in this study differentiated between the activity of the targeted RGD 
(which strongly bound to the αvβ3 receptor) and the control liposome modified with the 
control peptide sequence, RAD (Glycine (G) replaced by Alanine (A)), which has no 
affinity for the receptor.    
 
1.3.2 Further Tumour Imaging Methods 
 
Raatschen et al. have been able to use a novel contrast agent, Gd-GlyMe-DOTA-
perfluorooctyl-conjugate (Gadofluorine M™), to differentiate between benign and 
malignant tumour lesions, in addition to evaluating the severity of the lesions and 
identifying necrotic areas.110 This agent has a tendency to form micelles in aqueous 
media due to its molecular weight (1528 Da) and lipidic structure, and as such is able 
to accumulate in tumour tissue.  
 
MRS has also been used to study tumour metabolites. Diffusion rate and vascular 
permeability are all indicative of diseased states such as cancer, MRS methods 
which measure differences in intracellular hydrogen, carbon or phosphorous atoms 
can be used to measure tumour pH and metabolism. MRS has been useful in 
detecting abnormal levels of brain chemicals associated with cancer and has shown 
potential to distinguish between two common brain tumours: gliomas and 
metastases.111 
 
The conjugation of RGD in various forms to contrast agents, and labelling probes of 
various kinds continues to highlight the effectiveness of integrin targeting for both 
angiogenesis imaging and therapy. In particular, αVβ3 integrin is considered a logical 
target for the evaluation of angiogenesis and the pursuing of anti-angiogenic therapy. 
PET, SPECT and MRI have all continuously contributed to this assessment within the 
last few decades.112,113 40,114,115 
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1.3.3 Nanotechnology and Tumour Imaging 
 
The application of nanotechnology platforms to cancer imaging has opened up 
opportunities for the use of multifunctional nanoparticle systems in the study of 
cancer detection and therapy. This process has been made possible through the use 
of specific probes that are able to target to tumours whilst allowing simultaneous 
imaging, whereby the particles can be tracked, monitored and their distribution 
quantified. Medrova et al. have recently developed exactly such particles, where they 
demonstrated the targeting, delivery and therapy of a novel siRNA multimodal 
nanoparticle system.116 The triply labelled dextran-coated superparamagnetic particle 
was modified with a NIR dye; Cy5.5, a cell penetrating peptide; myristoylated 
polyarginine peptide (MPAP) and also contained siRNA for the specific silencing of a 
gene that encodes for Survivin. Survivin is involved in the inhibition of apoptotic 
proteins. This very original study demonstrates the effective use of both MRI and 
optical techniques in imaging the delivery of siRNA to cancers whilst allowing for the 
concomitant assessment of their silencing effect.  
 
The recent use of quantum dots has presented a sensitive method of imaging 
tumours.117 Segupta et al. have developed unique and novel nanoscale delivery 
“nanocell” systems which have also been made with a quantum-dot core for 
fluorescence imaging.118 These drug-loaded nanocells showed unique demonstration 
of temporal release of two therapeutic agents, an anti-angiogenesis agent and a 
chemotoxic drug.  
 
It has been shown that macromolecular nanoparticles of 40 kDa and above are able 
to accumulate in tumour tissue due to the enhanced permeability and retention effect 
(EPR).119 This describes tumour endothelium vasculature, which due to its “leakiness” 
allows the penetration of macromolecular particles through to tumours. Poor 
lymphatic drainage is in part a cause of this effect and it has been shown that the cut 
off size of leaky vasculature in peripheral human blood vessels is between 200 – 600 
nm.119 Particulate systems such as liposomes, micelles, and polymeric nanoparticles, 
which are capable of encapsulating drugs, nucleic acids and diagnostic imaging 
agents, can be used to image tumours by utilising the EPR effect. However, there is a 
continuing need to target cancer cells effectively so that therapeutic and imaging 
agents can internalise into cells efficiently, no matter what the tumour type or size. 
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1.4 Imaging Modalities 
 
Molecular imaging techniques make use of modalities which cover a range of 
frequencies from the electromagnetic spectrum. The most commonly used 
techniques in molecular imaging are MRI, optical imaging and nuclear imaging (PET 
and SPECT).120 PET and SPECT techniques have been most extensively used as 
imaging modalities, since the earliest molecular imaging agents were 
radiopharmaceuticals that used radionuclides such as radioactive iodide 131I 
(diagnosis of thyroid gland disease and the assessment of thyroid gland function), 
and the fluorinated glucose derivative [18F]-fluorodeoxyglucose ([18F-FGD]) which is 
an analogue of glucose (once taken up into the cell it is phosphorylated and therefore 
trapped inside the cell indicating localisation by radioactivity).121 Both PET and 
SPECT allow for the detection of radiopharmaceuticals in vivo and are used to study 
gene expression. The sensitivity of these techniques is very high and small quantities 
of probes can be detected in diagnostic imaging. As such, nuclear imaging modalities 
are applied extensively to clinical research, clinical diagnosis and drug discovery. A 
range of commonly used in vivo imaging modalities along with their characteristics 
are summarised in Table 1. Each technique has advantages and disadvantages with 
respect to sensitivity, resolution, tissue penetration depth, clinical viability and costs.  
 
The imaging modality of choice is usually based on the biological process under 
investigation and can differ between an in vitro and in vivo setting. For example, 
fluorescence based techniques offer low-cost alternatives for imaging small animals 
in gene expression studies. BLI has minimal background noise and can be used in 
small animals relatively easily. The advantage of MR imaging in, for example, gene 
expression studies is the excellent spatial resolution of MRI. Where MRI lacks in 
sensitivity, PET imaging does not, since as little as 10-11-10-12 M of tracer is detected 
using this nuclear imaging technique. 122 
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Table 1. Summary of imaging modalities used in molecular imaging in vivo.123-125  
 
 
The above imaging modalities are useful tools in studying the biodistribution of 
targeted probes, gene and drug delivery vectors, and also the migration of cells in 
vivo. 
Resolution 
Modality 
Form of 
energy 
used 
Spatial 
(mm) Temporal Contrast 
Molecular 
sensitivity  
mol/l 
Tissue 
penetration 
depth (mm) 
 
Example 
reporter 
Agent 
 
 
PET (used 
for both  
animal and 
clinical 
imaging) 
 
Annihilation 
photons 
 
1-4  
(animals) 
 
6-10 
(clinical) 
 
Mins 
 
Medium 
 
10-11 - 10-12 
 
No limit 
 
18F 
11C 
15O 
124I 
 
SPECT 
(used for 
both animal 
and clinical 
imaging) 
 
Gamma 
rays 
 
0.5-5 
(animals) 
 
7-15 
(clinical) 
 
Mins 
 
Low 
 
10-10 - 10-11 
 
No limit 
 
99mTc 
111In 
 
MRI 
(used for 
both animal 
and clinical 
imaging) 
 
Radio- 
frequency 
waves 
 
0.025-0.1  
(animals) 
 
0.2+ 
(clinical) 
 
Min/hour 
 
High 
 
10-3 - 10-5 
 
No limit 
 
Gd3+ 
Fe2+ 
Mn2+ 
1H 
19F 
31P 
23Na 
13C 
 
 
FRI-visible 
(mainly small 
animal) 
 
Visible to 
infrared 
light 
 
 
2-10 
 
 
msec 
 
 
High 
 
 
10-9 - 10-11 
 
1-20 
 
Fluorescent 
proteins,  
photoproteins 
fluorochromes 
NIR 
fluorochromes 
 
BLI 
(mainly small 
animal) 
 
Visible to 
infrared 
 
3-10 
 
msec 
 
High 
 
10-13 - 10-16 
 
1-10 
 
Luciferin 
 
CT 
(used for 
both animal 
and clinical) 
 
X-rays 
 
0.03-0.4 
(small 
animal) 
0.5-1 
(clinical) 
 
 
Mins 
 
High 
 
N/A 
 
No limit 
 
Iodine 
 
Ultrasound 
(used for 
both animal 
and clinical) 
 
 
High 
frequency 
sound 
waves 
 
0.05-0.5 
(small 
animals) 
0.1-1 
(clinical) 
 
 
Mins 
 
Medium 
 
N/A 
 
No limit 
 
Microbubbles 
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1.4.1 X-Ray and CT imaging 
 
X-Ray imaging also known as radiography is the most commonly used technique in 
medical imaging. X-rays are a form of electromagnetic radiation with a wavelength in 
the range 10 nm to 100 pm.  X-rays are often used to determine the type and extent 
of fractured bone and are also commonly used to determine pathological changes in 
the lungs. Contrast agents such as barium can be employed to visualise structures in 
the stomach and intestine, leading to the diagnosis of cancers and disease. X-rays 
however are ionising radiation and repeated scanning can pose health risks to 
patients. 
 
An alternative imaging technique used mainly for soft tissue imaging is CT, originally 
referred to as computed axial tomography (CAT), uses computer software in 
conjunction with X ray images to produce a 3D image. This is done by using digital 
geometry processing (fast algorithm generation for 3D model creation) to generate a 
3D image of the interior of an object from a large series of two-dimensional X-ray 
images taken around a single axis of rotation. Although quite a fast imaging 
technique, repeated CT scanning should also be avoided due to the use of ionising 
radiation.126 
 
1.4.2 PET Imaging 
 
PET imaging is based on the decay of a single radioisotope which produces a single 
positron (positron emitters); this emitted positron then collides with an electron to 
produce two high energy photons that propagate in opposite directions. These 
propagating photons are detected by scintillography. The image is then acquired by 
successively summing all the detected positron emission events in either two or three 
dimensions. PET uses tracers which are based on a number of positron emitting 
radioisotopes including 11C, 15O, 13N, 18F, 124I, 64Cu, 68Ga, 76Br and 99mTc. The 
progression and regression of cancer is routinely studied in patients using PET to 
detect the decaying nuclides of 11C, 15O, 13N, 18F and 124I incorporated into tumour 
targeted radiopharmaceuticals. PET scanners are then used to construct volumetric 
images of the positron-emitting probes.8 A typical example of a molecular assay with 
PET imaging would involve the injection of the positron-labelled tracer followed by 
PET scanning which will provide measurements of the tissue concentration of the 
probe and its targets over a period of time. This data is then correlated with plasma 
probe concentrations and a compartmental model is then obtained.127 Although a 
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very sensitive technique, PET suffers from low spatial resolution, making it difficult to 
localise original signal from biological samples.  
PET-CT has evolved to be a hybrid nuclear imaging technique that has been widely 
used by radiologists in oncology. Combining PET with CT imaging offers advantages 
over using single-photon nuclear imaging alone; the advantage here is the effective 
anatomical correlation with computed tomography. PET-CT offers a greater 
sensitivity and superior spatial resolution over a large field of view and as a result 
small lesions can be detected more readily.128 The combined technique does 
however require cyclotron access and involves the use of ionised radiation energy. 
Recently PET-MRI machines have also been designed and made which will allow for 
both imaging techniques to be applied to the same subject successively. 
 
1.4.3 SPECT Imaging 
 
SPECT is a nuclear imaging technique that is able to detect and quantify γ-emitting 
radionuclides and is frequently used in cancer imaging. The radioisotopes used for 
SPECT emit only one single high energy γ photon (γ emitters) and they have half 
lives ranging from 6 hours to 8 days, which does allow for short-time spanned 
experiments. The γ emitting isotopes used in SPECT are, for example, 67Ga, 99mTc 
and 123I. These isotopes produce a single photon upon decay and the photons that 
escape from the body are detected by large scintillation detectors placed around the 
subject. With SPECT imaging, due to the longer half-lives of the single photon 
emitters such as 99mTc, endogenous ligand interactions, as well as slow kinetic 
processes, and the simultaneous probing of multiple molecular pathways can be 
achieved.129 The main constraint with SPECT is that only a small quantity of the γ-
rays radiating from a subject can actually be detected because of the requirement for 
collimation, which limits its sensitivity (SPECT tracers can illuminate areas other than 
the target area and need co-registration with another imaging modality by computer 
tomography). PET imaging is more sensitive and has better resolution than SPECT 
because collimators are not necessary to exclude scattered photons.  Reconstruction 
methods produce images that have a much higher sensitivity (nanomolar 
concentrations) with PET than those achieved with SPECT.130 PET has 
disadvantages compared to SPECT, as the positron emitting radionuclides have 
short half-lives and instrumentation is relatively expensive. The most frequently used 
positron-emitting radionuclide 18F has a half life of less than 2 hours. As mentioned 
cyclotron laboratories are necessary to generate the radionuclides (e.g. 11C, 13N and 
15O) required for PET and therefore this technique can only be used in specialist 
centres.  
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1.4.4 Magnetic resonance imaging (MRI) 
 
MRI has an excellent spatial resolution, clinical potential, and can consistently image 
structures in the millimetre range without the use of ionising radiation such as that 
used in X-ray, CT, PET and SPECT imaging. The fundamental nature of the MRI 
technique is the interaction of paramagnetic nuclei under an applied magnetic field. 
Contrast agents used in MRI have paramagnetic metal cations and can therefore 
alter the relaxation rate of nearby paramagnetic nuclei, such as the hydrogen nuclei 
of water molecules. The excitation of these paramagnetic nuclei by radio frequency 
pulses and their subsequent relaxation rate after the pulses are suspended is a tissue 
specific event which is characterised by the two time parameters T1 and T2 usually 
expressed in milliseconds. See section 1.5 for a more detailed discussion on MR 
imaging.  
 
1.4.5 Optical Imaging  
  
Optical imaging detects the emission of light from biological tissues and 
encompasses optical tomography, near infrared fluorescence imaging (NIR), 
fluorescence protein imaging and bioluminescence imaging (BLI). Fluorescence 
techniques most widely used make use of the green fluorescent protein (GFP) 
however; they require genetic manipulation and therefore are not suitable for human 
use, and may also cause immune responses, although they can be used in animal 
studies. NIR fluorescence imaging is a technique that is based on the absorption and 
emission of light (between 700-1000 nm wavelengths). NIR imaging in this range 
minimises the autofluorescence from non-targeted tissue and makes NIR probes the 
preferred choice for in vivo fluorescence imaging.  
 
Near infrared imaging systems that use proteases such as Cathepsin D (detects 
fluorescence increase upon enzyme cleavage of imaging agent) have proven to be 
more valuable owing to the fact that these wavelengths can penetrate tissue further 
than other wavelengths used in optical imaging.111 However, the problem with 
fluorescence techniques is that it is not possible to wash away unbound fluorescent 
agents in vivo so there is the issue of target-to-background noise ratio before imaging 
unless agents with a very high binding affinity are used. 
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Bioluminescence occurs when the enzyme luciferase (from Firefly) catalyses the 
reduction of luciferin. The luciferase gene comes from several organisms, including 
the firefly. Luciferase-mediated catalysis uses ATP hydrolysis to convert luciferin (the 
substrate) to oxyluciferin that emits a detectable photon.131  
 
 
 
 
 
 
Scheme 1. Bioluminescence reaction catalysed by firefly luciferase. 
 
 
Reporter genes with bioluminescence signatures have been used in cell culture, in 
small organisms and in ex vivo analyses after expression in larger animals.  In these 
kinds of assays reporter genes are linked to genetic regulatory elements and can 
reveal spatial and temporal information about biological processes at the level of 
transcription. The use of BLI however is clinically limited as it involves genetic 
manipulation and the introduction of foreign genetic material. 
 
1.4.6 Ultrasound Imaging   
 
Molecular imaging agents detectable by ultrasound are now being investigated in 
animal studies. Microbubbles are used in ultrasound imaging; these agents have 
shells that are composed of lipids, proteins or polymers. Microbubbles can contain 
different gases based on the nature of the membrane.  Microbubbles vibrate strongly 
in reaction to the high frequency sound waves used in diagnostic ultrasound imaging 
which amplifies their reflection several thousand times over than normal tissues 
allowing for picogram detection ranges. However, this imaging technique lacks a high 
spatial resolution.132 
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1.5 Magnetic Resonance Imaging (MRI) – Background and 
Principles   
 
The first MR experiment to produce proton images of two glass capillaries containing 
water, immersed in a bath of D2O was accomplished by Paul C. Lauterbur in 1971 
using an in-house built MR machine.133 Today MR scanners have become much 
more developed and are capable of producing high resolution 3D images of tissues 
containing water. The behaviour of paramagnetic nuclei under a magnetic field is the 
fundamental principle of this technique. In clinical imaging, hydrogen is the most 
frequently used nucleus, other possible nuclei used in MRI are 13C, 23Na, 19F and 31P. 
Hydrogen is an ideal atom for MR imaging as it has a large magnetic moment 
indicating that once placed in a magnetic environment it has a relatively high 
tendency to line up to the direction of the magnetic field.  
 
 
 
 
 
Figure 6.  Spin states of a hydrogen’s nucleus in a magnetic field where E is the energy, B0 is 
the magnetic field, γ is the gyromagnetic ratio, m is the spin quantum number, h is Planck’s 
constant and ν is the Larmour frequency at which resonant transitions occur.  
 
 
The magnetic moment of protons is proportional to their angular momentum, where 
the constant of proportionality is the gyromagnetic ratio, γ. Once placed in a magnetic 
field (B0), the proton spins can be separated in energy (Figure 6), and adopt one of 
two possible orientations; parallel or antiparallel to the external magnetic field. To 
align their spins parallel to the applied magnetic field requires less energy and 
therefore this remains the preferred alignment state. Antiparallel alignment requires 
more energy and is hence the higher energy state.  
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However, the number of spins that remain after parallel and anti-parallel states cancel 
each other out is actually very small indeed (+1/2 spin versus – 1/2 spin), and is the 
direct cause for the lack of sensitivity in MRI. The very few spins that are not 
cancelled out are then able to establish a net magnetisation vector in an MR scanner.  
The individual protons do not completely align with this established magnetic vector 
and in fact wobble or precess around the direction of this external magnetic field 
(Figure 7). The frequency (ν) of this precession is dictated by the Larmour equation 
as shown in Figure 7, and is proportional to the applied magnetic field (B0), and the 
gyromagnetic ratio of the hydrogen nucleus (γ). The phase of precession, in other 
words the direction of the spin in the X-Y plane is different for each individual nucleus 
(see Figure 8).  
 
 
 
 
Figure 7.  Hydrogen atoms precess or “wobble” around a magnetic field, the speed of which 
is governed by the Larmour equation shown, ν = γB0. At 1.5 Tesla, the precessional frequency 
for hydrogen is equal to 63.86 MHz. 
 
The established magnetisation vector in the Z direction described (Figure 8) is static 
and in order to measure signal, energy must be applied.  
 
 
 
 
Figure 8. Magnetisation vector (orange arrow) established in the Z direction, from precessing 
hydrogen nuclei around the applied external magnetic field (B0).  
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Energy is applied to the magnetisation vector through the induction of a 
radiofrequency pulse (RF) with the Larmour resonance frequency, for a defined time 
corresponding to either 90º or 180º degrees rotation. The purpose of the RF pulse is 
to change the direction of the magnetisation vector. When the short pulse is 
administered, the thermal equilibrium of the spinning nuclei is disturbed and energy is 
absorbed (Figure 9). The net magnetisation flips 90º or 180º from the positive Z axis 
to the transverse plane, where they precess at the Larmour frequency. This newly 
established rotating magnetisation induces an electrical signal which is picked up by 
the receiver coil placed around the subject or sample being imaged. 
 
 
 
 
 
Figure 9. RF pulses “whip” the spinning nuclei into the transverse plane and cause them to 
precess at the Larmour frequency (same frequency as the RF pulse). 
 
 
When the RF pulse is switched off, two independent events occur (see Figure 10). 
The magnetisation vector relaxes back to its original Z direction and as such, realigns 
to the external magnetic field B0. This event is denoted as spin-lattice relaxation and 
has a time constant T1. This is also sometimes referred to as “longitudinal relaxation”.  
The second event that can occur is the spin-spin relaxation of the proton nuclei in the 
direction of the X-Y plane, which is given the time constant T2. These spins precess 
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in phase together in the X-Y plane shortly after the RF pulse, however, with time, 
their coherence and therefore their signal decays. This is caused by the spins losing 
their phase (dephasing) due to spin-spin interactions with other nuclei, and local and 
external magnetic field inhomogeneities. Spin-spin relaxation is also sometimes 
referred to as “transverse relaxation”. The return of the magnetisation vector to the 
equilibrium state is favourable as it is the lower energy state. The magnetisation and 
therefore the induced signal decays over time and is called free induction decay 
(FID). The time required for the signal to return to thermal equilibrium is determined 
by T1 relaxation time.  
 
 
 
 
 
Figure 10. Two relaxation processes occur once the RF pulse is switched off: T1 and T2, 
which are termed spin-lattice and spin-spin relaxation respectively. 
 
 
Spin-lattice relaxation, T1 is in fact the time taken for the magnetisation vector to 
return to 63% of its equilibrium state post RF pulse (typically a 90º pulse). This 
relaxation is exploited in body MR imaging, since different tissues and organs have 
differing T1 relaxation times. Spin-spin relaxation, T2, is the time period in which the 
  56
spins decay through dephasing, to 37% of their original value. The T2 relaxation 
period is also tissue dependent and is usually shorter than T1 (Figure 11). 
 
 
 
 
 
Figure 11. Graph showing T1 and T2 relaxation parameters. T1 is time taken for excited spins 
to return to 63% of the original net magnetisation vector, and T2 is the time taken for the spins 
to decay through dephasing to 37% of the original net magnetisation vector.  
 
 
In order to obtain a black and white or contrasted image, information from the position 
of all hydrogen atoms in the subject is necessary. The processes by which this can 
be achieved are; slice selection, frequency encoding, and phase encoding (see 
Figure 12). Since the precessional frequency of hydrogen nuclei is proportional to the 
magnetic field and only resonating nuclei produce a signal, by applying a magnetic 
gradient from the direction of the foot to the head, the location of hydrogen nuclei can 
be pinpointed. By using combinations of magnetic gradients in three directions of X, Y 
and Z, information for a single slice of a few millimetres can be obtained. The 
frequency and phase encoding processes yield information on the local hydrogen 
environments of individual points or pixels in a slice. In phase encoding, a change in 
magnetic field is applied between the RF pulse and signal readout. This causes the 
precessional frequency of the hydrogen atoms to change, in turn, changing their 
phase also. This process can be repeated by using temporary gradients until spins 
with differing phases are generated and the alternating current is recorded. 
Frequency encoding is another parameter that can be manipulated in order to 
distinguish points with the same phase encoding. A further magnetic gradient is 
applied during the readout of the signal which changes the precessional frequency. 
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Apart from slice selection, which is the excitation of a single slice in space, phase and 
frequency encoding involve the application of a progressive gradient throughout the 
subject.   
 
 
 
 
Figure 12. Top box: a single slice through the subject can be selected by superimposing a 
small magnetic gradient on to the main applied magnetic field. Bottom: Phase encoding 
further manipulates the spins and frequency encoding is used to distinguish pixels with the 
same phase encoding. Diagram adapted from Van Guns et al.134 
 
 
Once phase and frequency data has been combined, a spatially encoded grid can be 
generated consisting of pixels with unique phase and frequency information (Figure 
12). A Fast Fourier Transform (FT) is then produced in both the frequency and phase 
encoding directions and this process is repeated until all the data from the pixels is 
generated into an image using computer software (Figure 13).  
 
  58
 
 
 
 
Figure 13.  The overall process of image acquisition is presented: after the RF pulse is 
administered, the electrical signal generated by the magnetisation vector changing plane is 
picked up by an RF receiver and a Fourier Transform of the FID produces the NMR signal, 
which through the application of a magnetic gradient can be converted into a 3D image using 
slice selection, phase and frequency encoding. 
 
The FID signal is short lived and the spatial encoding described thus far cannot be 
carried out fast enough, not least within the duration of the FID signal. As a result, a 
second electrical signal can be produced and sustained in order to gain further 
contrasted and better quality MR images. By applying a second RF pulse at 180º, a 
second electrical current is generated which reverses the spins (Figure 14). This 
rephasing of the spins causes an increase in the electrical current generated and is 
referred to as time of echo (TE). This echo signal is generated as a result of 90º and 
180 º pulses and is referred to as a spin-echo sequence in MR imaging. 
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Figure 14.  A second 180º RF pulse causes the dephasing spins to rephase and the height of 
the echo generated by this is called the time of echo (TE).  
 
The time delay between the applications of RF pulses is known as time of repetition 
(TR) and is a parameter that can be controlled in order to obtain T1 and T2-weighted 
images of different tissues. For example, if the TR is short and a short TE is used, 
then the contrast in the image will be dependent on spin-lattice T1 differences, and is 
said to be T1-weighted. If a long TR and a long TE is used, then the image is 
dependent on spin-spin relaxation differences and the image is said to be T2-
weighted.  
 
 
 
Figure 15.  This figure presents a spin-echo sequence, EG = encoding gradient. Spatial 
encoding of the echo signal is carried out using gradient switches. Firstly, the slice selection 
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gradient is switched on during the first RF pulse, and one single thin slice through the subject 
is excited with the protons precessing at the Lamour frequency (RF pulse). The phase 
encoding gradient is applied during the second RF pulse and readout of the echo signal. 
Lastly, frequency encoding gradient is applied during the readout of the echo signal. This 
sequence can be repeated according to the number of pixels in the image matrix. For 
example, 256 x 256, this means 256 frequency encoding and 256 phase-encoding steps are 
required.  
 
 
A great advantage of MR imaging is also the ability to image subjects in any plane 
(Figure 16), three planes are used in MR imaging, axial (perpendicular to the head-
foot axis), sagittal (parallel to the left-right symmetry plane), and coronal 
(perpendicular to the dorsal-ventral axis). 
 
 
 
 
Figure 16.  Three different orientations in which slices are obtained in MRI. 
 
 
In addition to manipulating pulse sequences, using optimal RF coils and appropriate 
computer software parameters, MR imaging also utilises contrast agents in order to 
enhance the T1 or T2 relaxation of relevant localities. A discussion of contrast agents 
used in MR imaging is presented in section 1.7. 
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1.6 Fluorescence Imaging – Background and Principles  
 
Fluorescence imaging involves the use of in general, microscopy to visualise 
fluorescent molecules that absorb light. These molecules are usually polyaromatic or 
heterocyclic molecules referred to as fluorophores, fluorochromes or fluorescent 
dyes. These molecules are able to absorb light and in doing so become excited, 
transitioning to a measurable excited state. Their return to the ground state is a decay 
process which emits fluorescent photons. This process is summarised in Figure 17.   
 
 
Figure 17. Jablonski diagram showing the electronic states involved in fluorescence emission. 
A represents the excitation state after optical absorption, B the excited-state life-time and C 
the emission state.  
 
 
The production of fluorescence from fluorophores involves the three stages of 
excitation, excited-state life-time and the emission state. In the excitation stage 
(Figure 17, A), photons coming from a light source, for example either a lamp or 
laser, are absorbed by the fluorophore and this can lead to the electronic singlet state 
S1’ (Figure 17). During this excited time (of the order of few nanoseconds) the 
fluorophores may go through conformational changes and become affected by 
environmental interactions. Some of the energy of this state is dissipated until the 
lower energy relaxed singlet state S1 is reached (Figure 17). At this state energy 
photons are emitted (hνEM), and the fluorophores return to their ground states, S0. 
Some fluorescence techniques may not result in all the excited fluorophores returning 
to their ground states, these processes may involve for example, fluorescence 
resonance energy transfer (FRET) and collisional quenching. For fluorophores, the 
term fluorescence quantum yield is used to describe their fluorescence efficiency and 
refers to the ratio of the number of fluorescence photons emitted (Figure 17, C) to 
the number of photons absorbed in the excitation stage (Figure 17, A). Often a 
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charged-coupled device (CCD) camera is used to measure the intensity of the 
fluorescence emitted and this information is used to produce digital images of various 
samples. The fluorescence detection instrumentation generally consists of an 
excitation source, a fluorescent sample, appropriate wavelength filters and a detector 
component to measure the emitted photons (Figure 18). Fluorescence emission can 
be localised, measured and quantitated in this manner.  
 
 
 
 
Figure 18. General example of a fluorescence detection system. 
 
 
Fluorescence detection techniques are highly sensitive due to the fact that the same 
fluorophore can in fact be repeatedly excited and detected in a cyclical process, 
however photo-bleaching is an inherent property of fluorescent molecules. 
Fluorescent probes are used in many biological assays and techniques, and can 
provide highly sensitive detection of biologically tagged molecules. These probes 
have characteristic excitation and emission wavelengths and often can be used in 
multicolour experiments, where more than one fluorescence colour can be observed.  
 
 
 
Figure 19.  Fluorescence emission spectrum of two fluorophores, Alexa 488 and Alexa 633 
(Invitrogen®).  
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The sensitivity of fluorescence techniques and reasonably low cost makes them an 
invaluable tool in molecular imaging. Cells can be labelled using a variety of 
techniques and followed both in vitro and in vivo. Perhaps one of the most frequently 
used fluorescence techniques in molecular imaging is the inducible expression of 
GFP which is an excellent marker used in gene expression studies.124  
 
Fluorescence imaging has had prominent use in cell studies in vitro and histological 
analysis, however, in vivo imaging has recently benefited from the development of 
unique black box imaging systems which are capable of both fluorescence and 
bioluminescence imaging in real-time. These applications mainly make use of the 
near-infrared (NIR) spectrum wavelengths (700-1000 nm) in order to obtain the best 
tissue penetration depths and also to minimise autofluorescence from biological 
tissue. Bioluminescence measuring systems also exist for small animal imaging, 
which allow for multiple small animals to be imaged simultaneously.  
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1.7 MRI Contrast Agents 
 
MRI contrast agents are routinely used in clinical diagnosis as they provide reliable 
means to interpret MRI images and play a key role in clinical imaging, with more than 
35% of examinations routinely using contrast agents in the clinic.52 The most 
commonly used contrast agents are thermodynamic and kinetically stable low 
molecular weight gadolinium compounds which, in general, enhance the relaxation 
rate of water protons within the blood pool. Commonly, these agents consist of a 
paramagnetic metal core, which is complexed to a strongly chelating ligand. In 
general, MR contrast agents consist of Gd3+ complexes, monocrystalline iron oxide 
nanoparticles, or Mn2+ chloride complexes. As well as characterising MR contrast 
agents according to the metal centre, another approach to categorise these agents is 
to distinguish them based on their biodistribution characteristics. Traditionally MR 
contrast agents have been classified as extracellular or intracellular agents, and 
some may even show organ specificity, in particular for the liver and can be termed 
tissue specific contrast agents. 
 
1.7.1 Gadolinium Contrast Agents (T1 Agents). 
 
Gd.DTPA (Figure 20) was the first water soluble, renally excreteable contrast agent 
approved for clinical use by the FDA since mid 1988, and is currently routinely used 
under the commercial name Magnevist®.135 This complex contains one inner sphere 
water molecule that exchanges rapidly with outer sphere water molecules and in turn 
relaxes the surrounding water protons simultaneously. Figure 20 presents a few 
examples of the most commonly utilised contrast agents in the clinic.  
 
 
 
 
Dotarem® (Gd.DOTA)-             Pro-hance® (HP-DO3A)          Magnevist® (Gd.DTPA)2- 
 
 
Figure 20. Gadolinium based clinical contrast agents approved by the FDA. 
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These compounds are generally inert stable complexes where the metal ion is 
strongly chelated to the poly(aminocarboxylate) ligands. These types of agents are 
non-specific, mainly reside within the blood stream and also accumulate in the 
kidneys due to their glomerular filtration and are generally excreted unmetabolised.136 
Nevertheless, their use in clinical MR imaging has great value as anatomical 
abnormalities such as gliomas and lesions within the brain can be visualised, since 
under normal physiological conditions these agents do not cross an intact blood brain 
barrier. Pathologies within the liver and other organs can also be visualised since 
these contrast agents rapidly accumulate into interstitial spaces and can therefore 
increase the signal to noise ratio, in such regions of increased fluid volume.137 
  
Gadolinium is used in MRI because of its high magnetic moment (7 unpaired 
electrons in its outer shell, 7.9 Bohr magneton) and its relatively slow electron spin 
relaxation time which is also comparable to that of hydrogen nuclei. Once chelated to 
Gd3+, the linear poly(aminocarboxylate) DTPA ligand forms a stable chelate in the 
form of a distorted tricapped trigonal prism and the DOTA macrocycle forms an even 
more stable chelate in the form of a monocapped square antiprism cage (see Figure 
21).138  
 
 
 
 
 
 
Figure 21. The crystal structures of the two common contrast agents Gd.DOTA and Gd.DTPA 
can generally be best described as a monocapped square antiprism and a tricapped trigonal 
prism respectively. 
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The principle mechanism of relaxation is due to the interaction of the inner sphere 
water molecule with the fluctuating local magnetic field on the Gd3+ ion (Figure 22). 
The inner sphere water molecule coordinates to the 9th coordination site of the Gd 
metal, which leads to the subsequent relaxation of this water molecule. This 
relaxation has a catalytic effect which leads to the relaxation of the surrounding bulk 
water molecules in the vicinity of this co-ordinated water molecule via a chemical 
exchange process. A process that could be envisaged by the role of the Gd3+ ion 
polarising the O-H bond of the coordinated water molecule which in effect enhances 
the magnetic moment of this molecule, and therefore dynamically affects all other 
surrounding water molecules through hydrogen bonding (the outer water molecules 
are termed outer sphere water molecules).   
 
 
 
 
 
 
Figure 22. Gd relaxation mechanism and parameters. 
 
 
As shown in Figure 22, various parameters exist that can influence the relaxation 
rate of water molecules within the contrast agent’s vicinity. These parameters can be 
thought of as; the average time (nanoseconds) a water molecule remains co-
ordinated to the metal ion in the first inner sphere (tM), how fast the contrast agent 
tumbles in water, which is measured by the rotational correlation time (tR) and the 
translational diffusion time of the outer sphere water molecules (tD). This latter 
parameter is related to the hydrogen bonding of the carboxylate oxygens with 
surrounding water molecules that hydrate the complex (oxygen atoms are relaxed via 
dipolar mechanisms).  
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In summary, it can be concluded that three main points influence relaxivity; 1. The 
number of water molecules coordinated onto the paramagnetic metal ion and their 
exchange rate (tM), 2. The rotational correlation time of the Gd complex (tR), and 3. 
The electronic relaxation rate of the paramagnetic metal ion.139 In addition to these 
contrast agent dependent qualities, the local concentration of the Gd metal also 
affects T1, as above a given concentration (~mM), T1 effects may lead to T2 
enhancement. 
 
Gadolinium contrast agents most commonly administered are used with the 
postulation that they will remain intact in the blood before secretion. However, trans-
metallation by other metallic ions in the body and protonation of the ligand are factors 
that may hinder their efficiency as they can cause their dissociation in vivo.  Ions that 
could compete for the binding site of the ligands may be Ca2+, Zn2+, and Cu2+ ions, 
another factor that can cause dissociation is the precipitation of Gd3+ salts and may 
be a contributing factor to recent toxicity reports for Gd based clinical contrast 
agents.140 It is a general belief that slow clearance from the body is likely to 
significantly increase the toxicity of any Gd3+ complexes. Charge density, size of the 
metal ion and the rigidity of the ligand are aspects that can influence the stabilities 
and dissociation speeds of contrast agents in the presence of protons.141 An 
awareness of the abovementioned competitive reactions of Gd contrast agents under 
in vivo circumstances is necessary, although the incidence rate of adverse affects 
reported from their clinical use has remained low.141 Other contrast agents based on 
Fe and Mn are also used clinically, however Gd based agents are most frequently 
used, with in excess of 10 million clinical MRI scans using Gd based contrast agents 
on an annual basis.142 
 
Gadolinium containing contrast agents have the advantage of being very effective 
contrast agents as gadolinium is the most paramagnetic element and is very versatile 
in its nature in order to be incorporated into a variety of complexing ligands.  There 
are no susceptibility issues with gadolinium based contrast agents, and it is far easier 
to visualise T1 enhanced brightness in vivo against, for example, organs that appear 
dark. A valuable addition to the potential of chelating agents such as DOTA and 
DTPA is their ability to also complex metallic radioisotopes such as indium, yttrium, 
gallium and lutetium.  This bifunctional chelation enhances the capabilities of imaging 
using these agents as multiple types of imaging are made possible. Here, the 
complexation of Gd can allow for MR imaging and the complexation of radiotracers to 
the ligands can allow for PET and SPECT imaging.143 This is very useful as there are 
many examples of radiometal labelled DOTA macrocycle derived tumour targeted 
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agents used in cancer and radioimmunotherapy medicines.144 This inter-
exchangeable metal ion centre approach offered by DOTA and DTPA ligands makes 
the use of Gd contrast agents indispensable since the biodistribution of these 
targeted therapeutic agents can be imaged in vivo dynamically when Gd is 
complexed, and therapy can be achieved by complexation of the radioisotope.145 
 
1.7.2 Small Molecular Weight Gadolinium Contrast Agents 
 
Traditional MR contrast agents distribute mainly into the intravascular and interstitial 
spaces. These non-specific agents allow for the evaluation of physiological 
parameters, such as renal function. Agents such as Magnevist® show an organ 
specific distribution due to their glomerular filtration; these agents accumulate in the 
kidneys at much higher concentrations than in the blood or any other tissue.136 
Extracellular gadolinium chelates are known to also improve the diagnosis of focal 
liver lesions, and contrast agents such as Teslascan® (mangafodipir, MnDPDP, 
Amersham Health-US), MultiHance® (gadobenate, Gd-BOPTA, Bracco) and Eovist® 
(gadoxetate, Gd-EOB-DTPA, Schering AG) have been shown to have specific uptake 
in  hepatocytes.137 There is clearly a high demand for pathology and receptor-specific 
contrast media and the field of MR contrast agents has subsequently geared towards 
the design of such specific contrast agents targeted to molecular disease markers of 
interest. Second generation contrast agents are now being continuously designed for 
molecular MRI. The successful coupling of Gd.DOTA or Gd.DTPA to various 
targeting molecules of interest has been described in the literature, with MR imaging 
providing a rapid visualisation and validation for the end point of targeting. Many 
newly investigated agents are evaluated against the efficiency of these 
poly(aminocarboxylate) ligands as they are approved compounds for human use.146  
 
The general criterions for new potential contrast agents can be summarised as; an 
increased thermodynamic stability, favourable rate of excretion, lowered toxicity, 
lipophilicity, target specific biodistribution and an increase in MR relaxation. These 
points have been addressed in the design and synthesis of a range of Gd.DOTA and 
Gd.DTPA contrast agents which exhibit specificity and, pre-clinically, much effort is 
currently focused on molecular imaging using contrast agents as discussed in 
previous sections, for example, by targeting contrast agents to the αvß3 integrins in 
angiogenesis, to fibrin present in blood clots or to cells in order to track their 
biodistribution.  “Smart” contrast agents have also been developed that are sensitive 
to pH147-149, or enzymatic activity.150 Figure 23 depicts some examples of small 
molecular weight Gd contrast agents developed recently.  
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                       Biotinylated Gd.DTPA.151             Gd-TREN-bis(Me-3,2-HOPO)-TAM-Me 
      contrast agent for high relaxivity.152       
 
 
Gd.DTPA(bisamide)-boronic acid derivative.153 
                 
 
Tetrazole Gd.DOTA.154 EPTA-Gd, water soluble contrast agent for the 
estrogen receptor localisation by MRI.155  
 
 
 
 
An enzymatically labile β–glucuronic acid contrast agent.150 
 
 
                    
 
 
Dimeric Gd.DOTA contrast agent.156 Poly(hydroxymethyl) Gd.DOTA, a  
new low toxicity contrast agent.157 
 
 
Figure 23. Examples of some targeted contrast agents from the literature. 
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1.7.3 Large Molecular Weight Contrast Agents 
 
An effective means of increasing the signal-to-noise ratio of MR contrast agents 
involves the incorporation of more than one Gd moiety on molecules. This has been 
an approach undertaken in the design and synthesis of many large macromolecular 
Gd contrast agents, whereby the conjugation of many Gd.DOTA or Gd.DTPA 
moieties together in the form of polymers, dendrimers and other macromolecular 
structures greatly enhances the T1 relaxation properties of these types of agents. The 
main area where these macromolecular agents have been used is for the imaging of 
the blood pool, as due to their increased size and sheer bulk they benefit from 
prolonged blood circulation times. However, their routine use in the clinic may be 
hampered due to their slow clearance and inherent toxicity if they are not broken 
down in vivo, although efforts to make these agents biodegradable have been 
undertaken. Nevertheless, macromolecular blood pool agents can be useful in 
applications such as MR angiography.158 An advantage that a range of these 
dendrimers and polymers have, is the fact that most can be binfunctional, capable of 
condensing nucleic acids, hence acting as transfection agents, or they may also carry 
drug pay loads, making them useful drug delivery agents in addition to their 
paramagnetic properties.159 
 
1.7.4 Polymeric and Dendrimeric Contrast Agents 
 
Macromolecular contrast agents have the advantage of achieving high relaxivities 
and their large size allows for a longer blood pool circulation time, but perhaps the 
main advantage of multiple paramagnetic residues is the significant relaxation rates 
that these types of contrast agents provide. The conjugation of Gd moieties on to pre-
existing polymeric or dendrimer structures is an attractive option which has been 
utilised frequently in the design of macromolecular contrast agents. Conjugation of 
paramagnetic Gd.DOTA or Gd.DTPA to the polyethylenglycol (PEG) polymer,160-165 
various sugar polymers,166-168 oligomers,169 and polyamino dendrimers has been 
achieved.170-173 In addition to paramagnetic MR signal enhancers, these agents may 
also incorporate targeting moieties specific to targets of biological interest. For 
example, macromolecular contrast agents have been synthesised by conjugating 
various cell penetrating peptides for effective cell uptake.11,174-177 
 
Dendrimers are highly branched synthetic polymers and many posses exposed end 
groups at their spherical peripheries for further functionalisation (usually primary 
amines). These dendrimers are grown using a “divergent” or “convergent” approach 
  71
whereby they are grown from a central core unit, with branching units added in a 
controlled manner. The potential of these dendrimers has been harnessed in MR 
imaging, whereby the empty spaces within them have been used to encapsulate Gd 
contrast agents, or contrast agents have been covalently attached. Kobayashi and 
co-workers have demonstrated the use of polyamidoamine dendrimers as contrast 
agents in MRI.178 These dendrimers were reacted with 153Gd for studying their 
biodistribution and blood clearance or they were reacted with 157Gd for MRI studies in 
mice. The compounds showed high MR signal intensities in the kidneys of mice 
where they accumulated. The polyamidoamine (PAMAM) dendrimers are a relatively 
new class of highly branched spherical polymers that are highly soluble in aqueous 
solution and have a coated surface of primary amines available for further 
conjugation (Figure 24). Although good contrast agents for vasculature imaging, 
these agents are far too large for more specific imaging such as cellular imaging. 
 
 
 
 
 
Figure 24. A core type PAMAM dendrimer, n = generation, 178 
 
 
 
1.7.5 CEST and LIPOCEST Contrast Agents 
 
Amongst novel contrast agents; chemical-exchange saturation transfer (CEST) 
agents are an emerging class of MRI contrast agents which facilitate an activatable 
signal. As a substitute to T1 shortening agents for MR contrast enhancement, contrast 
can also be introduced by altering the proton density or total water signal detected by 
the MRI scanner. This can be accomplished using an old NMR technique called 
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magnetisation transfer (MT), first introduced by Forsén and Hoffman.179 Many protons 
in the body exchange with bulk water and so these exchanging protons can be 
selectively RF excited. After irradiating a mmol pool of metabolites (such as amino 
acids, sugars, nucleotides or other heterocyclics having exchangeable OH or NH 
groups that exchange protons with bulk water), the energy is transferred to a nearby 
pool of water, producing a strong increase in enhancement by chemical exchange.  
 
Using CEST agents, contrast can be switched “on” or “off” as required, as each 
response is uniquely related to the specific absorption frequency of the CEST mobile 
protons and this makes the detection of several agents in the same place possible.  
The sensitivity of CEST can be improved further by incorporating larger numbers of 
exchangeable protons into a polymeric CEST agent. This has been done by 
LIPOCEST agents, whereby liposomes containing a paramagnetic shift reagent for 
water protons in their aqueous inner cavity have been made.180 
 
1.7.6 Superparamagnetic Contrast Agents (T2 agents) 
 
T2 contrast agents as mentioned previously consist mainly of iron oxide 
nanoparticles; superparamagnetic iron oxide (SPIO, size: 80-150 nm), very small 
paramagnetic iron oxide (VSPIO, size: 4-8 nm) or ultrasmall superparamagnetic iron 
oxide (USPIO size: 20-40 nm). These particles usually consist of a crystalline iron 
oxide core surrounded usually, by an outer layer that will facilitate uptake into the 
biological target. The advantage of these nanoparticles is that each particle can 
contain thousands of iron atoms, resulting in very high T2 relaxivities of up to 200 
(mM)-1.181  
 
Superparamagnetic iron oxide crystalline structures consist of the general formula 
Fe23+O3M2+O, where M2+ can be either Fe, Mn, Ni, Co or Mg. Within this type of 
crystal material, the occurrence of regions of groups of unpaired spins can occur, 
which can exist as thermodynamically independent areas termed single domains. 
Once placed in a magnetic field these domains can therefore all line up to the 
external magnetic field in a similar fashion to other paramagnetic agents. This 
arrangement leads to much greater magnetic moments in comparison to other 
paramagnetic agents and is the cause of the high magnetic susceptibility attributed to 
superparamagnetic agents.  
 
Although superparamagnetic contrast agents are very efficient signal enhancers and 
have been studied extensively, the problem with using iron contrast agents is the 
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issue of their hypersensitivity. Iron particles exert a magnetic susceptibility far beyond 
the local margin (Figure 25). For example iron particles provide targeted labelled 
cells with a large magnetic moment that creates substantial disturbances in the local 
magnetic field, leading to a rapid dephasing of protons, including those not directly in 
the vicinity of the targeted cell. 
 
 
 
 
 
Figure 25. T2 weighted MR image of cell pellets labelled with iron nanoparticles.93 
 
 
Many examples of superparamagnetic agents exist to date, with successful agents 
entering clinical trials more readily. However, improved methods are still under 
investigation for the control of important characteristics of these compounds, 
including particle size, charge, and outer layer coating.182 These particles are also 
under investigation for rendering them target specificity.  
 
1.7.7 Nanoparticle Contrast Agents 
 
Nanomedicine is set to make considerable contributions in the important areas of 
drug delivery, disease detection, therapy and stem cell based therapeutics. It is 
envisaged that the detection of disease by means of molecular imaging and 
subsequent therapy aimed only to the diseased sites can become standard practice 
in medical clinics. As such, the design and development of nanoparticle based 
contrast agents can be of significant value in medical practice. 
 
Moffat et al. have been able to produce magnetic nanoparticle contrast agents with 
extremely high T2 relaxation properties.183 They were able to encapsulate multiple 
crystals of iron oxide within a polyacrylamide matrix and image gliomas in the rat 
brain. The addition of PEG polymers to the surface of these nanoparticles prolonged 
their blood circulation and accumulation in tumour tissue as validated by MRI. 
 
In summary, the relaxivity of a contrast agent can be increased by restricting the free 
rotation by means of increasing the molecular weight. This has been achieved by 
using polymeric backbones or in vivo binding of small-sized contrast agents to serum 
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proteins.184 The tissue concentration necessary to image with T1 contrast agents is 
considerably higher than that of T2 contrast agents and as discussed various labelling 
solutions have been developed. A number of approaches have been made to attain 
this result by the synthesis of covalently or non-covalently bound macromolecular 
gadolinium chelates such as dendrimers, linear polymers or proteins and also the use 
of gadolinium liposomes. 
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1.8 Paramagnetic Liposomes and MR Imaging 
 
Liposomes are composed of lipid constituents, with hydrophobic head groups and 
hydrophilic tail groups (Figure 26). When hydrated, these lipids aggregate together to 
form self-assembled bilayer vesicles that enclose an aqueous compartment. Due to 
this aqueous cavity, they have traditionally been used as drug delivery vehicles, 
encapsulating water soluble drugs in order to improve drug pharmacokinetics.185-187 In 
addition, nucleic acids have also been condensed into liposome formulations for 
effective transfection and gene delivery.188-191 Despite these additional functionalities, 
liposomes were originally studied as models of biological membranes, and this is a 
key concept in the realisation of their biocompatibility.192 
 
 
 
 
 
Figure 26. Liposome formation from amphipathic lipids. 
 
 
The versatile nature of liposomes can be altered to change their interaction with 
various molecules or even larger structures such as cells. This can be done by 
altering the overall charge of the liposome surface by incorporating lipids with highly 
charged polar head groups in the liposome formulation. For example, the 
incorporation of cationic lipids in the formulation produces cationic liposomes. 
Cationic lipids have been used to formulate liposome/DNA complexes (lipoplexes) 
used as gene delivery systems in vitro and in vivo.193-195 
 
Liposomes are typically characterised by their size, shape and lamellarity. They may 
be composed of a single bilayer (unilamellar), a few bilayers (oligolamellar), or 
multiple bilayers (multilamellar).  The rigidity of the membrane can be modified with 
the use of suitable lipids; and the fluidity of the membrane may be varied by using 
phospholipids with high or low phase transition temperatures. In general lipid 
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derivatives of steric acids (fully saturated C18 lipidic chains) bestow rigidity and 
impermeability to the membrane, whilst lipid derivatives of oleic acid (unsaturated 
C18 lipidic chains) result in a more permeable and less stable lipid bilayer. 
 
For in vivo applications and prolonged circulation of liposomes the liposome bilayer is 
frequently coated with the neutral polymer polyethylene glycol; PEG, which is 
routinely, used in the modification of the physiochemical properties of liposomes and 
the minimisation of bioadhesion and immunological response.  In addition to this, 
PEG incorporation has been shown to increase relaxivity of agents used in MR 
imaging as the polymer adds bulk to a macromolecular structure, leading to reduced 
tumbling rates and hence increased Gd-metal water contact. The incorporation of 
PEG in liposomes as drug delivery systems significantly reduces their liver uptake 
and prolongs their circulation half-life. Steric stabilisation offered by the inclusion of 
PEG in the liposome formulations has proved extremely valuable in MR imaging of 
tumours in vivo.196 Without a PEG layer, liposomes are extremely prone to uptake by 
the reticuloendothelial system (RES).197 The biodistribution efficacy of liposomes can 
be improved by taking into account factors such as: liposome formulation 
composition, liposome size, surface charge, concentration of constituent lipids, the 
route of injection and the total volume injected in vivo.  
 
Due to the variability of their composition liposomes have been used in a large range 
of biological developments. Their use has been applied to most imaging modalities 
discussed thus far, and they have also been targeted to a whole host of disease 
signatures of interest. An analysis of their use in all these various applications is 
beyond the scope of this thesis and therefore their utility only in MRI will be 
discussed.  
 
By incorporating Gd lipids into the membranes of liposomes or by encapsulating 
paramagnetic contrast agents in their aqueous core, they can be rendered MRI 
visible and supramolecular systems with a better control of size can be 
obtained.198,199 Liposomes are well suited as carriers of a high payload of Gd into 
cells. The incorporation of amphipathic gadolinium complexes into liposomal 
membranes has yielded paramagnetically labelled liposomes which significantly 
enhance proton relaxivity. These paramagnetic liposomes have been used in a 
number of investigations including that of cellular labelling and tracking.76 The 
incorporation of Gd lipids into the liposome formulations was demonstrated by 
Kabalka et al. over 20 years ago and the Gd lipid (Gd.DTPA.BSA) used in their 
studies is frequently used to prepare paramagnetic liposomes today.200 
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Recently Vuu et al. presented an elegant study, demonstrating the effectiveness of 
bimodal paramagnetic liposomes in the labelling of breast cancer cells and the 
imaging of tumours in mice.201 These bimodal liposomes were prepared using a novel 
Gd lipid that is designed to cross-link to other Gd lipids within the liposome 
formulation, producing stable covalently linked paramagnetic nanoparticles. A 
fluorescent rhodamine lipid was also included in the liposome formulation for in vivo 
fluorescence imaging and co-validation of MR results.  
 
1.8.1 Paramagnetic Liposomes by Contrast Agent Encapsulation 
 
The initial use of liposomes in MRI has mainly involved the encapsulation of the Gd 
or Fe label, where water-soluble agents were entrapped in the aqueous core of the 
liposomes or where the lipid soluble agents were held in the bilayer structure by van 
der Waals and hydrophobic interactions.   
 
The encapsulation of the FDA approved clinical contrast agent Magnevist (Gd.DTPA) 
is the most common method of preparing paramagnetic liposomes, since this 
compound has excellent solubility and MR signal enhancement properties. Many 
paramagnetic contrast agents have been prepared using this agent with a range of 
applications.202 Recently Port et al. demonstrated the simultaneous sustained release 
of a chemotherapeutic drug, fludarabine monophosphate and Gd.DTPA in rats.203 
This experiment was carried out to show the effectiveness of MR imaging using 
contrast agents for the assessment of the sustained-release of cytostatic agents. It 
was postulated that, upon drug release from the aqueous interior of liposomes, the 
contrast agent would also simultaneously release as evident by tumour signal 
enhancement at the injection site. The fluorinated drug and contrast agent were 
studied by 19F MRS and MRI at 1.5 T over a period of six weeks. They were able to 
conclude that upon an initial lag time, the drug and contrast agent half-lives were 9 
and 6 days respectively. This excellent study demonstrates the feasibility of 
monitoring drug release using contrast agent release from liposomes. 
 
The incorporation of PEG into liposome formulations that encapsulate Gd.DTPA have 
also been reported, where due to this added masking layer their in vivo circulation 
times have been prolonged. Ayyagari et al. reported the use of PEGylated Gd.DTPA 
encapsulated liposomes in MR angiography, where their findings showed these 
liposomes to have a significant sustained (> 4 h) contrast enhancement of rat 
vasculature.204 The utility of PEG coated liposomes for prolonged systemic circulation 
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was also demonstrated by Erdogan and co-workers who prepared anti-body 
immunoliposomes targeted to cancer cells.205 The Gd encapsulation efficiency of 
these particles was increased through the usage of membrane-incorporated 
polychelating amphiphilic polymers. These polymers have attached multiple Gd metal 
chelating groups per single unit and also posses a lipidic moiety for anchoring into the 
liposome membrane. This method increases the Gd payload per particle, in addition 
to exposing most of the Gd chelating groups on the surface of the liposome, allowing 
for increased water contact. 
 
Various other targeted Gd loaded liposomes have also been prepared and applied to 
glioma imaging,206 and investigated for target-site delivery of their entrapped contrast 
agents.207 In addition to Gd loaded liposomes; superparamagnetic liposomes have 
also been prepared with very high relaxivities. Superparamagnetic liposomes consist 
of magnetic fluid loaded liposomes that are capable of significantly reducing T2 
relaxation.192,208 These highly efficient MR contrast agents have been further 
functionalised with the incorporation of PEG polymers for steric stabilisation and 
prolonged in vivo circulation times.209 The properties and preparation methods of 
these Fe containing superparamagnetic liposomes is subject to continuous 
improvement, and their utility in MR angiography has also been established.210-213 
 
In terms of an encapsulation method, liposomes can be useful for entrapping drugs 
within their internal aqueous compartments, however when encapsulated with MR 
contrast agents there are drawbacks. There are limitations such as contrast 
enhancement being limited to water flux across the membrane.  This can be partially 
overcome by making the liposomes very small, such that a high surface to volume 
ratio facilitates water exchange.  Alternatively, the membranes can be designed so 
that they can be permeable to water, but this raises issues of instability in media and 
serum.214 Unger and co-workers however, attempted to develop the encapsulation 
method further. They carried out liposome encapsulation of non-lipidic Gd.DTPA in 
the aqueous compartment by implementing a freeze-thaw extrusion process where 
the encapsulation efficiency of the vesicles was greater than 35% (400 nm vesicles), 
although the relaxivity of encapsulated liposomes can only be improved marginally.215 
 
1.8.2 Paramagnetic Liposomes by Gd Lipid Incorporation 
 
 The relaxivity of Gd encapsulated liposomes is a lot less than that of the free 
compound and therefore the incorporation of the Gd into the liposome membrane, 
where the Gd.DTPA or Gd.DOTA moiety will protrude on the surface of the liposome 
  79
will greatly enhance the relaxivity (more water contact is offered in this way, hence a 
more rapid relaxation event). Kabalka et al. demonstrated that the attachment of two 
hydrophobic chains to the DTPA chelate had little effect on the ability of DTPA to 
complex Gd.216 They also showed that liposomes containing paramagnetic 
amphipathic agents significantly enhanced the MR signal intensity in T1-weighted 
MRI. They observed that these agents were suitable for the imaging of liver, spleen, 
bone marrow, and other organs that are rich in macrophage activity. As such, a range 
of paramagnetic liposomes have been prepared using mainly, the lipidic contrast 
agent Gd.DTPA.BSA shown in Figure 27. 
 
 
 
 
 
Figure 27. N,N-Bis-stearylamidomethyl-N`-amidomethyl]-diethylenetriamine tetraacetic acid 
(Gd.DTPA.BSA). 
 
 
The effectiveness of  paramagnetic liposomes as contrast agents has prompted a 
diversely investigated field for over 20 years and as well as exploring their passive 
targeting nature, they have also been altered by the incorporation of tissue targeting 
antigens and antibodies on the liposomal surface. The in vivo stability of these 
paramagnetic systems has been made favourable by the adjustment of their lipid 
composition; here, the huge variety of natural and synthetic lipids available provides 
many opportunities for the customisation of liposomes.   
 
1.8.3 Targeted Gd Liposomes for MRI 
 
The versatile nature of liposomes allows for their targeting to various disease 
markers. Targeting moieties in the forms of ligands, peptides, proteins or specific 
antibodies can be conjugated onto the surface of liposomes via the use of standard 
bioconjugation techniques. Gd based paramagnetic liposomes were formulated using 
the Gd.DTPA.BSA lipid by Brandwijk et al.217 The incorporation of a maleimide PEG 
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lipid into the liposome formulation allowed for the surface attachment of anginex, a 
33-mer angiostatic peptide which has been shown to home to activated endothelium 
undergoing angiogenesis. MRI and fluorescence microscopy of these targeted 
liposomes which also incorporated a fluorescent lipidic probe showed specific binding 
of these agents to activated endothelial HUVECs. A similar approach and liposome 
model was also used by Mulder et al. for the conjugation of an anti-E-selectin 
monoclonal antibody as a targeting ligand towards activated endothelial cells.218 
 
The conjugation of proteins to the surface of liposomes was demonstrated by Reulen 
and co-worker’s use of a cysteine-functionalised phospholipid, incorporated into 
liposome formulations, and shown to readily react with the mercaptoethanesulfonate-
thioester of a model protein.219 This conjugation method was also extended to the 
conjugation of a collagen-binding protein. This work demonstrated the feasibility of 
directly conjugating recombinant proteins to liposome surfaces specifically through 
native chemical ligation. 
 
The surface functionalisation of liposomes by conjugation of a NIR-tagged annexin 
A5 protein was recently demonstrated by van Tilborg et al.220 Here, bimodal Gd lipid 
based liposomes were prepared and a maleimide PEG-tethered lipid was also 
included in the liposome formulation. This targeted paramagnetic liposome was 
capable of specific binding to apoptotic cells and can be useful in the detection of cell 
death in vivo by MRI. The same researchers have developed similar systems for 
bimodal quantum dot and MR imaging of annexin A5-conjugated liposomes for the 
detection of apoptotic cells.221  
 
1.8.4 Further Applications of Paramagnetic Liposomes 
 
Due to the ease of liposome formulation and the flexibility offered with regards to the 
range of lipidic and lipophilic agents available for incorporation into their bilayers, 
liposomes have been used in a variety of MRI applications. As such, Gd liposomes 
have been used in various applications other than their intended original use in liver 
and spleen imaging. There are a number of areas in which paramagnetic liposomes 
have been utilised, allowing for optimal MR imaging systems to be designed. For 
example their use in CEST imaging and the development of thermosensitive and pH 
sensitive paramagnetic liposomes adds to their excellent utility profile.  
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LIPOCEST Agents 
In chemical exchange saturation transfer (CEST), the total water signal observed can 
be altered by using selective irradiation at the resonance frequency of the contrast 
agent’s protons. Once the contrast agent‘s hydrogens are excited at a selected RF, 
then the bulk water signal will decrease due to chemical exchange. In this manner, 
the MRI contrast can be switched on or off by using selected irradiative RF pulses at 
an exchangeable site close to the bulk water. This effect is greatest if the shift 
resonance of the probe and that of the bulk water is large. Liposomes (Liposome-
CEST) have been used in this area since a large number of moving water molecules 
are enclosed in their aqueous core and if paramagnetic agents are also encapsulated 
or form part of the liposome membrane, then the difference in their chemical shift 
resonance is even more pronounced. This difference in intra-liposomal water 
chemical shift and external water resonance has been exploited by Terreno et al. 
extensively.218 In a recent study, they demonstrated the use of encapsulated shift 
reagents (paramagnetic agents capable of effecting water chemical shifts) in 
liposomes and were able to show large irradiation frequency differences for these 
systems. This is important since, the larger the difference of the chemical shift of the 
protons inside the liposome in comparison to the outside, the more improved the in 
vivo signal can become.  
 
LIPOCEST agents are capable of achieving excellent sensitivities and these 
saturation transfer techniques used can even be applied to specific compounds in a 
mixture within the liposomal core.180 
 
 
 
 
Figure 28.  A cartoon of a prototype NMR spectrum of a LIPOCEST system. 
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Thermosensitive and pH Sensitive Paramagnetic Liposomes 
Paramagnetic thermosensitive liposomes have been used to provide tumour 
temperature measurements. These types of liposomes can encapsulate temperature-
dependent chemical shift paramagnetic chelates or they can have on or off switches 
as defined by the gel-to-liquid crystalline phase transition temperature  
(Tm) of the lipids that constitute the liposome membrane. These types of liposomes 
can be very beneficial in the real-time spatial non-invasive temperature 
measurements of areas where catheter probes are hard to reach. The mechanism of 
operation for paramagnetic thermosensitive liposomes relies on the phase transition 
that the phospholipid constituents undertake once hyperthermic temperatures 
(generally ~ 40-57 ºC) are reached. Here, the transition state of the lipids changes 
from a gel-phase to a liquid-crystalline phase, and in doing so increases the 
transmembrane permeability towards water. This in turn leads to an enhancement of 
the MR signal, since more water contact is allowed for the encapsulated contrast 
agents. Paramagnetic liposomes with a transition temperature of ~ 57 ºC have been 
used for MR-thermometry of thermal ablation at temperatures above 55 ºC in vivo for 
the imaging of rabbit liver and kidney.222 Heating was carried out by using ultrasound. 
The enhanced areas which were due to the subsequent release of entrapped 
contrast agents within the liposomes were super-imposable with isotherms estimated 
from MR temperature images. This data also correlated with histological findings of 
damaged areas where the T1 signal was also significant.  
 
The acidic nature of tumour tissue has led to the development of novel pH-sensitive 
paramagnetic liposomes with improved MR properties. This method relies on the 
degradation of the liposome structure once in a tumour region in order to allow for the 
liposomal contents, such as drugs, to be released to the target site. This theory has 
also been investigated in the field of gene therapy, where the endosomal pH inside 
the cell could also be a trigger for liposome degradation and therefore the release of 
the therapeutic nucleic acids into the cytoplasm for eventual transport to the nucleus.  
Similarly, these systems must be stable in the blood stream, and subsequently able 
to release encapsulated materials upon exposure to the acidic pH in target tissue 
such as cancers.223,224 
Other areas where paramagnetic liposomes have been used are in convection-
enhanced delivery of liposomes in the brain (contrast agents are directly injected into 
the brain). This approach can be used to deliver greater volumes of drug loaded 
liposomes to solid tumours in the brain and MR imaging has been applied to the 
monitoring of liposomal distribution in gliomas in murine models.225,226 
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1.9 Thesis Synopsis 
 
The aim of this project has been to design, synthesise and evaluate novel Gd lipids 
for liposomal cell labelling in vitro and solid tumour imaging in vivo.  
Effective cell labelling agents should be capable of delivering a high payload of the 
labelling agent into cells. Liposomes which are composed of thousands of lipid 
molecules make ideal cell labelling systems, as they are able to deliver many 
molecules of contrast agent. By incorporating paramagnetic lipids into the liposome 
formulation, paramagnetic liposomes are created. This is an excellent method of 
improving contrast agent delivery in vitro or in vivo, since the versatile nature of 
liposomes allows for a good degree of control of parameters that can improve uptake 
and specificity of liposomes such as size, surface charge and targeting. As such, a 
unimodal paramagnetic lipid was synthesised, bearing a Gd.DOTA head group and a 
fully saturated hydrocarbon tail. This lipid was then used to optimise paramagnetic 
liposome formulations for effective cell labelling and uptake, utilising visualisation by 
both MRI and fluorescence microscopy which was made possible through the 
inclusion of a fluorescent lipid in the liposome formulation (DOPE-Rhodamine). These 
bimodal liposomes are useful for the labelling of cells in vitro and due to the presence 
of an excess cationic charge can also effectively encapsulate DNA within their 
aqueous cores. This results in bimodal fluorescent and paramagnetic liposomes that 
are also bifunctional, capable of simultaneous cellular imaging and nucleic acid 
delivery into cells.  
An improvement on these bimodal liposomes would be to develop a lipid that bore 
both the fluorescence and paramagnetic moieties on the same structure and as such 
this was a further aim of this project. The co-validation of contrast agent labelling 
either in vitro or in vivo by two techniques is valuable as in this manner, MR imaging 
can provide anatomical information with excellent spatial resolution and fluorescence 
analysis can provide sensitive and further proof of liposome biodistribution.  In 
addition, progression from a unimodal, to bimodal fluorescent and paramagnetic 
lipids led to the design of trimodal agents, work towards which is presented. 
 
The utility of the Gd lipids synthesised was assessed both in vitro and in vivo and 
their MRI signal enhancement efficacy measured and compared to clinical contrast 
agents. The results presented in this thesis show the effective use of novel contrast 
agent lipids for MR imaging of tumours and the labelling of cells; these results provide 
insight into the behaviour of nanoparticles as concomitant tumour imaging and 
therapy delivery agents for both in vitro and in vivo use.  
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2 . Synthesis and MRI Analysis of 
First Generation Gadolinium Lipid -
Gd.DOTA.DSA
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2.1 Paramagnetic Gd Lipids 
 
Gd based lipids have been incorporated into liposome formulations to achieve 
paramagnetic liposomes for over two decades now. The design of these lipids has 
mainly involved the conjugation of the FDA approved Gd.DTPA MRI contrast agent 
moiety onto a suitable lipidic tail for anchoring into the liposome bilayer. Some 
examples of paramagnetic lipids synthesised by various research groups are 
presented in Figure 29.  
 
 
       Gd.DTPA.BSA.227,228              PPL: polymerisable paramagnetic lipids.229 
 
 
A paramagnetic dipalmitoylphospho lipid.230    Gd.DTPA(DSPE)2 derivative.231 
 
                     
Gd.DTPA.Cholesterol.232           Gd.DTPA with aromatic side chain groups.233 
 
 
 
 
Gd.DOTA lipid derivatives.234 
 
 
 
Figure 29. Examples of paramagnetic lipids with various hydrophobic tails. 
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Leclercq et al. have designed and synthesised a gadolinium paramagnetic lipid with 
an additional functionality.235 They synthesised the novel gadolinium lipid MCO-I-68 
(see Figure 30), which also incorporates a cationic head group for DNA 
condensation and liposomal gene delivery. This lipid showed successful transfection 
of NIH 3T3 cells in vitro and was injected into mouse tumours, where the transfection 
efficiency of the paramagnetic liposomal DNA system was analysed by MRI.  
 
 
 
 
 
Figure 30. MCO-I-68/Gd complex. 235 
 
 
Lipidic Gd contrast agents allow for liposomal based MRI whereby thousands of 
contrast agent molecules can be incorporated per liposome leading to increased 
concentration of the paramagnetic metal agent and an increase in T1 signal. 
 
2.2 Synthesis of Gd.DOTA.DSA 
 
Previous work in the group has shown the novel gadolinium lipid Gd.DOTA.Chol  1 to 
be an effective MR signal enhancer, and MAGfect a liposome formulation containing 
this gadolinium lipid an efficient cellular dual labeling and transfection vehicle.76  
 
 
    
Figure 31. Gd.DOTA.Chol, a T1 lipidic contrast agent component of MAGfect.76 
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Although an effective cellular labelling lipid, formulation of high liposome 
concentrations using this lipid was observed to be problematic, perhaps due to the 
poor anchoring of the cholesterol tail in the liposome bilayers at high concentrations.  
Therefore, due to this limitation, the need to provide a more robust membrane anchor 
designed for in vivo applications where higher concentrations of liposome are 
required; lead us to the investigation of an alternative saturated alkyl chain moiety in 
place of the cholesterol anchor. For this purpose a novel paramagnetic lipid 
Gd.DOTA.DSA 2 (Figure 32) was synthesised using a combination of solution and 
solid phase chemistries.  
 
 
 
 
 
Figure 32. Paramagnetic gadolinium lipid target, Gd.DOTA.DSA. 
 
 
 
The DOTA chelate was conjugated to the lipid via a stable yet biodegradable amide 
functional group. Gadolinium lipid 2 was also designed with a five-atom spacer 
between the gadolinium chelator and lipidic alkyl chain moieties. This spacing 
between the head group and the lipidic alkyl tail was considered to be optimal in 
order to ensure maximum exposure of the gadolinium chelate to water on the 
hydrophilic surface of the liposome particles.  
 
Furthermore, gadolinium lipid 2 was also designed with the DOTA ligand rather than 
the more frequently used DTPA, since the former macrocyclic ligand is considered to 
be a more effective chelator of gadolinium, able to retain the metal ion even in the 
acidic environment of the endosome.236 The FDA approved Gd.DOTA chelate was 
chosen, since due to their higher stability constants, DOTA based conjugates are 
known to be more stable in vivo in comparison to DTPA ligands.237  
 
A retrosynthetic analysis of the target lipid Gd.DOTA.DSA (Gadolinium (III) 2-{4,7-bis-
carboxymethyl-10-[(N,N-distearylamidomethyl-N`-amido-methyl]-1,4,7,10-tetra 
azacyclododec-1-yl}-acetic acid) 2, is presented in Scheme 2. Firstly, the gadolinium 
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lipid is made from the metal free ligand 6 (DOTA.DSA) by the addition of a 
gadolinium source such as gadolinium chloride. Ligand 6 is formed by the removal of 
the tert-butyl groups on the carboxylic acids of macrocyclic 5 in acidic conditions. 
Disconnection of the amide bond on 5 results in the protected macrocyclic DOTA 3 
and the lipid amine 4.  
 
Most applications that involve conjugation to the DOTA macrocyclic ring are carried 
out through covalent linkage of a suitable synthon (usually an amine functional group) 
to one of the four carboxylate groups of the DOTA macrocycle. However, mono-
functionalisation of the DOTA ring is necessary in order to prevent cross-linked 
products. 
 
 
 
 
 
 
Scheme 2.  Retrosynthetic analysis of Gd.DOTA.DSA. 
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2.2.1 Synthesis of Protected DOTA Ligand 
 
Polyacetate derivatives of cyclen (Figure 33) such as DOTA (9) are part of a family of 
azacrowns that display excellent metal chelating properties, in particular towards 
heavy metal lanthanide cations. The synthesis of selectively N-functionalised cyclen 
derivatives has been met with many challenges.238 
 
 
 
 
 
 
Figure 33:  Cyclen macrocycles. 
 
 
Several selective functionalisations of cyclen to prepare compounds such as 8 have 
been reported. Prior to alkylation, three of the amines are usually temporarily 
protected by using stoichiometric amounts of protecting groups such as tert-
butyloxycarbonyl, tosyl, formyl, trifuoroacetyl, or by the use of sterically hindered 
species like glyoxal aminal, and metal compounds M(CO)6 (M= Cr, Mo, W).239 All 
these procedures involve a protection, alkylation, and deprotection step, which in turn 
do not guarantee pure end-products, as competing reactions can yield di- and tri- 
functionalised side products.   
 
Solid phase synthesis offers a cleaner and more selective option for the synthesis of 
compounds such as 8; a range of nucleophilic groups such as carboxylic acids, 
alcohols and amines can be functionalised on to solid phase supports. The use of 
solid phase resins such as chlorotrityl resins, which can be generated by treating 
hydroxytrityl resins with thionyl chloride or acetyl chloride,240 allow for the 
functionalisation of three sites on the azamacrocycle, in addition to the further 
temporary protection of the site attached to the resin itself. 2-Cholorotrityl resin is an 
acid labile resin, and its steric bulk allows for the mono attachment of cyclen. Also, 
the mild acidic conditions required for cleavage make this resin suitable for the 
synthesis of compounds such as 3 (Scheme 3). Any unreacted material could easily 
be washed away with appropriate solvents. 
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For the synthesis of compound 3, initially, MeOH partial capping was used to prevent 
molecular over-crowding of the chlorotrityl resin (Scheme 3). The resin was then 
functionalised with bromoacetic acid to yield acyl bromide 13. An excess of cyclen 
was then added leading to resin-bound cyclen 14 wherein each cyclen was combined 
with the resin via a single acyl bromide leaving three uncombined secondary amine 
sites per bound cyclen. These remaining free amine sites were then further modified 
with the introduction of three tert-butyloxycarbonyl (Boc) protecting groups, and the 
reaction was then judged to have reached completion using the chloroanil test. A 
facile resin cleavage in mildly acidic conditions yielded macrocycle 3, in reasonable 
purity and yield (60-70% yield, depending on the freshness of resin used).  
 
 
 
 
 
Scheme 3. a) MeOH, DIEA, CH2Cl2, rt, 4 h; b) BrCH2COOH, DIEA, CH2Cl2, rt, 12 h; c) 
Cyclen, rt, 4 h; d) BrCH2CO2C(CH3)3, Et3N, DMF, rt, 12 h; e) TFEtOH:CH2Cl2, rt, 2 h, 69%;  
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In each step the resin was washed by alternating between mainly protic solvents to 
filter any excess unreacted bromoacetic acid, cyclen or bromo-tert-butyloxycarbonyl. 
The final cleaved product was purified by an optimised flash coloumn 
chromatography method employing basic conditions and characterised by 1H NMR, 
13C NMR, HPLC and MS.  
 
2.2.2 Coupling of Protected DOTA and Lipidic Amine 
 
Macrocycle 3 was then reacted with lipidic amine 4 under typical peptide bond 
synthesis conditions to yield 5, employing 2-(1H-benzotriazol-1-yl)-1,1,3,3-
tetramethyluronium hexafluorophosphate (HBTU) and dimethylamino pyridine 
(DMAP) as carboxylic acid activators (Scheme 4). Initially, amide bond formation 
appeared to be significantly hindered by steric crowding imposed by the bulky Boc 
groups on DOTA, leading to poor yields of coupled product 5. However, this problem 
was overcome by making use of highly pure reagents, dry chloroform and elevated 
reaction temperatures, leading to improved yields (ranging from 60-88%) and product 
quality. The DOTA cyclic ring is a highly conformationally strained system and can 
therefore adopt a more flexible conformation upon heating, rendering better access to 
the pre-activated carboxylate site for conjugation with lipid amine 4. 
 
 
 
 
 
Scheme 4. a) HBTU, DMAP, dry CHCl3, 40 ºC, 12 h, 88% 
 
A simple deprotection of 5 using HCl: dioxane at a 1:1 v/v ratio, gave DOTA.DSA 6 in 
good yield and purity. With 6 in hand, Gd complexation was carried out by simple 
stoichiometric addition of GdCl3.6H2O to 6 in water at 90 ºC for optimum solubility of 
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the starting materials, thereby generating Gd-DOTA.DSA 2. No significant free Gd3+ 
ions were detectable post complexation according to the xylenol orange assay (see 
below), and the pH was observed to have dropped to 3.5 (Scheme 5). Potentiometric 
studies of Moreau et al. have shown that the complexation of lanthanide cations to 
DOTA involves the instantaneous formation of metal ion complexes as soon as metal 
ions are combined with the ligand, leading to proton release and a sharp reduction in 
reaction pH.141  
 
 
 
 
Scheme 5.  a) c.HCl: dioxane, rt, 2 h, 68%; b) 6H2O.GdCl3, H2O, 90 ºC, 12 h, 99%. 
 
 
Due to the paramagnetic nature of lipid 2, NMR spectroscopy was not suitable as a 
characterisation tool due to the extreme peak broadening caused by the 
paramagnetic gadolinium metal. All gadolinium lipids were analysed by electrospray 
mass spectrometry (ESI-MS), HPLC and the xylenol orange assay was used to test 
for the presence of any free Gd3+ in the product samples. The xylenol orange assay is 
a colourimetric test whereby a colour change from orange to purple is indicative of 
Gd3+ complexation to the xylenol orange dye. This causes a bathochromic shift from 
440 nm to 573 nm. Here, by using a standard calibration curve of known gadolinium 
concentrations versus absorbance, the amount of free Gd3+ in the sample could 
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therefore be assessed. As presented in Figure 34 HPLC and MS analysis of 
Gd.DOTA.DSA 2 was carried out and no free Gd3+ was shown to be present, and the 
compound was prepared with 98% purity and excellent yields. The isotopic peaks of 
gadolinium were also visible in the MS trace and as a result the observation of the 
abundant isotopes of gadolinium confirmed complexation of the metal with the DOTA 
lipid. The HPLC, MS and the isotopic gadolinium peaks for compound 2 are shown in 
Figure 34. Subsequent gadolinium lipids were also analysed in a similar manner. 
 
 
 
 
 
Figure 34. Characterisation of Gd.DOTA.DSA 2: a; electrospray mass spectrum of 
Gd.DOTA.DSA, m/z: 1117.2 (M-H), the isotopic peaks of Gd are visible in the top right corner 
and b; HPLC trace of Gd.DOTA.DSA 2: tR  = 36.22 min, column C-4 peptide; gradient mix A = 
MeCN/0.1%TFA; mix B = H2O/TFA; mix C = MeOH/CHCl3 mix D = MeOH, 0.0 min [100% B], 
15-25.0 min [100% A], 25.1-45.0 min [100% D]; flow 1 mL/min.  
a 
b 
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2.2.3 Synthesis of Lipidic Amine Tail 
 
 Synthesis of precursor lipid amine 4 was accomplished in two steps as shown 
(Scheme 6). Amide coupling of Boc-glycine 17 with distearylamine 16 resulted in 
protected lipid amine 18. A facile deprotection afforded lipid amine 3 [N,N-
distearylamidomethylamine (DSA)] in good yield and purity (Scheme 6). 
 
 
 
 
 
 
Scheme 6. a) HBTU, DMAP, rt, 12 h, 38%; b) TFA:CH2Cl2, rt, 3 h, 94% 
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2.2.4 Synthesis of Control Paramagnetic Lipid Gd.DTPA.BSA 
 
Gd(III) [N,N-bis-stearylamidomethyl-N`-amidomethyl]-diethylenetriamine tetraacetic 
acid (Gd.DTPA.BSA) 19 was also synthesised for control MRI relaxivity studies since the 
use of this compound to formulate paramagnetic liposomes has had precedence in recent 
literature. The method of Jasanada et al. was adapted for the synthesis of this 
paramagnetic lipid.241 
 
The synthesis for compound 19 involved two steps, the first step consisted of a 
nucleophilic attack of the octadecylamine 21 on the DTPA bisanhydride 20 to give 
DTPA-bis(octadecylamido) 22 (Scheme 7). DTPA.BSA 22 was solubilised in neat 
TFA for characterisation with NMR, MS and HPLC. The final step involved an 
analogous gadolinium complexation (Scheme 8) similar to that undertaken to obtain 
Gd.DOTA.DSA, 2. 
 
 
 
 
 
Scheme 7. a) DMF: CH2Cl2, 40 ºC, 2h, 40%. 
 
 
DTPA.BSA lipid 22 was easily complexed with Gd3+ by using gadolinium chloride in 
water at 90 ºC to yield compound 19 in good yields and purity (Scheme 8). This 
paramagnetic lipid was also characterised by HPLC, ESI-MS and the absence of free 
Gd3+ was confirmed with the xylenol orange assay (Figure 35). 
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Scheme 8. a) 6H2O.GdCl3, 90 ºC, 12h, 98%, 
 
 
 
 
 
Figure 35. Characterisation of Gd.DTPA.BSA 19: a; electrospray mass spectrum of 
Gd.DTPA.BSA, m/z: 1051.10 (M+H)+, the isotopic peaks of Gd are visible in the top right 
corner and b; HPLC: tR  = 34.59 min, column C-4 peptide; gradient mix A = MeCN/0.1%TFA; 
mix B = H2O/TFA; mix C = MeOH/CHCl3 mix D = MeOH, 0.0 min [100% B], 15-25.0 min 
[100% A], 25.1-45.0 min [100% D]; flow 1 mL/min.  
a 
b 
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2.3 MRI Analysis of Paramagnetic Lipids Gd.DOTA.DSA and 
Gd.DTPA.BSA 
 
 
In order to establish the relaxation properties of Gd.DOTA.DSA 2, MRI studies of the 
lipid in aqueous solution were performed and T1 values and relaxivity parameters 
generated in milliseconds. The efficacy of gadolinium lipid 2 was compared to the 
clinical contrast agent Magnevist® (Schering AG) and Gd.DTPA.BSA 19 (see Table 
2), and was found to compare favourably at the clinically relevant dose. These data 
also showed 2 to have a comparable, if slightly better, T1 relaxation than the widely 
used Gd.DTPA.BSA lipid. A standard T1 saturation recovery method (spin echo 
sequence) was used to determine T1 values (according to Eq. 1), where x is TR (time 
to repeat), and Si is the measured signal for a given TR. 
 
 
Si = S0(1 - e(-x/T1))  
 
 
 
Equation 1. T1 saturation recovery equation used to determine T1 values. 
 
 
Table 2 presents T1 relaxation values for the synthesised Gd lipids in addition to 
relevant controls.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 2. T1 values and images of Gd.DOTA.DSA 2 and Gd.DTPA.BSA 19 with relative 
controls. 
Sample  T1 (ms) 
 
0.5 mM Gd.DOTA.DSA  2 
 
400.1 ± 15.92 
0.5 mM DOTA.DSA  6 2356 ± 112.588 
Magnevist® 371.0 ± 4.321 
H2O 2750 ± 121.8 
0.5 mM Gd.DTPA.BSA  19 687.5 ± 26.03 
 
0.5 mM DTPA.BSA  22 2760 ± 211.7 
6 
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The relaxivity of Gd.DOTA.DSA 2 was measured both in free lipid form in solution, 
and as part of liposome formulations. Relaxivity can be defined as the capability of a 
contrast agent to increase the relaxation rate of surrounding water proton spins within 
a range of Gd concentrations. For relaxivity measurements gadolinium liposomes 
were prepared using the series of formulations shown in Table 3. Five liposome 
formulations were prepared with gadolinium concentrations between 0.2 to 0.66 μM 
in 200 µL of distilled water. The relaxivity for Gd.DOTA.DSA 2 in these liposome 
formations was found to be 4.90 ± 0.60 mM-1s-1 (see Figure 36) according to 
calculations made using Eq. 2, where r1 is the relaxivity, and 1/T1[C] is the measured 
solvent relaxation rate in the presence of Gd.DOTA.DSA liposomes, with α1 and [C] 
being the T1 relaxation and gadolinium  concentration values respectively. The 
relaxivity for Gd.DOTA.DSA 2 in liposome form is comparable to the relaxivity of 
other paramagnetic liposomes at 4.7 T.242 
 
 
r1 [C] = 1/T1[C] + α1 * C 
 
 
Equation 2. Relaxivity equation to obtain r1. 
 
 
 
Liposome Formulation    
DOTAP 
(mol %) 
Cholesterol 
(mol %) 
Gd.DOTA.DSA
(mol %) 
[Gd] 
μM 
Liposome size 
(nm) 
T1 
(msec) 
 
50 
 
0 
 
50 
 
0.662 
 
120.9 ± 33.2 
 
117.4 ± 6.806 
50 10 40 0.573 90.1 ± 45.8 157.2 ± 9.872 
50 20 30 0.445 125.2 ± 36.7 196.5 ± 11.85 
50 30 20 0.348 102.6 ± 31.9 247.2 ± 14.42 
50 40 10 0.197 141.1 ± 45.9 285.6 ± 21.90 
 
 
Table 3. Gadolinium liposomes used to calculate r1 relaxivity of non-PEGylated liposomes. 
 
 
Our choice of lipids (Table 3) for the liposome relaxivity measurements were based 
on the intended use of these lipids in preliminary in vivo experiments for 
intramuscular injections. However, it is important to note that relaxivity of 
Gd.DOTA.DSA may differ with respect to differing liposome formulations with varying 
sizes, and the inclusion or exclusion of PEG.  
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Figure 36. R1 relaxivity measurement for Gd.DOTA.DSA liposomes (see Table 3 for 
formulations). R1 relaxivity is given by the slope of the linear fit, and is expressed in mM-1S-1. 
R1 was found to be 4.90 ± 0.60 mM-1S-1 for these liposomes. 
 
 
The r1 relaxivity of the paramagnetic lipids Gd.DOTA.DSA 2 and Gd.DTPA.BSA 19 in 
aqueous solutions were obtained at 4.7 T. These values were found to be 0.62 ± 0.01 
mM-1s-1 and 0.83 ± 0.04 mM-1s-1 respectively (Figure 37).  
 
 
 
 
 
 
 
Figure 37. The r1 relaxivities for aqueous solutions of the paramagnetic lipids alone; a: 
relaxivity graph for Gd.DOTA.DSA 2, b: relaxivity graph for Gd.DTPA.BSA 19.  
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The low values obtained for the r1 relaxivity of the free Gd lipids in solution can be 
explained by the poor solubility of these lipids in water and their existence in a non-
macromolecular liposome form (Figure 37). For the r1 measurements in this instance, 
samples for both lipids were prepared with a gadolinium atom concentration within 
the same concentration range used for the liposomal relaxivity measurements (0.20 – 
0.66 μM). These results show that paramagnetic lipids that are anchored into the 
liposome membrane once liposomes are formed, exhibit a much higher relaxivity than 
the free lipid in solution, based on these results, as high as eight fold.  
 
Gadolinium lipid 2 was shown to have similar T1 relaxation behaviour to the common 
clinical contrast agent Magnevist at the clinically relevant dose of 0.5 mM (see Table 
2). This can be attributed to the mixed micellar structures of the Gd.DOTA.DSA lipid 
in water at the given concentration, whereby the rotational tumbling rate is reduced 
as a result of micelle aggregates. In addition, Gd.DOTA.DSA 2 was shown to be ~ 
10% more effective than the commonly used Gd.DTPA.BSA lipid (19) at reducing 
bulk water T1. The relaxivity of the paramagnetic liposomes has been shown to be 
mainly effected by the exchange rate (tM) of the coordinated water molecule to the Gd 
metal centre of the membrane anchored paramagnetic lipid.243 In addition to the 
exchange rate, the coordination number and the rotational correlation time (tr) are 
also factors that affect the relaxivity of macromolecular contrast agents.244 The 
possible motions through which the Gd metal water vector of the anchored lipid can 
lead to  relaxation of surrounding water protons is shown in Figure 38.  
 
tr tD(transl) tint tD(rot)
O
H H
Gd
a b c d  
 
Figure 38. Cartoon of the possible motions that may occur involving the water molecule 
bound to the gadolinium atom of the lipid head group. Here, a shows the rotational motion of 
the whole liposome in water (tr), b shows the translational diffusion of individual gadolinium 
molecules protruding the liposome surface (tD(transl)), c presents the rotation of the gadolinium 
head group attached to the lipid tail (tint) and d depicts the rotational diffusion of the entire 
gadolinium lipid in the liposome membrane (tD(rot)).243 
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2.3.1 Chapter Summary 
 
In conclusion, the synthesis of a novel gadolinium lipid was achieved and the MR 
relaxation efficacy of this lipid was evaluated. It was shown that T1 measurements of 
aqueous solutions of this lipid at the clinically relevant dose compared favourably to 
Magnevist (FDA approved clinical contrast agent) and the relaxivity of this novel lipid 
was found to be comparable to similar paramagnetic liposomes studied at similar 
magnetic field strengths.242 The difference in r1 relaxivity between the lipid solutions 
and the liposome solutions is explained in terms of rotational tumbling rates, whereby 
as single lipids in solution, the gadolinium lipids are rotating at very high rates in 
comparison to their rotational behaviour once incorporated into liposome 
formulations. Liposomes are macromolecular structures, a property that reduces their 
molecular tumbling rates in water, leading to an increase in gadolinium metal water 
contact and an enhanced relaxation rate. 
 
In order to gain more insight into the relaxation properties of the paramagnetic 
liposomes formulated with lipid 2, future work could involve determining relaxivity as a 
function of magnetic field strength. This can be achieved by obtaining nuclear 
magnetic resonance dispersion (NMRD) profiles of the liposome series shown in 
Table 3. Information on the rotational tumbling rates (tr) of these liposomes can also 
be deduced from such spectra. The effect of temperature on relaxivity of these 
paramagnetic systems can also be studied, since it has been shown that in general, 
r1 increases with temperature which may suggest that at higher temperatures the 
liposome membranes are less rigid, resulting in an increased permeability, in turn, 
allowing for increased water contact with the inner-liposome gadolinium head 
groups.242  In general, it is expected that Gd.DOTA based chelates used in the design 
of gadolinium lipid 2 will have faster water exchange rates (tm) than their Gd.DTPA 
counterparts when studied at higher temperatures.245  
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3 . In Vitro and In Vivo Biological 
Evaluations of Gd.DOTA.DSA 
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3.1 In Vitro Evaluation of Gadolinium Liposomes 
 
Cellular labelling to date has mainly involved the use of iron oxide nanoparticles, as 
strong signal enhancement arises due to the superparamagnetic nature of these 
labelling particles. However, recently gadolinium based probes have also been 
applied to the labelling of various cell lines and their subsequent in vivo tracking 
achieved using MRI. Cellular imaging is a growing field, for which novel probes and 
labels are under continuous development. For example, in addition to the labelling 
and tracking of cells of interest, novel contrast agents are being developed that are 
capable of monitoring functional cell status. Himmelreich et al. have recently studied 
a responsive gadolinium MRI contrast agent that is insoluble once outside the cell, 
however, once the probe enters cells through pinocytosis it is activated through 
enzymatic hydrolysis, and hence rendered soluble by intracellular lipases.246 This 
type of cellular labelling can be applied to the monitoring of cell behaviour, for 
example, activation or differentiation of stem cells, and can be modified to respond to 
a range of enzymes that are expressed at various times within a particular cell cycle. 
 
Given that cell membranes are themselves composed of lipids, the use of liposomes 
for the labelling of cells can be considered optimal, since liposomes also constitute 
lipids. It can be expected that a facile membrane fusion between these biocompatible 
agents and the extracellular cell membrane leads to their cell internalisation and 
entrapment. As such, we undertook to test the cell labelling efficiency of gadolinium 
liposomes formulated with the novel lipid Gd.DOTA.DSA 2. The liposome formulation 
was optimised to allow for maximum cell uptake and the toxicity effects of the added 
liposomes were also assessed, cell labelling, and visualisation by both MRI and 
fluorescence microscopy was performed. 
 
3.1.1 Gadolinium Liposome Formulation optimisation 
 
A simple method to quantify the uptake of gadolinium liposomes into cells is to 
include a fluorophore-tagged lipid in the liposome formulation. A very small molar 
percent of fluorescent lipids such as DOPE-Rhodamine is sufficient for this. Once 
liposomes are fused with the cell membrane and subsequently internalised into the 
cell via endocytosis, the liposome and therefore its constituents are trapped in the 
cytoplasm, and hence the emission of fluorescence from the cell lysate is indicative of 
the amount of intracellular liposome uptake. Any non-internalised liposomes will be 
washed away after the uptake period is complete, resulting in a fluorescence reading 
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obtained purely from cell internalised liposomes. The measured intensity at the 
appropriate excitation and emission wavelength of the fluorescent lipid probe is an 
indication of the amount of liposome, and more importantly the amount of gadolinium 
lipid that is internalised by the cells. Additionally, the incorporation of the fluorescent 
lipid also allows for fluorescence microscopy studies. A range of fluorescent 
gadolinium liposomes were prepared with various mol % ratios of Gd.DOTA.DSA 2 
and the cationic lipid N1-cholesteryloxycarbonyl-3,7-diazanonane-1,9-diamine 
(CDAN) 23, the neutral lipid dioleoyl-L-α-phosphatidylethanolamine (DOPE) 24, in 
addition to the red fluorescent lipid DOPE-Rhodamine 25. These formulations were 
designed in order to assess the effect of increased cationic charge (CDAN lipid) of 
the liposome, increased neutral charge (DOPE lipid), and a high gadolinium lipid 
(Gd.DOTA.DSA) content on the efficiency of cellular uptake. The structures of CDAN, 
DOPE and DOPE-Rhodamine are shown in Figure 39. 
 
Other parameters investigated in addition to percent fluorescence uptake of the 
gadolinium liposomes into cells were incubation time and liposome concentration. 
The objective here was to determine a formulation, dose and incubation period that 
resulted in the most ample liposome uptake into cells without the appearance of 
cellular toxicity. 
 
The incorporation of CDAN into the formulations renders a positive surface charge to 
the liposome membrane as CDAN has a cationic polyamino head group. Cellular 
uptake of liposomes is mediated by adsorption of these nanoparticles onto the cell 
surface followed by endocytosis. Charged liposomes are taken up more readily by 
cells in culture, due to the electrostatic interaction of the cationic liposome with the 
anionic cell surface. Thus, the fraction of positively charged lipid in a liposome is 
critical to cellular uptake, although a high percentage of cationic lipid results in toxicity 
and cell death.247 It is therefore necessary to maintain the cationic nature of the 
liposome formulation whilst also balancing the molar ratio of the other constituents.  
 
The inclusion of DOPE in the formulations is believed to aid in endosomal disruption.  
This is due to the fusogenic nature of DOPE. As the DOPE lipids fuse with the 
cellular or endosomal membrane, the endosome and its components are destabilised 
and readily released, therefore aiding in the cytoplasmic delivery of the liposomes in 
vitro.248 
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Figure 39.  Lipids used in Gd Liposome formulations. 
 
 
In order to establish the cellular labelling efficiency of liposomes prepared with 
Gd.DOTA.DSA 2, a series of eight liposome formulations were tested on HeLa cells 
so that an ideal non-toxic cell labelling liposome formulation could be determined able 
to deliver a maximal amount of Gd to the cells (Table 4). HeLa (human ovarian 
carcinoma) cells were chosen since they require minimum handling, are a robust cell 
line and therefore adequate for our proof of concept study of cellular labelling prior to 
progressing to more challenging and specialised cells. The gadolinium liposomes 
were prepared using the thin-film technique, hydrated in water, sonicated, and sized 
using photon correlation spectroscopy (sizes were between 200 – 300 nm on 
average, see Table 4). 
 
 
2 
Cl_ 
 + 
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Table 4.  Liposome formulations prepared for the labelling of HeLa cells, with their respective 
sizes as measured with photon correlation spectroscopy. 
 
 
The fluorescence uptake assay used to quantitate the amount of internalisation of the 
gadolinium liposomes into HeLa cells is depicted in Figure 40. Here, liposomes 1-8 
(Table 4), were added to ~ 80,000 HeLa cells in three doses (6, 12 and 18 µg of total 
lipid/well) and the liposomes were allowed to incubate with the cells for four 
incubation periods (4, 6, 8, and 10 hours). After completion of the incubation period, 
the cells were washed with PBS, and lysis buffer was added, upon a freeze-thaw 
cycle, the cell lysates were subjected to an organic extraction, where a MeOH: CHCl3 
(6: 1 v/v) organic solution was used to extract the DOPE-Rhodamine lipid out of the 
lysate mixture. The fluorescence emission of this layer was then measured on a 
spectrofluorophotometer at 585 nm. The % fluorescence uptake was calculated using 
a positive control, which consisted of 100 % of the added liposome dose, and a 
negative control, consisting of the organic extract from cell lysate with no added 
gadolinium liposomes.  
 
 
 
 
Liposome 
Gd.DOTA.DSA 
mol % 
CDAN 
mol % 
DOPE 
mol % 
DOPE-
Rhoda 
mol % 
Liposome 
size (nm) 
1 30 40 29.5 0.5 263.6 ± 45.67 
2 30 30 39.5 0.5 275.1 ± 53.4 
3 40 30 29.5 0.5 206.5 ± 20.5 
4 40 40 19.5 0.5 209.6 ± 38.9 
5 50 49.5 - 0.5 242.5 ± 46.5 
6 50 - 50 0.5 261.6 ± 35.66 
7 60 29.5 10 0.5 228.2 ± 34.56 
8 60 19.5 20 0.5 297.0 ± 55.89 
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Figure 40. Fluorescence uptake assay used to assess uptake of gadolinium liposomes into 
HeLa cells. Liposomes were prepared with various mol % ratios of DOPE, CDAN, 
Gd.DOTA.DSA and DOPE-Rhodamine (maintained at 0.5 mol % for all formulations, see 
Table 4. for liposomes). The liposomes were incubated with HeLa cells for defined periods 
and post uptake, the cells were washed, the lysate obtained and the DOPE-Rhodamine 
fluorophore extracted using organic solvents. Fluorescence intensity measurements of lysates 
were used to calculate the amount of gadolinium uptake into cells. 
 
 
 
Gadolinium liposomes 1-4 (Table 4) displayed a high percentage fluorescence 
uptake consistent with the presence of both CDAN and DOPE at high mol % (Figure 
41). Gadolinium liposomes 5 and 6 were less effective, consistent with the absence 
of either DOPE or CDAN, supporting the hypothesis that both the cationic charge and 
fusogenic properties of CDAN and DOPE lipids respectively, are necessary for 
effective cellular entry and cytosolic delivery. Gadolinium liposome 8 was similarly 
less effective due to lack of effective cationic charge for cell surface adhesion.  
 
The fluorescence uptake data was normalised to the total protein content per well 
using the BCA assay. As a result, the % fluorescence uptake into cells was also used 
to calculate the amount of gadolinium lipid taken up in cells and this was normalised 
to the protein content per well. Since the level of fluorescence emission from the cell 
lysate correlates to the total amount of liposome added to each well, the amount of 
Gd in each well was also calculated and expressed per mass of total protein content 
(see Figure 42). 
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Figure 41. Fluorescence emission of HeLa cell lysate post incubation with gadolinium 
liposomes. Liposomes were added at three doses, 6, 12 and 18 μg’s and incubated for a: 4, b: 
4 hr incubation
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6, c: 8 and d: 10 hours. The mol % of DOPE-Rhodamine was kept at 0.5 mol % in all 
liposome formulations. DOPE-Rhodamine fluorescence was measured at λex 545 nm and λem 
585 nm. 
 
 
The trend for Gd uptake into cells (Figure 42), as evident, is similar to the 
fluorescence uptake results measured, in general liposomes 1-4 show increased 
uptake in comparison to formulations 5-8 due to the presence of an optimum balance 
of cationic CDAN and neutral DOPE lipids. 
 
Upon normalisation of the results to protein content per well, a large uptake of Gd is 
apparent for liposomes 1-4 at the 18 μg dose (Figure 42, d). Liposome 6 has the 
poorest uptake into cells due to the total lack of cationic charge (Figure 41 and 42). 
 
Liposomes 1, 4 and 7 both have an excess of cationic charge, and liposome 2 has an 
excess of DOPE. From the normalised data (see Figure 42, d), it can be concluded 
that gadolinium liposome 2 delivers the highest amount of Gd into the HeLa cells 
upon a 10 h incubation period. However, prior to determining an optimal liposome 
formulation, the toxicity of each formulation should also be assessed. Cell toxicity 
studies were subsequently performed with gadolinium liposomes 1, 2 and 7. 
Gadolinium liposome 4 showed the highest fluorescence uptake (see Figure 41, d), 
however it was not carried forward for toxicity studies due to the presence of an 
excess of cationic charge (i.e. twice the amount of neutral DOPE lipid present in the 
formulation). 
 
The fluorescence assay utilised in this cell uptake study (Figure 40) was designed in 
order to screen large numbers of liposome formulations for effective cell uptake, in 
triplicate, for the three administered concentrations and four incubation periods. This 
method is a quick and cost-effective means of assessing liposome cell internalisation, 
however a caveat to its use is the estimation of Gd uptake into cells in comparison to 
the actual measurement of Gd content, carried out by sensitive techniques such as 
inductively coupled plasma mass spectrometry (ICP-MS). The inclusion of a 
fluorescent lipid in liposome formulations is still a commonly used method for 
assessing liposome uptake into cells and can be used to refine large batches of 
liposome formulations to a smaller number of formulations that can be further 
characterised for their Gd delivery efficacy into cells using ICP-MS. 
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Figure 42. Calculated mass of Gd.DOTA.DSA lipid taken up into cells with 8 liposome 
formulations (Table 4). Liposomes 1-8 were added at three concentrations of 6, 12, 18 µg’s of 
total lipid content and incubated with HeLa cells for a: 4, b: 6, c: 8 and d: 10 hours. 
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3.1.2 MTT Cell Viability Assay with Gadolinium Liposomes 
 
The determination of cellular proliferation and viability are key areas assessed for in vitro 
assays of a cell population’s response to external factors, therefore an MTT assay was 
carried out to measure the effect of the gadolinium liposomes on cell viability. The MTT 
assay measures the cell proliferation rate and conversely, when metabolic events lead to 
apoptosis or necrosis, the reduction in cell viability (balance between proliferation and 
cell death). This assay involves the reduction of tetrazolium salts by mitochondrial 
dehydrogenase enzymes. The yellow tetrazolium MTT (3-(4,5-dimethylthiazolyl-2)-2, 5-
diphenyltetrazolium bromide) is converted to the purple product Formazan, by 
metabolically active cells, through the action of dehydrogenase enzymes (Figure 43). 
The resulting intracellular purple formazan can be solubilised and quantified 
spectrophotometrically.249 In this manner, the viability of cells in the presence of the 
added gadolinium liposomes can be measured and quantitated.  
 
 
      MTT (yellow)                        Formazan (purple) 
 
 
Figure 43:  Reduction of MTT to Formazan in metabolically active cells in part, by the action 
of dehydrogenase enzymes. 
 
 
Gadolinium liposomes 1, 2 and 7 (Table 4) were tested for their effect on cell viability 
at the three previously used doses of 6, 12, and 18 µg/well, and were also incubated 
with HeLa cells for the same four hour incubation periods (4, 6, 8, and 10 h). Cells 
with no added liposomes were used as the positive control, and cell viability was 
measured and expressed as a percentage (Figure 44, a, c, e, and g).  
 
In addition to the initial uptake periods (4-10 h), a further 24 h analysis of cell viability 
was also assessed, this involved removing the media and washing the cells after 
each incubation period, replacing the media and allowing the cells to grow for a 
further 24 h. The amount of Formazan in the media was then measured so that the 
effect of the added gadolinium liposomes could be determined for a full 24 cell 
growth-cycle (Figure 44, b, d, f, and h). 
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Figure 44. MTT cell viability assay for liposomes 1, 2, and 7 (Table 4) incubated with HeLa 
cells. Graphs on the left are for incubation periods of 4, 6, 8 and 10 h. Graphs on the right 
show cell viability of the added gadolinium liposomes with a further 24 h growth period. Here, 
the cells were washed post uptake period, the media replenished, and the cells were allowed 
to grow for a further day. 
 
 
The MTT assay results showed acceptable levels of cell viability post incubation with 
gadolinium liposomes (Figure 44). As expected, cell viability decreases with 
increasing dose and incubation period. However, cell viability was not effected by 
more than, on average 40 % as a result of the added liposomes as observed for the 
highest dose and incubation period. Furthermore, when the cells were allowed to 
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grow for a further 24 h post uptake, their cell viability and therefore metabolism was 
not affected to any perceptible degree. From these results it could be concluded that 
gadolinium liposome 1 appears to effect cell viability the least. In general, cell viability 
data seem consistent for the 6 and 12 μg doses and the 8 h incubation period for all 
added gadolinium liposomes (Figure 44, e). However, since the MTT assay does not 
provide an assessment of cell death due to toxicity, as it only conveys information on 
the viability of cells, a further lactate dehydrogenase (LDH) cytotoxicity assay was 
carried out to quantify the level of cell death due to the added gadolinium liposomes. 
 
3.1.3 Lactate Dehydrogenase Cytotoxicity Assay with Gadolinium Liposomes 
 
In order to assess the toxic effects of the three liposome formulations chosen from 
the fluorescence uptake studies on HeLa cells, a toxicity assay was carried out using 
the CytoTox 96® Non-Radioactive Cytotoxicity Assay (Promega). The LDH assay is a 
non-radioactive colourimetric cytotoxicity assay that quantitatively measures LDH, 
which is a stable cytosolic enzyme that is released upon cell lysis during cell death. 
The amount of LDH released in the cell media is measured with a 30-minute coupled 
enzymatic assay, which results in the conversion of a tetrazolium salt (INT) into a red 
formazan product (Figure 45). The amount of colour formed is proportional to the 
number of lysed and therefore dead cells. The results are then normalised against 
controls such as the LDH released from cells with no compounds added to them. 
 
 
 
Figure 45. General chemical reactions for the LDH cytotoxicity assay. 
 
The three selected gadolinium liposome formulations (see Table 4, liposomes 1, 2 
and 7) chosen from the fluorescence uptake studies on cells were added to HeLa 
cells in a similar manner to the MTT assay, at three concentrations (6, 12, and 18 
μg/well) and incubated for 4, 6, 8 and 10 h (Figure 46, a-d). In addition, the cells 
were washed post uptake period, the media replaced and the effect of toxicity 
measured during a full 24 cell growth-cycle (Figure 46, e-h). 
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Figure 46. a-d: LDH assay results calculated to show % cytotoxicity as a result of added 
gadolinium liposome formulations 1, 2 and 7 at three liposome doses (6, 12 and 18 μg/well) 
and four incubation periods (4, 6, 8, and 10 h). e-h: LDH assay calculated to show % 
cytotoxicity as a result of added gadolinium liposomes, in addition to cells being washed after 
the initial incubation periods and then allowed to grow for up to 24 h. These results show 
cytotoxicity induced by the added gadolinium liposomes to be in general < 10% of total cell 
death. 
 
a e 
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h 
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There was little difference in toxicity between all gadolinium liposome formulations 
studied irrespective of incubation times (4, 6, 8, 10 and an additional 24 h) and total 
lipid doses (6, 12 and 18 μg/well). After initial incubation periods (4, 6, 8, and 10 h), 
the cells were allowed to grow for 24 h, LDH release from these cells was minimal in 
all cases suggesting that normal cell growth and proliferation was taking place in 
spite of the presence of gadolinium liposomes (Figure 46). From the liposome 
fluorescence uptake assay, MTT and LDH toxicity assay data, it was concluded that 
the optimal formulation for cellular uptake and Gd cell labelling could be gadolinium 
liposome formulation 1 (Gd.DOTA.DSA/CDAN/DOPE/DOPE-Rhodamine: 
30/40/29.5/0.5 mol %), administered at a total lipid dose of 12 μg/well (48-well plate, 
containing 0.716 μg/well of Gd) and an incubation period of 8 h. The zeta potential of 
gadolinium liposome formulation 1 was found to be 51.8 ± 3.58 mV, which 
corroborates the positive charge of this liposome formulation.  
 
Although the MTT cell viability and LDH toxicity assays do not reveal major 
differences between liposome formulations 1, 2 and 7, formulation 1 has shown 
consistent uptake and an acceptable low level of toxicity. This formulation contains an 
optimal mol % of cationic and neutral lipid for effective cell entry and the use of 30 
mol % gadolinium lipid in the formulation, resembles molar ratios of gadolinium lipids 
used by others formulating gadolinium liposomes.218,244 
 
3.1.4 Inductively Coupled Plasma – Atomic Emission Spectroscopy (ICP-MS) 
of Gadolinium Liposomes 
 
Once favourable in vitro conditions for gadolinium liposome cellular uptake were 
determined, ICP-AES studies were carried out using cell lysate post incubation with 
gadolinium liposome formulation 1 to further assess the amount of Gd internalised 
into the cells more precisely. The cell lysates were subjected to nitric acid destruction, 
and the samples analysed for their 157Gd content. From this, it was determined that 
21% of the administered Gd was retained within the cells, this is equal to 0.150 μg of 
Gd per well (~ 80, 000 cells), amounting to 1.880 picograms of Gd per HeLa cell. This 
result is within a 10% error in comparison to the fluorescence uptake assay results 
obtained for liposome 1, which showed uptake for this liposome to be ~ 31 % (see 
Figure 41, c: liposome 1, 12 μg/well, containing 0.716 μg of Gd per well), and 
validates this fluorescence uptake method as a quick and simple method for 
screening large numbers of differing formulations prior to more accurate ICP-MS 
analysis of Gd content.  
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3.1.5 MRI Visualisation of Gadolinium Liposome Labelled Cells 
 
The ability of gadolinium liposome formulation 1 to produce in vitro MRI contrast 
enhancement post administration to cells was assessed with the labelling of HeLa 
cells. The optimised liposome dose of 12 μg per well, was scaled up 12.5 fold in order 
to label approximately 1 x 106 HeLa cells. After 8 h incubation with gadolinium 
liposome formulation 1, cells were spun into pellets in PBS and imaged by MRI at 4.7 
T using a spin echo T1 weighted sequence. The MRI analysis of HeLa cell pellets 
labelled with gadolinium liposome 1 produced a brightly visible mass of cells, and the 
T1 value for these cells was measured (Table 5). The T1 values measured for the 
labelled cells were ~ 65% lower than the level measured in control cells labelled with 
control liposomes containing no Gd (Table 5). This promising result demonstrated the 
cell labelling efficiency of the novel gadolinium liposome formulation 1 in vitro. 
 
 
Table 5.  T1 values for gadolinium liposome formulation 1 incubated with HeLa cells and 
controls (sample 3; control liposome: CDAN/DOPE/DOTA.DSA: 40/30/30 mol %). Gadolinium 
liposome labelled cells were ~ 68% brighter than HeLa cells with no labelling. 
 
T1 weighted images of the samples are shown below (Figure 47), here vial 2 contains 
a clearly visible bright cell pellet, demonstrating the cell labelling efficiency of 
gadolinium liposome 1, and hence successful MRI visualisation of the labelled HeLa 
cells. 
 
 
Figure 47. T1 weighted images obtained of samples 1-5 (Table 5). Vial no. 2 contains a cell 
pellet of ~ 1 x 106 HeLa cells (in PBS), labelled with the optimised gadolinium liposome 1. 
Here, a 65% signal T1 enhancement is measured from these cells, compared to the control 
liposomes (eppendorf 3, where the formulation contained no Gd). 
Sample no. Sample T1 (msec) 
1 Gadolinium liposome 1 in water 311.4 ± 40.10 
2 Gd liposome 1 incubated with HeLa cells 688.6 ± 53.60 
3 Control liposome incubated with HeLa cells 1940 ± 65.95 
4 HeLa cells alone 2149 ± 92.70 
5 PBS 1750 ± 47.80 
1         2         3         4         5 
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3.1.6 Fluorescence Microscopy of Gadolinium Labelled Cells 
 
In order to examine the intracellular uptake of gadolinium liposome formulation 1 into 
HeLa cells, we chose to take advantage of the imaging-bimodality of this liposome, in 
that a fluorescent lipid was included with the paramagnetic liposome (DOPE-
Rhodamine). In this instance, the cell labelling dose was scaled up for the labelling of 
1.25 x 105 HeLa cells, and any non-internalised gadolinium liposomes not taken up 
were washed away after the conclusion of the uptake period of 8 h. Fluorescence 
microscopy revealed that the cellular uptake of these bimodal gadolinium liposomes 
led to intracellular, cytosolic accumulation of the fluorescent label which is in 
accordance with an endocytosis-mediated uptake (Figure 48). This result is 
consistent with successful Gd labelling implied by reduction of T1 values, relative to 
controls (see Table 5). 
 
  
 
 
Figure 48. Left: bright field image of HeLa cells labelled with gadolinium liposome formulation 
1, middle: red fluorescence image of HeLa cells labelled with this formulation, and right image: 
merged bright field and fluorescence image (40 × magnifications).  
 
The labelled HeLa cells were further examined by confocal microscopy and images 
were obtained in a serial manner through the cells (Figure 49). These results show 
an ample level of fluorescence visible within the cell cytoplasm due to the DOPE-
Rhodamine lipid included in the formulation, and hence, in addition to the MRI results, 
also provide proof of gadolinium liposome uptake into the HeLa cells. It is clearly 
apparent that uptake is ubiquitous throughout the cytoplasm, the cell nucleus is 
clearly visible, and contains no fluorophore, suggesting that the lipids may not 
interfere with cellular DNA processes (Figure 49). The appearance of localised 
hyperintense fluorescence dots in these confocal images may indicate the endosomal 
enclosure of the DOPE-Rhodamine probe. Further analysis of the Z plane through 
the cells did not reveal these regions to be outside of the cell or liposomal aggregates 
on the surface (see Figure 49, part b). For these initial fluorescence microscopy 
studies the cells were not counterstained further (for example with the nuclear 
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labelling dye DAPI) in order to observe purely, the fluorescence signal from the 
DOPE-Rhodamine lipid within the cells.  
 
 
 
 
Figure 49.  a: X-Y confocal microscopy images obtained from HeLa cells labelled with 
gadolinium formulation 1. Stacks start at bottom of the cell (top left) and show sections 
through the cell, ending at the cell surface (bottom right), stack thickness: 0.05 µm, at 40 x 
magnification. b: Confocal Z plane projection through the cell (thickness: 0.50 µm, beam 
wavelength; 543 nm) at 40 x magnification. 
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3.1.7 Plasmid DNA Transfection with Gadolinium Liposomes 
 
The cationic nature of the optimised gadolinium liposome formulation 1 allows for the 
encapsulation of DNA within its aqueous core. This produces bifunctional gadolinium 
liposomes, capable of both labelling cells and delivering nucleic acid payloads into 
cells. This is a valuable characteristic which can be further exploited to achieve a fully 
theranostics approach, whereby the delivery of therapeutic genetic material into cells 
can be monitored by both MRI and fluorescence imaging. Synthetic cationic lipids 
(also referred to as cytofectins) as DNA condensers are considered promising 
nonviral gene carriers in gene therapy.248 These lipids once mixed with polyanionic 
DNA form lipoplexes (liposome plus DNA) which can be used to transfect cells.  
 
The transfection ability of the novel gadolinium liposome 1 for delivering DNA into 
cells was assessed by introducing plasmid DNA encoding for the luciferase reporter 
gene. The expression of the luciferase gene allows for a quantitative measure of 
transfection efficiency in cells. The luciferase assay system (Promega) was used to 
assess the transfection ability of gadolinium liposome formulation 1. Here, once the 
gene is transcribed and the enzyme luciferase is produced, the substrate luciferin is 
then added, the product of which gives oxyluciferin. This process produces 
bioluminescence once the enzyme and substrate have reacted. This emission is then 
measured on a luminometer and the amount of light is proportional to the transfection 
efficiency of the gadolinium lipoplex system.   
 
HeLa cells were transfected with lipoplexes containing either; the gadolinium 
liposomes, control Gd free liposomes, and Trojene® (Trojene is a commercial 
transfection agent composed of a 1:1 DOPE and CDAN formulation) complexed with 
plasmid DNA (all liposomes were ~ 250 nm in size). The Trojene® transfection 
protocol was used to prepare the lipoplexes.250 The lipoplexes were prepared by the 
addition of plasmid DNA to the gadolinium liposomes. This led to the formation of 
lipoplexes as evident from the increase in size of the gadolinium liposomes once 
DNA was encapsulated. The lipoplexes were then incubated with HeLa cells for 4 h. 
After this incubation period the cells were washed, the media replaced and 
transfection was allowed to take place over a 24 h period. The cell lysates were 
analysed for their bioluminescence content once luciferin was added, and this 
emission was normalised to the total cell protein content using the BCA (bicinchoninic 
acid) assay and expressed as relative light units per mg of protein (RLU/mg protein). 
The transfection data obtained showed the transfection efficiency of the gadolinium 
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lipoplexes to be at an acceptable level when compared to the commercial 
transfection agent Trojene® (Figure 50). The transfection efficiency of Gd liposomes 
is a log lower than Trojene® which can be explained by the lower molar ratio of 
cytofectins (CDAN). 
 
 Figure 50. Gadolinium lipoplex (gadolinium liposome 1 plus DNA, black bar) transfection of 
HeLa cells compared with control Gd-free lipoplex (white bar) transfection, and Trojene® 
(CDAN/DOPE: 50/50 mol %, grey bar).  
 
 
Interestingly, transfection and therefore effective DNA encapsulation in liposomes 
does not appear to be affected by presence of Gd3+ metal, as the transfection levels 
are very similar for both lipoplexes prepared with the Gd.DOTA.DSA and Gd free 
DOTA.DSA lipids (Figure 50, black and white bars). This result confirms the 
suitability and transfection “inertness” of the Gd.DOTA.DSA lipid in terms of its lack of 
interference with the functional DNA, and validates its use in the preparation of 
bifunctional paramagnetic liposomes. The cytotoxicity of the gadolinium lipoplex was 
also investigated using the LDH assay and was found to be no greater than 10 % 
(Figure 51). 
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Figure 51.  LDH assay of lipoplexes used in luciferase transfection assay. Lipoplexes were 
added to HeLa cells at the same dose used in transfection studies and incubated for the same 
4 h period. After which the cells were washed, the media replaced and the level of cell death 
due to the added lipoplexes was measured 24 h later.  
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3.1.8 In Vitro Evaluation of Gd.DOTA.DSA: Conclusions 
 
Gadolinium liposome formulation 1 mediated transfection of HeLa cells was 
investigated with plasmid DNA (pDNA) expressing the luciferase gene. Here, the 
level of luciferase enzyme activity in cells post pDNA delivery represents a 
quantitative measure of transfection efficiency. Gadolinium liposome formulation 1 
was combined with pDNA to form Gd lipoplexes (Figure 50). Gadolinium liposome 
formulation 1 mediated transfection appears to be comparable to Trojene® mediated 
transfection, demonstrating that the Gd incorporation does not interfere with 
liposome-mediated transfection of HeLa cells to any perceptible degree. Furthermore, 
successful Gd lipoplex mediated transfection of HeLa cells provides functional proof 
for gadolinium liposome cellular entry by endocytosis followed by endosomolysis and 
cytosolic accumulation, as observed by fluorescence microscopy, since transfection 
is contingent on successful endocytosis and endosomolysis. Gd lipoplex particles 
prepared with gadolinium liposome formulation 1 were also shown not to be toxic to 
the cells and normal cell proliferation was not affected to any major degree (Figure 
51).  
 
The mechanism of cationic liposome entry into cells is believed to occur through 
endocytosis (pinocytosis).251 However, in addition to this, it is thought that other 
events occurring within the plasma membrane can also be causative of cellular 
uptake, including membrane destabilisation reactions. Lipoplexes that contain DOPE 
in particular, have been shown to be capable of fusion to both the cellular and 
endosomal membranes. Xu et al. have postulated that the DNA is released from the 
cationic lipid/DNA complexes in cells by the action of anionic lipids initially located in 
the cytoplasmic face of the endosome.252 Here, it is thought that cationic lipoplexes 
are initially internalised into the cytoplasm through electrostatic interactions with the 
cell membrane. This complex is then taken up into the early endosomes, and causes 
the destabilisation of these endosomes, inducing a flip-flop exchange of the anionic 
lipids from the cytoplasmic facing endosomal monolayer, which laterally diffuse and 
mix into the complex. This leads to the formation of charge neutral ion pairs with the 
cationic lipids and the displacement of the DNA into the cytoplasmic milieu.  
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3.2 In Vivo Evaluation of Gadolinium Liposomes 
 
The effective cellular signal enhancement properties of Gd.DOTA.DSA in vitro led us 
to investigate the potential of paramagnetic liposomes prepared with this lipid for in 
vivo imaging of tumours. The ability to tune liposome size, surface charge and 
specificity allows for potential pathological imaging such as the imaging of solid 
tumours in vivo. This tuning of liposomes is made possible by adjusting the 
composition of the liposome formulation. Surface charges tending to neutrality are 
best suited for in vivo purposes in order to reduce the recognition of liposome 
particles by plasma proteins and the reticuloendothelial system (RES). This can be 
achieved through the inclusion of charge neutral lipids in the liposome formulation. 
The blood circulation time of the liposomes can be prolonged by incorporating a PEG 
polymer tethered onto a lipid and incorporated into the liposome formulation. Finally, 
the liposomal accumulation in sites of pathology such as tumours can be achieved by 
tuning their size, or by adding targeting moieties to the liposome, either directly 
attached to the surface or inserted into the liposome bilayer. These aforementioned 
points are further discussed in forthcoming paragraphs.  
 
3.2.1 In Vivo Considerations of Liposome Size 
 
Liposome based therapeutics have found their way to the clinic over the last few 
decades. The use of liposomes as drug delivery systems in cancer therapy has been 
achieved by formulations such as Doxil® which consists of a liposome formulation 
encapsulating the anti-cancer drug doxorubicin. This liposome formulation has been 
approved for clinical use in AIDS-related Kaposi’s sarcoma, and recurrent and 
metastatic breast cancer.253 Doxil® has a size distribution of between 85 – 100 nm. 
This size range is considered optimal for the accumulation of liposomes in solid 
tumours due to the characteristics of tumour tissue. Tumour tissue has been 
described to possess a universal affinity for lipidic and macromolecular agents, 
termed the enhanced permeation and retention effect (EPR), whereby 
macromolecular agents accumulate in tumour tissue. EPR was first introduced by 
Maeda et al.,254 here, it is believed that tumour properties such as increased 
angiogenesis, a heterogeneous and destructive vascular infrastructure, impaired 
lymphatic drainage and a “leaky” endothelial layer are all factors that contribute to the 
accumulation of macromolecular structures within tumour tissue (Figure 52).  
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The EPR effect has become a standard model for the targeting of macromolecular 
drugs and polymeric or liposomal macromolecules to tumours. These agents are 
easily adapted for the imaging of tumours through their modification to include an 
imaging probe or moiety for signal localisation. The key mechanism here, being the 
retention of macromolecules in solid tumours, in contrast to low-molecular weight 
agents, such as Gd.DTPA (Magnevist™) which are re-circulated into blood through 
diffusion and cleared through the kidneys in relatively short periods post injection. 
This retention effect or particle accumulation within tumour tissue is also referred to 
as passive-targeting, and it has been shown that due to this effective phenomena 
very high levels (10-50 fold) of polymeric drugs can accumulate at tumour sites within 
a few days.255 The mechanism of tumour accumulation of nanoparticles in tumour 
tissue has been established as the extravasation of large molecules through the 
disrupted endothelium lining tumour blood vessels. Yuan et al. have shown that the 
maximum particle size threshold above which the particles can no longer extravasate 
through the endothelial layer is approximately 400 nm.256  
 
 
 
 
 
 
 
Figure 52. The EPR effect, normal tissue does not have endothelial gaps wide enough to 
allow for macromolecular or nanoparticulate agents to leak into the extracellular tissue lining 
blood vessels. Tumour tissue has a disrupted endothelial layer, allowing for larger particles to 
“seep” into the tumour extracellular domain.  
 
Normal tissue 
Tumour tissue 
Erythrocyte 
Macromolecules/nanoparticles
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It has been reported that the pore sizes in solid tumour vasculature vary from 100 – 
780 nm, which is considerably larger than junctions in normal tissue where the gaps 
are usually < 6 nm. 257 
 
We chose to take advantage of this effective accumulation of macromolecular 
particles in tumour tissue by designing gadolinium liposome formulations to observe 
signal enhancement of tumour tissue in vivo by MRI, and ex vivo by fluorescence 
microscopy of excised and sectioned tumour slices.  
 
In addition to complying with the tumour extravasation size threshold, a further 
reason for liposome size to remain within the 100 nm range for in vivo injections is 
due to clearance of large liposomes through the liver. Large liposomes are taken up 
by liver cells which include hepatocytes and Kupffer cells, liposomal particles may 
accumulate in liver or spleen tissue due to the larger endothelial lining in these 
organs.  
 
3.2.2  Liposome Surface Charge 
 
It has been shown that liposomes bearing a surface decorated with the neutral 
hydrophilic PEG polymer benefit from prolonged circulation times with half lives 
reported from 2 to 24 h in rodents, and as high as 45 h in humans.258 The theory here 
is that surface-grafted PEG liposomes have reduced uptake by liver cells as the 
liposomes are not effectively bound by plasma proteins.259 These liposomes are also 
referred to as sterically stabilised liposomes. Here, the PEG layer sterically inhibits 
both electrostatic and hydrophobic interactions of plasma components with the 
liposome bilayer. For in vivo purposes, phospholipids with neutral head groups have 
been incorporated in the liposome formulation, these include but are not limited to; 
1,2-dioleoyl-sn-glycero-3-phosphocholine (DOPC), 1,2-distearoyl-sn-glycero-3-
phosphoethanolamine (DSPC) or 1,2-dimyristoyl-sn-glycero-3-phosphocholine 
(DMPC) lipids. The utilisation of neutral lipids in addition to the incorporation of 
between 5-10 molar ratios of a PEGylated lipid in the liposome formulation, provides 
steric stabilisation and protection from blood plasma proteins such as opsonins, and 
leads to the reduction of Kupffer cell uptake. It is thought that stabilisation occurs by 
the formation of highly hydrated shields of polymer molecules around the liposome 
surface. Due to this “shielding” characteristic, these types of liposomes are often 
referred to as “Stealth” liposomes.  
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3.2.3 Liposome Tumour Specificity 
 
In addition to the accumulation of liposomal particles within tumour tissue, their 
specificity to tumour sites can be improved through the use of receptor targeting 
approaches. This strategy involves the use of targeting moieties such as anti-bodies, 
peptide ligands, glycoproteins or small molecular ligands either conjugated to the 
surface of the liposome, or incorporated into the liposome bilayer by previous 
tethering to a lipid anchor. This effective approach leads ultimately to the 
internalisation of liposomes into tumour cells through endocytosis. 
 
 A targeting approach can increase the specificity of the interaction of liposomes with 
cancer cells and can be exploited to selectively deliver drugs into these cells. The 
targeting components can be directed to receptors that are over-expressed or 
selectively expressed on cancer cells. 260 This type of targeting to tumour tissue has 
been referred to as “active-targeting”. Allen et al. have shown the specificity of 
immunoliposomes designed with anti-body fragments on their surface, towards 
cancer cells.261  
 
Taking into consideration the aforementioned tenets, the novel gadolinium lipid 
Gd.DOTA.DSA was incorporated into liposome formulations in order to test the 
efficacy of such gadolinium liposomes for the imaging of xenograft tumours in mice.  
 
 
3.2.4 Preliminary In Vivo Evaluation of Gd.DOTA.DSA 
 
Prior to establishing a tumour model for MRI using gadolinium liposomes in vivo, 
preliminary experiments were carried out using Gd.DOTA.DSA 2, involving the direct 
intramuscular (IM) injection of gadolinium liposomes made with this lipid. The aim 
here was to assess MRI signal enhancement post injection of a high concentration of 
gadolinium liposomes containing Gd.DOTA.DSA. Liposome formulations consisting 
of Gd.DOTA.DSA, and DOTAP lipids (50: 50 mol %, gadolinium formulation 9) were 
injected into the hind leg muscle of C57BL/6 mice and the mice were imaged at 5 
min, 24 h and 7 days post injection at 4.7 T (Figure 53). Control liposomes made with 
Gd not complexed into the lipid (DOTA.DSA) were also injected in the opposite leg 
muscle of the mice. 
 
 
 a 
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Figure 53. T1-weighted MR images of intramuscular injection of gadolinium liposome 
formulation 9 into mice hind leg muscle, a: pre-injection slice, b: 5 min post-injection, c: 24 h 
post-injection and d: 7 days post injection. The T1 images show a clear enhancement 
observed at 5 min and 24 h post-injection (area within white circles, b and c) of the gadolinium 
liposomes. The clearance of the liposomes is also apparent 7 days post-injection as a loss of 
signal (d).  
 
Figure 53 shows the results of IM injections of the cationic Gd liposomes, we can see 
that within just 5 min and at 24 hours the injected region appears bright and a positive 
enhancement is visible (Figure 53, c and d). Signal enhancement appears to 
become more diffuse from 5 min to 24 h post-injection in the muscle tissue, this 
maybe due to the diffusion of the liposomes throughout the muscular region (white 
circles, Figure 53). In addition, the spreading of the liposomes as observed (c to d, 
Figure 53) may be due to the accumulation of interstitial fluid within the injected site 
and the mixing of the gadolinium liposomes with the accumulated lymphatic fluid. The 
gadolinium liposomes also appear to be cleared from the injection site within 7 days 
post injection which suggests clearance of the gadolinium liposomes from the site of 
injection. This promising data led us to develop further gadolinium liposome 
formulations for systemic circulation in vivo, with the aim of tumour imaging by MRI, 
utilising the widely reported EPR effect.  
Pre-injection 5 min post-injection 
24 h post-injection 7 days post-injection 
+ Gd  - Gd  + Gd  - Gd  
+ Gd  - Gd  + Gd  - Gd  
water phantom 
water phantom 
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3.2.5 Serum Aggregation Study with Gadolinium Liposomes 
 
Successful circulation of liposomes post intravenous injection in vivo may be 
hampered by events that can lead to their rapid clearance, such as their binding to 
serum proteins, in particular if the liposome surface is charged. The binding of serum 
proteins (opsonins) to liposome complexes may lead to structural re-organisations 
which can lead to the aggregation or dissociation of the liposomes. Aggregation can 
result in rapid clearance and increased toxicity of the injected liposomes. 
Subsequently, for the purpose of our in vivo tumour imaging efforts using the novel 
gadolinium lipid Gd.DOTA.DSA 2, we constructed neutral liposome formulations. 
However, the assessment of liposome aggregation in a serum model is necessary 
prior to injection. In this instance, we replaced the in vitro suited optimised cationic 
formulation 1 with a charge neutral gadolinium liposome formulation consisting of 
Gd.DOTA.DSA/DOPC/Cholesterol/DSPE_PEG2000 (30/32/30/7 mol %, gadolinium 
liposome formulation 10). This formulation also contained DOPE-Rhodamine (at 1 
mol %), for fluorescence microscopy following histology. This formulation was 
rendered stable to biological fluids by the incorporation of a stealth biocompatibility 
layer comprised of PEG, tethered to a distearoylphosphatidylethanolamine (DSPE) 
lipid anchor.  
 
Cholesterol was incorporated into the formulation since this lipid induces diverse 
effects on the liposomal bilayer. Cholesterol has been shown to increase the head 
group spacing in liposome formulations and stabilise the resulting bilayer 
membranes.262 Here, cholesterol presence in the liposome formulation controls 
membrane permeability of both fluid and rigid bilayers by inducing conformational 
ordering of the lipid chains (Figure 54). In addition, cholesterol can reduce serum 
induced aggregation as a direct result of its neutral charge.186 
 
In addition to cholesterol, the inclusion of DOPC in these liposome formulations is 
thought to add to the stability of the gadolinium liposomes, since this unsaturated 
phospholipid, in combination with cholesterol has been shown to yield monodisperse 
and stable liposomes with high relaxivities. Strijkers et al. have obtained cryo-TEM 
(transmission electron microscopy) images of liposomes containing cholesterol and 
DOPC, where spherical particles of good size (~ 100 nm) were obtained. In contrast, 
for gadolinium liposomes without cholesterol or with the saturated phospholipid 
DSPC, triangular shaped vesicles were observed. 242 
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Figure 54. Influence of cholesterol lipid on liposome bilayer permeability and rigidity. 
 
The serum aggregation effects of six liposome formulations were tested for their size 
aggregation in serum over a 10 h incubation period at 37 ºC. The molar ratio of the 
PEG lipid was adjusted for each formulation in order to test the effect of small 
increments of this stabilising lipid on liposome aggregation in serum. Initially, three 
gadolinium liposome formulations were tested for their aggregation in serum (see 
Table 6). Gadolinium liposome formulations were formulated and their size and 
polydispersity (PI) measured using photon correlation spectroscopy. The liposomes 
were sonicated for an appropriate length of time (30 min) in order to ensure an overall 
size uniformity of approximately ~ 100 nm.  
 
 
 
Table 6. Sterically stabilised gadolinium liposomes investigated for in vivo i.v injection. 
 
Liposome Formulation (mol %) 
 
 
 
Gd.DOTA.DSA 
 
DOPC 
 
Cholesterol
DOPE-
Rhodamine
DSPE-
PEG2000
 
Initial size 
(nm) 
PI 
 
30 
 
34 
 
30 
 
1 
 
5 
 
104.9 ± 34.6 
 
0.420 
30 33 30 1 6 114.5 ± 45.3 0.201 
30 32 30 1 7 104.3 ± 36.8 0.309 
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Once formed, the gadolinium liposomes were added to a 1:1 solution of fetal calf 
serum and HEPES buffer (20 mM, NaCl, 135 mM, pH 6.5) and incubated at 37 °C 
with their size and polydispersity index measured every hour for up to ten hours. 
These results indicated that there is indeed very little aggregation of the PEGylated 
liposomes as measured as a function of their size increase (Figure 55).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 55. The size (a) and polydispersity (b) distribution of PEGylated liposomes (Table 6) 
over a 10 h incubation period at 37 °C was measured by photon correlation spectroscopy. No 
major increase in size was observed.  
 
In order to test the effect of the chelated gadolinium of the Gd.DOTA.DSA lipid on 
liposome aggregation in serum, the above described incubation experiment was also 
carried out on three analogous liposome formulations containing the Gd free 
DOTA.DSA lipid in place of the gadolinium lipid (see Table 7).  
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Table 7. Sterically stabilised Gd free liposomes investigated for in vivo i.v injection. 
 
 
 
It was expected that the presence of the three carboxylic acid groups of the 
DOTA.DSA lipid (6) would lead to an increase in liposome size due to aggregation 
resulting from ionic effects. However, to the contrary, it was found that the size of the 
Gd free liposomes did not vary to any significant degree over the 10 h incubation 
period (Figure 56). It can be postulated that the presence of the PEG polymer (non-
ionic) on the surface of the liposome particles shields lipid charge, and reduces inter-
particulate attractive Van der Waals forces while increasing the repulsive barrier 
between two approaching liposome particles. Here, lack of aggregation is favourable 
as once liposomes aggregate, their size increases and the particles de-stabilise, 
which leads to their increased recognition by plasma proteins and also accumulation 
within the liver. 
 
PEGylation of liposomes is an excellent means of stabilising liposomes for the 
purpose of prolonging in vivo circulation. Trubetskoy et al. have shown the effect of T1 
signal enhancement of PEGylated gadolinium liposomes in the imaging of lymph 
nodes. This signal intensity was 3.5 fold greater in just 4 min post i.v injection of 
PEGylated paramagnetic liposomes compared to non-PEGylated liposomes.263 
 
The polydispersity index is a measure of the distribution of particles of different size 
and in general, values < 1 and nearing zero are considered optimal for liposome 
vesicles of uniform size and shape. The polydispersities measured for both sets of 
liposome formulations, incorporating Gd.DOTA.DSA or DOTA.DSA, were found to be 
less than 1.  
 
 
 
Liposome Formulation (mol %) 
 
 
 
DOTA.DSA 
 
DOPC 
 
Cholesterol
DOPE-
Rhodamine 
DSPE-
PEG2000 
 
Initial size 
(nm) 
PI 
 
30 
 
34 
 
30 
 
1 
 
5 
 
123.9 ± 43.5 
 
0.455 
30 33 30 1 6 111.6 ± 50.7 0.366 
30 32 30 1 7 114.8 ± 42.9 0.339 
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Figure 56. The size (a) and polydispersity (b) distribution of PEGylated Gd free liposomes 
(Table 7), was measured over a 10 h incubation period at 37 °C by dynamic light scattering.  
 
 
From the data obtained for the serum aggregation studies, it was concluded that no 
significant size increase due to liposome aggregation is envisaged for these 
PEGylated liposome systems. Therefore, it was established to utilise the gadolinium 
liposome formulation with the highest molar ratio of PEG lipid for in vivo use, in this 
case, the gadolinium formulation with 7 mol % DSPE-PEG2000 (Table 6). This 
liposome is hereafter referred to as gadolinium liposome formulation 10 
(Gd.DOTA.DSA/DOPC/Cholesterol/DSPE_PEG2000/DOPE-Rhodamine: 30/32/30/7/1 
mol %).  
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 90 nm 
The zeta potential of gadolinium liposome formulation 10 was also measured. The 
zeta potential of a particle is a measure of the overall charge that the particles have in 
a particular solution. The zeta potential of this liposome formulation should average to 
near zero, as any excess cationic or negative charge can affect the fate of the 
liposomes in vivo and lead to their clearance from the blood pool. A zetasizer 
nanoseries instrument was used to measure the eletrophoretic mobility of gadolinium 
liposome 10 in water and this value was found to be 5.76 ± 0.0673 mV, which is close 
to 0 and the overall surface charge of the liposomes is considered to be neutral.  
 
3.2.6 Cryo-Transmission Electron Microscopy (Cryo-TEM) 
 
In order to assess the uniformity and size distribution of gadolinium liposome 10, 
cryo-TEM images were obtained of the frozen liposomes (Figure 57). These images 
revealed the PEGylated liposome formulation 10 to be perfectly spherical and uniform 
in solution with an average size distribution of ~ 100 nm.  
 
 
 
 
 
Figure 57. Cryo-transmission image of gadolinium liposome formulation 10 
(Gd.DOTA.DSA/DOPC/Cholesterol/DSPE_PEG2000/DOPE-Rhodamine: 30/32/30/7/1 mol %), 
white bar represents 100 nm.  
 
Here, the inclusion of DOPC and cholesterol leads to the formation of uniform 
spherical paramagnetic liposomes as also demonstrated by others.242  
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3.2.7 Relaxivity of PEGylated Gadolinium Liposomes 
 
In order to evaluate the relaxivity efficacy of gadolinium liposome formulation 10, a 
series of liposomes were formulated using the same lipid components studied in the 
serum aggregation experiments. Here, the molar ratio of the gadolinium lipid 
Gd.DOTA.DSA was varied so that r1 relaxivity measurements could be obtained from 
the PEGylated liposomes (Table 8). It was expected that the relaxivity of PEGylated 
liposomes would be higher for these of liposomes, as the PEG polymer layer adds 
further bulk to the liposome macromolecular structure, leading to a decrease in 
rotational tumbling (tr) and an increase in T1 relaxation rates.  
 
 
 
Table 8. Gadolinium liposomes used to calculate r1 relaxivity of PEGylated liposomes for in 
vivo mouse tumour MRI.  
 
From the PEGylated gadolinium liposomes formulated to measure r1 relaxivity T1 
values were generated for 5 PEGylated gadolinium liposomes (Table 8) with Gd 
concentrations within the range 0.089 to 0.384 µmol. The r1 relaxivity of these 
liposomes was found to be very high, 16.879 ± 1.55 mM-1S-1 at 4.7 T (Figure 58), 
which is considerably higher than the non-PEGylated liposomes measured previously 
(4.90 ± 0.60 mM-1s-1 for cationic liposome formulation 1). Here, it can be envisaged 
that the PEG-polymer layer adds bulk to the overall liposome structure, in addition to 
providing further water solubility to the liposomes, leading to a greater degree of 
hydration around the liposomes. This property directly influences relaxation, whereby 
the co-ordinated Gd atom influences the relaxation of many water molecules within 
the second hydration sphere. In addition, the liposome size was smaller for these 
liposomes too, another factor that may contribute to an increased relaxivity.  
 
Liposome Formulation (mol %) 
 
 
 
Gd.DOTA.DSA
 
DOPC 
 
Cholesterol
DOPE-
Rhodamine 
DSPE-
PEG2000 
 
Initial size 
(nm) 
PI 
 
50 
 
13 
 
30 
 
1 
 
7 
 
176.37 ± 42.5 
 
0.498 
40 23 30 1 7 135.93 ± 33.5 0.737 
30 33 30 1 7 238.73 ± 38.5 0.539 
20 43 30 1 7 222.78 ± 47.5 0.669 
10 53 30 1 7 192.40 ± 36.2 0.590 
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Figure 58. Relaxivity of PEGylated gadolinium liposome formulation 10, at 4.7 T and ambient 
temperature. R1 relaxivity is given by the slope of the fitted linear regression of the graph 
(16.879 ± 1.55 mM-1s-1). 
 
Having demonstrated successful bimodal cellular MRI and fluorescence imaging of 
HeLa cells by means of gadolinium liposome formulation 1, in addition to bifunctional 
labelling and transfection, the efficacy of the novel gadolinium lipid Gd.DOTA.DSA 2, 
towards imaging of mouse xenograft tumours in vivo was investigated.  
 
3.3 In Vivo Tumour Imaging with Gadolinium Liposomes 
 
Mouse tumours of human cancer are a good model for preliminary investigations of 
imaging agents and their effectiveness as tumour signal enhancers. The human 
ovarian cancer cell line IGROV-1 was used to induce tumours in Balb/c nude mice. 
Here, cells were injected under the right flanks of 6-8 week old female mice, and after 
two weeks the mice had grown large enough tumours suitable for imaging. Stealth 
gadolinium liposomes (Gd.DOTA.DSA/DOPC/Cholesterol/DSPE-PEG2000: 30/32/30/7 
mol%, also containing 1 mol% DOPE-Rhodamine, total concentration; 30 mg mL-1, 
formulation 10) were prepared in HEPES buffer and injected through the tail vein of 
tumour bearing mice, a method that ensures rapid entry of the liposomes into the 
blood circulation. Prior to injection, baseline MRI scans were obtained on a 4.7 T 
magnet in order to identify the tumour and measure T1 baseline values. Post 
liposome injection, the mice were then imaged at 3 h, 16 h and 24 h post injection. 
T1-weighted images for each time point were obtained and the percent signal 
enhancement as a result of the accumulation of the PEGylated gadolinium liposomes 
within the tumour tissue was calculated from T1 values generated from the tumour 
tissue (Figure 59). 
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Figure 59. a: Pre-injection MR image of induced IGROV-1 tumours under the right flanks of 
nude Balb/c mice, the image on the right represents enlarged image of tumour area marked 
with white arrow. b: MR images 24 h post i.v. injection of stealth gadolinium liposomes 10; the 
pseudo colour-map shows enhancement of tumour area, together with the enlarged image to 
the right of the white arrow. c: T1 measurements from tumour slices 24 h post-injection. d: 
Image enhancement is supported by a 60 % measured reduction in tumour-T1 values 24 h 
post i.v.-injection relative to control liposomes (Gd.DOTA.DSA replaced with Gd free 
DOTA.DSA). 
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As confirmed by T1 measurements of tumours post injection of formulation 10, a clear 
and excellent level of tumour MR signal enhancement is achieved in comparison to 
pre-injection baseline T1 tumour images (Figure 59, a and b). The accumulation of 
the liposomes within the tumour area peaks at the 24 h end point measurement of T1 
signal, and conveys the gradual accumulation of the gadolinium particles within the 
tumour tissue. The presence of signal enhancement around the tumour vicinity is also 
visible and may suggest macrophage activity, or rather the uptake of the gadolinium 
liposomes by these cells. It has been shown that a prerequisite for the EPR effect is 
that the plasma concentration of the macromolecule or polymeric drug should remain 
high for > 6 h in rodents. 255 These results clearly demonstrate the prolonged 
residence time of the stealth gadolinium liposomes in the blood pool as signal 
enhancement peaks at 24 h post injection in our experimental model.  
 
At 24 h post injection, the mice were sacrificed and their tumours excised. The 
tumours were frozen, fixed and subjected to cryo-sectioning, where 10 μm sections 
were cut and the slides analysed for their fluorescence using microscopy. The 
inclusion of the red fluorescent lipid DOPE-Rhodamine in the gadolinium liposome 
formulations allows for the bimodal assessment of liposome localisation within the 
tumour tissue. As expected, histological analysis of the tumour sections revealed a 
very high level of fluorescence signal in the tumour tissue (Figure 60). These 
encouraging results confirmed the presence of the liposomes in the tumour tissue 
and revealed an extremely heterogeneous pattern of fluorescence emission 
throughout the tumour (tumour sections were taken from the surface levels and mid 
to deep middle layers of the tumours). The appearance of hyper fluorescence signals 
within the tumour tissue was observable. These fluorescence intensity results 
provided qualitative visual congruence with the MR images and validated the 
accumulation of the stealth gadolinium liposomes (formulation 10) within the 
xenograft tumours. Tumour tissue has microvessels with large fenestrations and as 
such the gadolinium liposomes are able to extravasate into the tumour. These 
extravasated liposomes are not cleared due to an impaired lymphatic drainage 
system and may accumulate within the tumour extracellular fluid (see Figure 60, c). 
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Figure 60. Fluorescence microscopy of tissue sections post gadolinium liposome injection. a: 
surface slices from the IGROV-1 tumours, images on the left are fluorescence images, 
images on the right are corresponding bright field. b and d: are mid-tumour slices. Other filters 
other than for Rhodamine were applied to tumour sections; no fluorescence was visible under 
these settings confirming the emission obtained to be due to the DOPE-Rhodamine included 
in the gadolinium liposome formulations alone (x 20). No fluorescence was observed from 
tumour sections of control liposomes injected containing no DOPE-Rhodamine (data not 
shown).  
 
 
From the fluorescence images obtained (see Figure 60), it can be concluded that the 
IGROV-1 tumours do indeed posses great spatial heterogeneity. As a consequence 
extravasated liposomes are heterogeneously distributed throughout the tumour and 
are mainly located in perivascular regions. The fluorescence pattern obtained from 
the tumour tissue may be indicative of chaotic structures within tumours, including; 
collapsing vessels, and fragile vessels lacking a smooth muscle cell lining. The 
hyper-intense areas of more localised fluorescence may also be due to hypoxic or 
a 
b 
c 
  138
necrotic tissue resulting from collapsing vasculatures, which are unable to meet the 
rapid growth of the surrounding cancer cells. It has been shown that only 20-80 % of 
the microvessels in tumours are perfused at any given time, which can explain the 
substantial heterogeneity of the microcirculation.264  
The fluorescence images obtained from the tumour periphery areas presented some 
hyper-intense emissions visible in patches (Figure 61). These signal intensities may 
be due to the increased host macrophage activity around tumour marginal regions, 
where it has been shown that macrophages can “cluster”.  
 
 
  
 
 
 
Figure 61. Peripheral tumour sections. a: red fluorescence image of peripheral tumour 
sections, b: corresponding bright field image and c: H & E stained section (x 20, white bar 
represents 50 μm).  
 
 
3.3.1 Laser Ablation – Inductively Coupled Mass Spectrometry of Tumour 
Sections. 
 
The presence of the gadolinium liposomes in the tumour tissue was further validated 
by the analysis of the sectioned tumour slices with laser-ablation inductively coupled 
plasma mass spectrometry (LA-ICP MS). This technique benefits from a coupled 
laser in addition to being capable of producing ICP-MS analysis of metal isotopes. 
LA-ICP MS is an incredibly versatile technique that can produce isotopic analysis of 
solid samples providing the laser can couple with the sample material. Figure 62 
shows the elemental profiles obtained from the mouse tumour sections post analysis 
with LA-ICP-MS. Signal enhancement for both iron and gadolinium at 90, 165, 200 
and 230 seconds were observed, this corresponds to blood present in the section 
and confirms the presence of the gadolinium liposomes in the tumour tissue, and the 
blood circulation of these nanoparticles. The signal response for the remaining 
elements, calcium, manganese, copper and zinc are relatively stable across the 
section. 
a b c 
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Figure 62. Single line raster via LA-ICP-MS through a section of mouse tumour showing 
elemental profiles for a: calcium, manganese, iron, copper, zinc, gadolinium and b: scaled to 
show the ion-time response for gadolinium. 
 
In conclusion, the passive targeting of the stealth gadolinium liposomes to tumour 
tissue was achieved. Signal enhancement post i.v injection of gadolinium liposome 
10 in xenograft tumours (n = 3) was monitored by MRI over a 24 h period. Over this 
period, a substantial 60% reduction in tumour-T1 values compared to the situation 
with control liposomes (without Gd) was observed, in addition to visibly enhanced 
tumour-image brightness (Figures 60 and 61). This outcome suggested that the 
neutral gadolinium liposome 10 was in fact a liposome system with a substantial 
systemic half-life capable of long term circulation in the blood and passive targeting to 
the xenograft tumor by an enhanced permeation and retention (EPR) mechanism. 
This finding was supported by fluorescence imaging of tumor tissue slices (post-
mortem) taking advantage of the bimodal imaging capacity of the gadolinium 
liposomes for both MRI and fluorescence microscopy. The fluorescence images 
obtained demonstrate liposome accumulation in subcutaneous tumour xenograft 
grown from implanted IGROV-1 cells.  
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3.3.2 Targeted Tumour Imaging with PEGylated Folate Gadolinium Liposomes 
 
As described previously, liposome accumulation in tumour tissue can be improved 
through the use of targeting moieties that are either conjugated to the surface of 
liposomes, or are attached to lipids that become incorporated within the liposomal 
bilayer. Since successful results were demonstrated with the IGROV-1 xenograft 
tumour model, the same cells were chosen for these series of targeted tumour MRI 
experiments. We chose to exploit the membrane-bound folate receptor (FR) in this 
study, as the natural ligand for this receptor (folic acid) tethered onto a PEG lipidic 
anchor (DSPE-PEG2000(Folate), Avanti Lipids inc, USA). Folic acid is a vitamin that is 
utilised in the biosynthesis of nucleotides and is consumed in very high levels by 
proliferating cells such as cancer cells. In fact, the FR is over-expressed in several 
cancers, in particular epithelial carcinomas such as ovarian cancer, in addition to 
brain, kidney, lung and breast cancers. It has also been shown that aggressive or 
undifferentiated tumours at an advanced stage have an increased FR density and 
this could suggest that cancer therapy could benefit from the broad approach that FR 
mediated drug delivery offers.265 The levels of FR on different cell lines can be 
assessed using immunohistochemistry techniques and fluorescence assisted cell 
sorting (FACS). In terms of FR expression levels, the human nasopharyngeal KB 
carcinoma cell line is considered to have the highest level of FR expression, 
however, the number of cases for this cancer are low in comparison to ovarian 
cancer which has the highest frequency (> 90 % of cases).266 As such, we were 
interested in using this receptor and target model in order to test the efficacy of in 
vivo targeted gadolinium liposomes for the imaging of tumours by MRI. Effective 
signal enhancement is expected here since the FR is expressed in significantly lower 
amounts in normal tissue, limited mainly to kidney tubuli, lung epithelium, and 
placenta tissue.253  
 
Folate targeted technology has been successfully applied to radio-imaging of 
therapeutic agents,267 MRI contrast agents,268  and gadolinium liposomes.269 Choi et 
al. have demonstrated the use of folate-targeted iron oxide nanoparticles for the 
imaging of induced KB tumours  and showed these particles to have a 38% signal 
intensity decrease compared to controls.270 The FR binding affinity (KD ~ 1-10 M) does 
not appear to be affected when its ligand, folic acid is conjugated to an imaging agent 
or therapeutic moiety via its γ-carboxyl.271  
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3.3.3 Immunohistochemistry Analysis of Ovarian Carcinoma Cell Lines 
 
In order to establish whether the IGROV-1 cell line does indeed express a sufficient 
level of the folate receptor, FACS analysis of four different cell lines were carried out. 
For this purposes, the α-folate receptor (α-FR) which is a folate transporter with 
restricted expression levels in normal tissues was chosen. To measure the α-FR 
expression levels of the human ovarian cell lines IGROV-1, OVCAR-3 and HeLa 
cervical cancer cells, both fluorescence microscopy and flow cytometry experiments 
were carried out. In addition to these cell lines a breast cancer cell line (SKBR-3) was 
also analysed as a negative control cell line with no FR expression. Cells were grown 
in folic acid free media and incubated with serum to block any non-specific 
interactions. Immunostaining was carried out with a monoclonal antibody (MAb 
Mov18/ZEL, Axxora, UK) specific for the α-FR, and post incubation with this antibody, 
a secondary FITC labelled antibody (Goat anti-body IgG, FITC conjugated, Santa 
Cruz Biotechnology, inc. USA) was allowed to incubate with the cells. Post staining, 
the cells were fixed and analysed by fluorescence microscopy. Firstly, qualitative 
results were obtained whereby fluorescence microscopy of the cell lines revealed a 
high level of FITC fluorescence from the IGROV-1 cells, in comparison to the 
OVCAR-3 and the control SKBR-3 cell lines (Figure 63).  
 
 
IGROV-1   OVCAR-3   SKBR-3 
 
Figure 63. Fluorescence microscopy images of three immunostained cell lines for α-FR. The 
presence of a higher level of α-FR is observed for the IGROV-1 cell line. There is some FITC 
fluorescence visible from the stained OVCAR-3 and non visible for the SKBR-3 α-FR negative 
cell line. The blue fluorescence observed is due to DAPI staining, which is a cell nucleus 
labelling agent. The images for the HeLa cell line are not shown as no FITC fluorescence was 
observable from these cells (x 40 for IGROV-1, x 20 for OVCAR-3 and SKBR-3 images). 
 
From the FACS (Figure 64) α-FR expression analysis, where all cell lines were 
cultured under the same standardised conditions using folate free cell culture 
medium, it was shown that the IGROV-1 cell line exhibited a distinctly higher level of 
α-FR expression. The α-FR expression was shown to be in the order: IGROV-
1>>OVAR-3>HeLa>SKBR-3 (Figure 64). 
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Figure 64. FACS analysis of four cell lines for α-FR expression levels. 
IGROV-1 control cells 
IGROV-1 Antibody labelled cells 
96.72%
OVCAR-3 antibody labelled 
OVCAR-3 control 
0.67%
HeLa control cells 
HeLa antibody labelled cells 
0.34%
SK-BR3 control cells 
SK-BR3 antibody labelled cells 
0.14% 
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3.3.4 Folate Targeted Gadolinium Liposomes for Tumour Imaging 
 
Having established the over-expression of the α-FR on the IGROV-1 cell line, folate 
targeted gadolinium liposomes were prepared for specific cell receptor binding and 
uptake into the IGROV-1 tumour cancer cells. These liposomes consisted of a similar 
formulation than the non-targeted PEGylated gadolinium liposomes prepared for 
passive-targeting to tumours in vivo (gadolinium liposome 10). For the folate targeted 
liposomes a 3 mol % of the targeting ligand; DSPE-PEG2000Folate (Avanti Polar 
Lipids inc. USA) was also incorporated into the formulation, rendering 
Gd.DOTA.DSA/DOPC/Cholesterol/DSPE-PEG2000/DSPE-PEG2000Folate/DOPE-
Rhodamine: 30/32/30/4/3/1 mol % (gadolinium liposome formulation 11, see Figure 
65).  
 
 
 
 
Figure 65. Folate-targeted gadolinium liposomes for IGROV-1 tumour imaging in vivo. 
 
The serum aggregation of these targeted liposomes was also assessed as per 
section 3.2.5, no significant change in liposome size was observed over a 24 h 
incubation of folate-targeted liposomes in a FCS: HEPES mixture (data not shown). 
The relaxivity of these liposomes was also measured by formulating a range of 
liposomes with varying Gd.DOTA.DSA lipid concentrations, and was found to be 
comparable to the non-targeted gadolinium formulation 10 (relaxivity for liposomes 11 
is 14.520 ± 1.55 mM-1s-1). The zeta potential of folate-targeted PEGylated liposome 
11 was also obtained, and this value was found to be close to zero, indicating an 
overall neutral charge for these liposomes (zeta potential: 3.21 ± 0.284). These 
liposomes were also formulated with a controlled size of approximately 105.23 ± 19.2 
and a good polydispersity index (0.23).  
DSPE_PEG2000(Folate) 26 
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The folate-targeted liposomes were injected into Balb/c nude mice in an identical 
manner to the non-targeted gadolinium liposomes, with the exception that the folate 
targeted liposomes were injected at half the dose of the non-targeted liposomes. It 
was postulated that due to the presence of the folate targeting moiety, an increase in 
tumour signal will be apparent post-injection by MRI, in comparison to the control 
liposomes (non-targeted). Indeed, this expectation was apparent at just 2 h post-
injection of the folate targeted liposomes (see Figure 67).  
 
 
 
 
 
 
Figure 66. a: MRI of IGROV-1 tumour bearing Balb/C nude mice, from left to right; pre-
injection, 2 h post-injection, 16 h and 24 h post injection of PEGylated gadolinium liposomes 
11 (white arrow shows location of tumour). b: Microscopy images of sectioned liver from 
tumour bearing mice injected with gadolinium liposome 11, these results do not show 
significant accumulation of the liposomes in the liver and c: microscopy images of sections 
from excised kidneys, where the presence of the fluorescent lipid DOPE-Rhodamine and 
therefore gadolinium liposomes is minimal 24 h post-administration (x 20 magnification).  
 
 
Figure 66 presents MR images taken from mice bearing IGROV-1 xenografts that 
were injected with the FR-targeted liposome formulation 11. From these results the 
positive enhancement of tumours 24 h post injection is visible (Figure 66, a) and the 
presence of the liposomes within other organs such as the liver and kidneys was 
found to be minimal (Figure 66, b and c). This suggests that these targeted 
Pre-injection 2 h post-injection 16  h post-injection 24  h post-injection 
a 
b 
DIC Hoechst Fluorescence 
c 
DIC Hoechst Fluorescence 
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gadolinium liposomes do not accumulate in the kidney tissue and therefore subjects 
may not suffer from nephrotoxic adversities reported recently with the use of 
gadolinium based contrast agents.  
 
The measured tumour T1 values show that within just 2 h post i.v. injection the active 
and specific targeting effect of the folate liposomes is apparent and a substantial 65% 
T1 reduction is achieved within 16 h post injection compared to ~ 13% for the non-
targeted gadolinium liposomes. This significant enhancement is observed despite 
injection of targeted liposomes at half the concentration of the non-targeted 
liposomes (Figure 67).  
 
 
 
 
Figure 67. Mouse tumour signal enhancement with folate-targeted (liposome formulation 11) 
and non-targeted gadolinium liposomes (formulation 10), a: tumour T1 measurements at 4.7 T, 
b: signal enhancement (%) calculated from mean tumour T1 values pre and post- liposome 
injections).  
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Following MRI, the mice were then sacrificed and their tumours excised, frozen, fixed 
and sectioned for histological analysis. As with the previous non-targeted liposomes, 
the inclusion of the fluorescent DOPE-Rhodamine lipid in the liposome formulation 
allows for post-mortem analysis of the presence of liposomes within the tumour 
tissue. Figure 68 presents fluorescence microscopy images of sectioned tumours 24 
h post folate-liposome injections. The presence of intense red fluorescence from 
these sectioned tumour slices is indicative of the accumulation of the targeted 
liposomes in the tumour tissue. The T1 tumour signals measured (Figure 60) indicate 
a rapid accumulation of the targeted liposomes, and histological results show that the 
folate-targeted gadolinium liposomes may be accumulating within areas of 
hyperpermeability in the tumour tissue.  
 
 
 
 
Figure 68. Fluorescence microscopy images of IGROV-1 sectioned tumours. Images on the 
left are red fluorescence and on the right are the corresponding bright field images showing 
heterogeneous tumour tissue. (x 20, white bar represent 50 μm).  
 
The fluorescence pattern observed for the targeted liposomes appears to be more 
localised, and the type of diffused and dispersed fluorescence observed for the 
passively accumulated liposomes is not reflected from these images (Figure 68). It 
has been suggested that, in particular with immunoliposomes targeted to tumours, 
there may exist a “binding site barrier” hypothesis that affects targeted liposome 
binding in tumours. Weinstein et al. have suggested that immunoliposomes will not 
penetrate deeply into the tumour but will bind to the first target cells encountered. 272 
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As such, it appears that the non-targeted gadolinium liposomes (see Figure 60) may 
show a better penetration into solid tumours, however, the folate-targeted liposomes 
show a more rapid accumulation within the IGROV-1 tumours. Here, it is important to 
note that the MR signal enhancement data for the folate-targeted liposomes were 
obtained by drawing regions of interest (ROI) around the entire surface area of the 
tumour slices and as such represent signal enhancement of the entire tumour 
section. As the molar ratio of the fluorescence lipid is far less than the amount of 
gadolinium lipid in the liposome formulation (1: 30), this explains the difference in the 
fluorescence and Gd enhancement signal levels within the tumours. In addition, the 
binding site theory may only be a limit of immunoliposomes with bulky 
antibodies/antibody fragments, further work to clarify the localisation of the folate-
targeted liposomes within the tumour, could involve the direct antibody staining of the 
sectioned tumour slices for α-FR expression.  
The enhanced and rapid onset of signal enhancement in the case of the folate-
targeted liposomes may be due to the uptake of the targeted liposomes by the 
tumour cells as demonstrated by the persistence of the signal for up to the 24 h end-
point (see Figure 67, a, b), which also suggests that the rate-limiting step for non-
targeted liposomes is indeed extravasation. Since a near 60% signal enhancement is 
achieved for the non-targeted liposomes only after 24 h post injection, suggesting 
continuous circulation and gradual accumulation of these passively-targeted 
liposomes, which is in line with current EPR theories. The dose used in these 
experiments is also noteworthy, the folate-targeted liposomes were administered at a 
gadolinium lipid concentration of 0.719 μmol per 20g mouse, which in comparison to 
the lower end of the clinical dose at which contrast agents are used (0.01 mmol/Kg), 
makes the injection dose approximately 14 fold lower.  
 
For the folate-targeted liposomes the ligand-liposome ratio was not optimised, at 3 
mol % of the overall liposome formulation, this may have been an excess of targeting 
ligand. It has been shown that effective in vivo tumour folate targeting may only 
require < 0.3 mol% of the ligand.273 It has been suggested that the folate receptor 
function is regulated by cellular folate requirements and therefore even a small 
amount of folic acid is sufficient to trigger the down-regulation of the folate receptor 
cycle.274 However, the observed 65% signal enhancement in our case may suggest 
that perhaps only a slight decrease in ligand ratio may be necessary to achieve even 
higher tumour signal enhancement rates.  
Another interesting point arising from the folate-targeted liposome data obtained may 
be that the folate ligand is indeed retained during circulation. Since if the ligand is lost 
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in vivo during circulation, then the liposome particles would have lost the ability to 
bind to the tumour cells. Gabizon et al. have tested the ligand-liposome association of 
folate targeted liposomes in vivo using an ascetic tumour that did not express folate 
receptors.265 Here, the injected folate liposomes were collected from the ascetic fluid 
48 h after i.v injection and were tested ex vivo for their FR binding on relevant FR 
expressing cell lines. They successfully showed that the folate-targeted liposomes 
retain their FR receptor binding post in vivo injection, and extravasation to the ascetic 
fluid.  These findings suggest that folate targeting for the in vivo imaging of tumours 
presents a robust and broad platform for both tumour imaging and the delivery of 
therapeutic agents over a prolonged period of time to the tumour tissue.  
 
A further interesting observation was made when the folate-targeted liposomes 
(formulation 11), were formed at larger sizes > 100 nm and injected into the Balb/c 
IGOV-1 tumour bearing mice. These liposomes which were on the order of 150-200 
nm in size did not reach the IGROV-1 tumours and were shown to accumulate 
extensively within the liver tissue (Figure 69). Non-targeted liposomes of a similar 
size were also injected for comparison and a significant difference within the liver 
accumulation of the PEGylated folate-targeted liposomes (gadolinium liposome 
formulation 11) and the PEGylated non-targeted liposomes (gadolinium liposome 
formulation 10) was observed 2 h post-injection of the liposomes.  
 
 
Figure 69.  Fluorescence microscopy of liver sections 2 h post gadolinium liposome injections 
of > 100 nm. a: Bright field image of the liver, b: Hoechst stain of liver, c: fluorescence image 
of the liver post non-targeted gadolinium liposome injection (formulation 10) and d: 
a b 
c d 
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fluorescence image of the liver post folate-targeted gadolinium liposome injection (formulation 
11).  
 
From the images in Figure 69 (part c and d), it is apparent that the folate-targeted 
liposomes have a more localised pattern of fluorescence and appear “internalised” 
into cells. This may most likely be as a result of Kupffer cell accumulation, however 
the liver fluorescence observed from the liver histology sections of the non-targeted 
liposomes shows a more distinct pattern of “extracellular” accumulation of the 
liposomes (Figure 69, c). From these results it can be concluded that due to the 
folate ligand on their surface, the folate-targeted liposomes are readily taken up by 
the Kupffer cells, in comparison to the non-targeted liposomes, suggesting that the 
Kupffer cells may have an affinity for the folate ligand. An alternative explanation may 
be that due to the surface folate ligand; the targeted liposomes are recognised by 
certain opsonins in the blood which mark these liposomes for Kupffer cell uptake, 
despite the presence of the PEGylation layer in these formulations.   
 
The fluorescence pattern observed from the liver sections of the non-targeted 
liposomes can be explained by the “endothelial massage” theory put forward by 
Wisse and McCuskey.275. This theory describes the movement of fluid and small 
particles in and out of the Space of Disse, which is the area located between the 
endothelial lining of the hepatic sinusoid and the hepatocytes. This is similar to the 
notion of the squeezing of white blood cells between the endothelial cells within the 
narrow sinusoidal spaces.259 Liposomes are also able to squeeze through 
fenestrations in the liver and due to their deformable nature can be squeezed into the 
Space of Disse and this may only require their transient electrostatic interaction with 
the endothelial lining. It has also been shown that Kupffer cells take up far more 
liposomes per cell than the hepatocytes and this may explain the strong fluorescence 
observed in Figure 69, part c. The uptake of the folate targeted liposomes may be 
due to opsonins binding, a whole host of opsonising proteins have been found that 
may absorb onto liposomal surfaces, amongst these are C-reactive protein, 
fibronectin, complement factor C3b, immunoglobulins, and alpha2-macroglobulin.259 
These results demonstrate the importance of nanoparticle size control and shed light 
on the behaviour of liposomes > 100 nm in size in vivo. Both targeted and non-
targeted liposomes of > 100 nm were shown to accumulate within the liver, 
suggesting that the size of gadolinium liposomes is indeed an important factor in their 
liver clearance and prolonged blood circulation in vivo.  
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3.4 Chapter Summary 
 
The in vitro cationic liposome 1 formulated with the novel Gd.DOTA.DSA lipid 2 was 
shown to be an effective bimodal cell labelling agent, which was made possible by 
mediating the delivery of chelated-Gd to HeLa cells and led to the subsequent 
shortening of cellular T1 relaxation times. This formulation was found to be non-toxic 
to the HeLa cells as assessed by MTT cell viability and LDH toxicity assays. In 
addition, the bifunctional capability of this gadolinium liposome formulation was 
demonstrated by the successful transfection of HeLa cells using a plasmid DNA 
encapsulated version of gadolinium liposome 1. This suggested that this formulation 
is capable of bifunctional labelling with transfection which is consistent with a cell 
labelling mechanism in which gadolinium liposomes enter by endocytosis followed by 
endosomolysis and subsequent cytoplasmic release of the gadolinium, fluorescent 
lipid and DNA.  
 
Further neutral PEGylated liposomes were developed and their serum aggregation 
and magnetic relaxation properties were assessed. Cryo-TEM images of the 
optimised paramagnetic liposome 10, showed this liposome formulation to be 
perfectly spherical and uniform in size (~ 100 nm). The in vivo PEGylated gadolinium 
liposome 10 was shown to enhance MR signal of xenograft tumours in mice 
substantially 24 h post injection, which led to the demonstration of the enhanced 
retention and permeation of these liposomes within the tumour tissue. The bimodal 
imaging approach of tumours using this formulation was successfully demonstrated.  
 
Tumour signals were drastically enhanced when folate-targeted liposomes were 
injected i.v into the same IGROV-1 xenograft models used to assess the passive 
accumulation of the gadolinium liposomes. These active-targeting results showed a 
rapid and persistent tumour signal enhancement, and merit the investigation of signal 
enhancement ability of these liposomes beyond the experimental 24 h time point.  
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4.1.1 Bimodal Fluorescent and MRI Probes  
 
Discoveries in molecular imaging are certain to play a vital role in the early detection, 
diagnosis and treatment of disease, and help decipher the biological mechanisms 
responsible for disease states at a molecular and cellular level. The field of molecular 
imaging has made use of imaging agents that mostly provide single signature 
information. Multi-modal imaging agents have the potential to provide more than one 
signal from a biological sample and in this way can enhance the visualisation of 
biological material.   
A number of multimodal probes with both MR and fluorescence signatures have been 
developed for cell labelling and use in the imaging of developmental biology. Thomas 
Meade and co-workers have been primary developers of such probes, where high-
molecular weight polymers with both gadolinium and fluorescent moieties 
(tetramethylrhodamine) were synthesised (Figure 70).276 These highly effective 
bimodal probes were used to study the initial stages of embryonic development, and 
were shown not to interfere with the normal development of the Xenopus laevis 
embryos post-injection. More recently, Brekke et al. demonstrated the use of one of 
these bimodal polymeric contrast agents (GRID, a gadolinium rhodamine dextran 
polymer) for the labelling of neuronal stem cells. The addition of this agent to the cells 
did not appear to affect the cellular viability, stem cell migration mobility or 
multipotency of these sensitive and delicate cells. This study also demonstrated the 
utility of a bimodal imaging approach, whereby the labelling of the neuronal stem cells 
was confirmed in vitro by both fluorescence and T1-weighted MRI.277 Neuronal stem 
cells were also labelled with GRID ex vivo, and their transhemispheric migration to 
stroke lesions was assessed by both longitudinal in vivo MRI and fluorescence 
analysis of histology samples from rat brain specimens.96  
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Figure 70. Two bimodal polymeric contrast agents.276 
 
 
Bimodal agents with target specificity have also been developed, Dirksen and co-
workers have recently designed and synthesised a bimodal contrast agent based on 
a cyclic peptide (target-specific sequence), Gd.DTPA, and conjugated to the dye 
Oregon green 488. This dual-labelled probe was shown to be suitable for both MRI 
and optical imaging of angiogenesis (Figure 71).278 
 
 
 
 
 
 
 
Figure 71. An angiogenesis specific bimodal fluorescent and paramagnetic contrasts agent 
(dotted line indicates targeting region).278 
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As demonstrated in Chapter 3, MRI and optical techniques are excellent 
complementary imaging methods, and as such a further aim of this project has been 
to synthesise a novel bimodal Gd lipid that also incorporates a fluorescent moiety. 
This contrast agent is thought to be valuable for the bimodal imaging of tumours or 
labelled cells, since in addition to MRI, fluorescence microscopy or in vivo 
fluorescence imaging could provide further proof of liposome localisation, and both a 
qualitative and quantitative analysis of liposome biodistribution may be achieved.  
 
4.1.2 Synthesis of the Novel Bimodal Lipid: Gd.DOTA.Rhoda.DSA 
 
Fluorescent lipids have been used extensively for the investigation of lipid trafficking 
and sorting in both model and real cellular membranes, in particular, fluorescent lipids 
have been used to highlight cellular processes such as membrane fusion.279 In 
principle there are two regions on lipids where a fluorophore may be attached, this is 
achieved either through covalent attachment of the fluorescent moiety to the head 
group region or attachment to the lipid chain. The most frequently utilised fluorescent 
lipids are fluorescent analogues of DOPE; which are DOPE-Rhodamine and DOPE-
NBD (Figure 72). 
 
 
 
 
Figure 72. Structures of two commonly utilised fluorescent lipids, DOPE-NBD and DOPE-
Rhodamine. 
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To our knowledge only one type of bimodal lipidic molecule has been developed thus 
far that incorporates both a paramagnetic contrast agent and a fluorophore onto a 
single molecular framework. Li et al. have designed and synthesised this bimodal 
probe which has lipophilicity due to the attachment of a single alkyl chain, that can 
incorporate into lipidic membranes (Figure 73).280 This bimodal agent was used to 
label low-density lipoprotein (LDL) particles for the in vivo detection of LDL receptors. 
 
 
 
 
 
Figure 73. PTIR267: a bimodal agent for MR and fluorescent imaging of low density 
lipoprotein receptors.280 
 
Most bimodal liposomal agents that have a fluorescent and paramagnetic signal are 
based on the use of two separate lipids in the liposome formulation, one lipid 
component bearing the Gd moiety and another a fluorescent moiety usually in place 
of the head group (most commonly DOPE-Rhodamine is used).220 However, we 
designed a bimodal lipidic molecule bearing both fluorophore and contrast agent 
groups on the same structure, in order to create a more robust bimodal liposome for 
both MR and fluorescence microscopy. The retrosynthetic analysis for this novel lipid 
(Gd.DOTA.Rhoda.DSA, 27) is presented in Scheme 9. The dual-modality concept 
considered in the synthesis of this new paramagnetic and fluorescent lipid is valuable 
in that anatomical information (MRI) as well as very sensitive localisation is 
achievable (ex vivo fluorescence microscopy). 
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Scheme 9. Retrosynthetic analysis of novel bimodal lipid Gd.DOTA.Rhoda.DSA 27. 
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The retrosynthetic analysis of Gd.DOTA.Rhoda.DSA 27 leads initially to the Gd free 
fluorescent rhodamine lipid 28. A disconnection of the sulfonamide bond of 28 yields 
the rhodamine sulfonyl chloride precursor 29 and the primary amine lipid 30 (Scheme 
9). The same lipidic anchor used for the synthesis of Gd.DOTA.DSA 2 was also used 
for 27 as it is a robust, fully saturated alky chain that bestows a good level of rigidity 
and anchorage into the liposome bilayer. The rhodamine sulfonyl chloride starting 
material is commercially available. We chose to take advantage of this readily 
available and cheap fluorophore since we had also used the rhodamine fluorophore 
in previous cell labelling studies in vitro and tumour imaging in vivo and as such, the 
use of an identical fluorophore will allow for analogous assessment of the efficacy of 
the new bimodal lipid also. In addition, the majority of conjugating dyes available are 
amine-reactive reagents and the rhodamine sulfonyl chloride seemed a suitable 
fluorophore since the sulfonamide product formed is stable in aqueous conditions.  
 
A retrosynthetic analysis of the amine lipid 30 arrives at the carboxybenzyl (CBz) 
protected lipid 31 (Scheme 10). Here, a disconnection of the amide bond results in 
the DOTA macrocycle 32 and structure 33. DOTA.NHS.ester is a commercially 
available source of the mono-carboxylate activated DOTA (Macrocyclics, USA) and 
was utilised in this synthesis for ease of reactivity due to the pre-activated carboxylic 
acid. The CBz protected lipid 33 results from Boc group removal from the 
orthogonally protected lipid 34.  
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Scheme 10.  A retrosynthetic analysis of precursor molecules utilised in the synthesis of 
Gd.DOTA.Rhoda.DSA 28. 
 
The Boc and CBz protected DSA lipid 34 is a direct product of reacting the 
orthogonally protected Nα-Boc-Nε-CBz-L-lysine-N-hydroxysuccinimide ester 35 
(Scheme 11) and the lipidic amine 4 synthesised previously as shown for the 
synthesis of Gd.DOTA.DSA 2 (Chapter 2). 
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Scheme 11. A restrosynthetic analysis of orthogonally protected lipid 34. 
 
 
Initially, prior to the coupling of the Rhodamine sulfonyl chloride fluorophore with lipid 
amine 30, a Rhodamine isothiocyanate version of the fluorophore was used since it is 
one of the most commonly utilised fluorescent probes for conjugation to primary 
amines, and as such was deemed to be very selective for the modification of the ε-
terminal amine of the lysine residue of the gadolinium amine lipid 36 (Scheme 12). 
The Rhodamine isothiocyanate coupling reaction involves attack of the amine 
nucleophile on the central, electrophilic carbon of the isothiocyanate group which 
leads to a thiourea bond with no leaving group involved (Scheme 12). Lipid 36 has 
the gadolinium metal complexed in the DOTA previous to the Rhodamine 
isothiocyanate coupling step. This order was initially adhered to since it has been 
shown that gadolinium complexation can be significantly hindered due to the 
presence of a bulky Rhodamine moiety within the vicinity of the polyamino ligand 
DTPA.276 
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Scheme 12. a) Et3N, DMF, rt, 24, 30 %. 
 
 
The synthesis of 38 however, led to poor yields and extremely difficult purification 
steps. Isothiocyanate compounds react most readily under basic conditions and it 
was thought that the aliphatic amine of the lysine’s ε-amino group is moderately basic 
and reactive towards most acylating agents, including the  
Rhodamine isothiocyanate fluorophore. In order to improve the yield of the thiourea 
product 38, the pH of the reaction was maintained around 8 and above, for the 
primary amine to remain mostly deprotonated. However, even the utilisation of 
various bases, and variations on reaction solvent, time and temperature did not lead 
to improved yields for this step (see Table 9).  
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Base Solvent Temperature (ºC) Time (h) Yield (%) 
3 eq. Et3N MeOH: DCM: 1:1 0 3 20 
3 eq. Et3N MeOH: DCM: 1:1 0 → rt 12 20 
3 eq. Et3N DMF 4 12 25 
3 eq. Et3N DMF rt 24 30 
3 eq. DMAP DCM 45 12 30 
0.5M NaHCO3 
DMSO: Pyridine: 
50:1 
85 24 31 
 
 
Table 9. Reaction conditions employed for the synthesis of Gd.DOTA.Rhoda.DSA 
(isothiocyanate product).  
 
The poor yields for the coupling of the Rhodamine isothiocyanate fluorophore to lipid 
36 may be due to the poor solubility of the Gd.DOTA head group (Scheme 12). This 
neutral head group may hinder an effective solvation of the amino group and in fact 
cause the formation of inverse micelles. Amphiphilic molecules may form micelles 
with the head groups on the inside and tail groups on the outside. Since the head 
group of lipid 36 is neutral in charge and non-ionic (no excess charge), there is a 
possibility that inverse micelle formation is favoured in solution.  
Lipid 30 was complexed with Gd using a stoichiometric amount of the chelating agent 
GdCl3 and heating the reaction in pure water, quantitative yields were obtained and 
the final compound (36) was characterised by ESI-MS and HPLC. The presence of 
free Gd3+ ions was investigated for by using the xylenol orange colourimetric assay 
and no free Gd ions were detected. In addition, the isotopic peaks of Gd were 
apparent in the mass spectrum of this compound. The next step was to couple the 
fluorescent Rhodamine isothiocyanate group, leading to the bimodal fluorescent and 
paramagnetic lipid 38 (Scheme 12). This lipid was also characterised by ESI-MS, 
HPLC and the xylenol orange assay was used to check for free Gd ions.  
The complexation of 31 with gadolinium was achieved with the addition of a 
stoichiometric amount of GdCl3 to this lipid in pure water and heating at 90 ºC 
(Scheme 13). The Gd complexed product was then characterised using HPLC and 
ESI-MS, the xylenol orange colourimetric assay revealed no free Gd3+ ions post 
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complexation and the Gd isotopic peaks were apparent in the mass spectrum of this 
product.  
The CBz deprotection of 40 was carried out with H2 gas and palladium on carbon 
(Scheme 13). This reaction led to very poor yields initially, and a range of conditions 
were assessed in order to improve the rate of hydrogenolysis (see Table 10). 
 
 
 
 
 
 
 
Scheme 13. a) 6H2O.GdCl3, H2O, 90 ºC, 12 h, quantitative; b) H2, Pd-C 10%, 1,4 
cyclohexadiene, MeOH: H2O, 60 ºC, 3 h, 60%.  
 
 
 
 
 
31 
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Catalyst Solvent Temperature (ºC) Time (h) Yield (%) 
H2, Pd-C 10% EtOH rt 2 10 
H2, Pd-C 10% EtOH 50 2 10 
H2, Pd-C 10% EtOH rt 17 24 
H2, Pd-C 10% EtOH: EtOAc: 1:1 rt 17 25 
H2, Pd-C 10%, 
1,2 cyclohexene 
EtOH 75 12 57 
 
H2, Pd-C 10% 
1,4 cyclohexadiene 
MeOH: H2O: 2:1 60 3 60 
 
 
 
Table 10. Hydrogenation conditions employed for CBz protecting group removal (Scheme 
13).  
 
A major improvement in hydrogenolysis of 40 was achieved by the addition of either 
1,2 cyclohexene or 1,4 cyclohexadiene hydrogen donors to the reaction mixture. The 
chelation integrity of Gd to the DOTA macrocycle was assessed post CBz removal 
and the chelated Gd ion was found to be intact as confirmed by HPLC and ESI-MS. 
The isotopic peaks of Gd were also still present, confirming that the use of Pd-C did 
not lead to any undesirable palladium-gadolinium exchange for instance. 
 
Lipid 36 was coupled further with a range of other fluorescent probes, including 
carboxytetramethylrhodamine (TAMRA) 41 (Scheme 14), carboxyfluorescein (FAM) 
44 (Scheme 15) and fluorescein isothiocyanate (FITC) 46 (Scheme 16).  
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Scheme 14. a) DMAP, HBTU, CH2Cl2, rt, 6 h  
 
 
The amide coupling of 41 with 36 was undertaken using HBTU and DMAP as 
carboxylic acid activators. This reaction did not proceed to completion and was not 
developed further (Scheme 14). It is believed that the activation and subsequent 
amide coupling of aromatic carboxylic acids of fluorophores such as 41 is often 
problematic due to the strong delocalisation of the carbonyl electrons with the 
benzene ring. 
 
A similar lack of amide bond formation was observed when using the 
carboxyfluorescein fluorophore 43, no reaction to form 44 took place when HBTU and 
DMAP were used for the activation of the aromatic carboxylic acid (Scheme 15).  
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Scheme 15. a) DMAP, HBTU, DMF, 40 ºC, 12 h  
 
 
In order to also utilise green fluorescence, a fluorescein isothiocyanate (FITC) 
fluorophore was coupled with the amino lipid 36, however, the yields for this reaction 
were poor and quantities obtained were not sufficient for in vitro or in vivo 
experimentation using this dual labelled fluorescent lipid (Scheme 16).  
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Scheme 16. a) Et3N, DMF, 4 ºC, 3 days, 25 % 
 
 
The excitation and emission wavelengths measured for 46 were found to be 497 nm 
and 535 nm respectively.  
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Scheme 17. a) Et3N, CH2Cl2, 40 ºC, 5 h, 92% 
 
 
The synthesis of the lipid tail and the lysine linker utilised for the synthesis of the 
bimodal lipid 27 is shown in Scheme 17. The orthogonally protected CBz and Boc 
lysine linker (35) was purchased as the activated NHS ester and reacted with the 
previously synthesised lipid amine 4 in dry DCM and the protected lipid 34 obtained 
in good yield and purity (Scheme 17).  
 
  168
 
 
 
 
Scheme 18. a) TFA: CH2Cl2: 1:1 v/v, rt, 2.5 h, quantitative, b) Et3N, CH2Cl2, 45 ºC, 12 h, 67%, 
c) H2, Pd-C 10%, MeOH: H2O: 2:1 v/v, 60 ºC, 3 h, 60%. 
 
 
The Boc protection was then removed using TFA to give the primary amine 33 
(Scheme 18). This was then reacted with the mono-activated DOTA macrocycle 32 
to give 31. The CBz group was removed using the optimised hydrogenolysis 
conditions and led to the amine DOTA lipid 30 (Scheme 18).  
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Since the Rhodamine isothiocyanate coupling led to poor yields of the conjugated 
product 38, and the complexation of Gd appears to lead to very poor solubility of the 
head group region, an alternative Rhodamine fluorophore in the form of Rhodamine 
Lissamine B sulfonyl chloride was utilised in place of 37. This sulfonyl chloride 
fluorophore has an extremely high extinction coefficient (up to 93 000 M-1cm-1) and 
forms a sulfonamide linkage with the primary amine of 30. The synthesis of the novel 
fluorescent lipid 27 was achieved in excellent yield and purity by using the sulfonly 
chloride Rhodamine fluorophore 47 in basic conditions (Scheme 19). This was then 
complexed with gadolinium in aqueous conditions to give the bimodal fluorescent and 
paramagnetic lipid 27 in excellent yields. This bimodal lipid was characterised with 
ESI-MS, HPLC and its gadolinium isotopic peaks were visible in the MS trace. The 
presence of free Gd ions was tested for by using the xylenol orange assay and no 
free Gd3+ ions were detected. The excitation and emission wavelengths measured for 
Gd.DOTA.Rhoda.DSA 27 were found to be 545 nm and 568 nm respectively.  
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Scheme 19. a) 1% Et3N, CH2Cl2, rt, 12 h, 95%, b) 6H2O.GdCl3, H2O, 90 ºC, 12 h, quantitative. 
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4.1.3 MRI Analysis of Bimodal Gd.DOTA.Rhoda.DSA 
 
With the synthesis of the bimodal gadolinium lipid successfully achieved, the T1 signal 
enhancement ability of this lipid in water was measured (Table 11).  Additionally, the 
r1 relaxivity of Gd.DOTA.Rhoda.DSA 27 in liposome form was also assessed at 4.7 T. 
Aqueous solutions of Gd.DOTA.Rhoda.DSA were prepared at the clinically relevant 
dose of 0.5 mM, and T1 measurements were obtained using Eq. 1. T1 measurements 
for controls including a 0.5 mM solution of Gd.DOTA were also obtained.  
 
 
 
 
 
 
Table 11. T1 images and values for Gd.DOTA.Rhoda.DSA 27 in addition to controls. 
 
The T1 measurement results obtained show the novel bimodal lipid 
Gd.DOTA.Rhoda.DSA to be an effective T1 signal enhancer, being 16% more 
effective than Gd.DOTA (Dotarem®) at reducing bulk water T1 (see Table 11).  
A series of neutral PEGylated liposomes were formulated in water incorporating 
Gd.DOTA.Rhoda.DSA 28, in addition to the same DOPC and cholesterol lipid 
components used previously for tumour imaging in vivo (liposome formulation 10). 
These PEGylated liposomes were prepared for subsequent tumour imaging in vivo 
and as such contained DSPE-PEG2000 (Table 12). The total Gd concentration in 
these liposomes ranged between 0.285 and 0.084 μM. The r1 relaxivity was 
determined by plotting 1/T1 (s-1) with the total Gd concentration (mM) and was 
measured to be 14 ± 4.605 mM-1S-1 (Figure 74). This relaxivity is quite high and may 
be attributed to the PEG polymer incorporated in these liposomes, which renders 
both steric bulk and additional hydrophilicity to the liposomes. It can be envisaged 
that due to the large and bulky head group of bimodal Gd.DOTA.Rhoda.DSA 27, the 
head group end of the lipid is further exposed on the surface of the liposomes as the 
Rhodamine moiety will most likely be protruding outwards from the surface of the 
liposomes.  
Sample  T1 (msec) 
1 0.5 mM Gd.DOTA 817.5 ± 93.5 
2 0.5 mM Gd.DOTA.Rhoda.DSA 205.8 ± 30.8 
3 0.5 mM DOTA.Rhoda.DSA 3735 ± 275.5 
4 H2O 3905 ± 311.3 
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Table 12. Liposome formulations used to determine r1 relaxivity of Gd.DOTA.Rhoda.DSA. 
 
   
 
 
 
 
Figure 74. a: R1 relaxivity for PEGylated neutral Gd.DOTA.Rhoda.DSA liposomes, b:T1-
weighted images of Gd.DOTA.Rhoda.DSA liposomes with 5 different Gd concentrations, 
decreasing left to right (last sample = water).  
 
 
Gd.DOTA.Rhoda.DSA was shown to have an effective T1 signal enhancement 
property and it appears to have a comparable r1 liposomal relaxivity (PEGylated 
liposomes) with that of PEGylated Gd.DOTA.DSA liposomes, suggesting that 
relaxivity is dominated by the Gd.DOTA head group moiety, regardless of the 
presence of the Rhodamine fluorophore nearby on the same molecule.  
 
 
 
 
Liposome Formulation (mol %) 
 
 
 
Gd.DOTA.Rhoda.DSA 
 
DOPC 
 
Cholesterol 
DSPE-
PEG2000 
 
Initial size (nm) PI 
 
50 
 
13 
 
30 
 
7 
 
256. 78 ± 23.10 
 
0.85 ± 0.12 
40 23 30 7 284.93 ± 3.88 0.20 ± 0.05 
30 33 30 7 239.20 ± 6.77 0.53 ± 0.12 
20 43 30 7 257.60 ± 7.10 0.64 ± 0.33 
10 53 30 7 257.50 ± 22.10 0.89 ± 0.11 
R1 relaxivity of Gd.DOTA.Rhoda.DSA PEG liposomes (7% PEG) 
0
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A 3D model of Gd.DOTA.Rhoda.DSA is shown in Figure 75; here the C-18 saturated 
alkyl chain extends in to a cone shaped tail structure. The rhodamine moiety is further 
away from the Gd.DOTA moiety and due to the lysine spacer between the tail and the 
rhodamine fluorophore; it can most likely protrude out of the liposome surface.  
 
 
 
 
Figure 75. 3D model of Gd.DOTA.Rhoda.DSA 
 
London et al. have demonstrated the location of fluorescent lipidic probes with 
charged groups in model membranes using parallax analysis; a fluorescence 
quenching method where the amount of quenching induced by nitroxide-labelled 
phospholipids located at different depths in the bilayer is used to measure 
fluorophore depth up to 1.4 Å of resolution. 281 It was shown that charged aromatic 
probes tend to locate at the polar surface of membranes; and due to the charged 
groups the deep burial of these lipids within the hydrocarbon region of the bilayer is 
prohibited. These findings also revealed that a charged group will rarely be closer 
than 16 – 18 Å from the centre of the bilayer, with lipid attached rhodamine occupying 
a shallow location; 31-55 Å from the bilayer centre.  
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4.2 Chapter Summary 
 
The bimodal fluorescent and paramagnetic lipid Gd.DOTA.Rhoda.DSA was 
successfully synthesised. T1 values and r1 relaxivity measurements at 4.7 T were 
conducted using this lipid and data obtained showed this novel bimodal lipid to have 
excellent T1 relaxation and relaxivity properties. The fluorescence excitation and 
emission values obtained for Gd.DOTA.Rhoda.DSA 27 were comparable to that of 
the free Rhodamine sulfonyl chloride precursor, suggesting that conjugation onto the 
lipid backbone does not interfere with Rhodamine’s fluorescence properties.  
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5 . In Vitro and In Vivo Biological 
Evaluations of Bimodal Gadolinium 
Lipid - Gd.DOTA.Rhoda.DSA 
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5.1 In Vitro Cell Labelling with Gd.DOTA.Rhoda.DSA 
 
The ability to label cells and to visualise these labelled cells using an appropriate 
imaging modality can be valuable in the tracking of therapeutic cells of interest, such 
as the imaging of stem cell migration in a stroke model, or the imaging of labelled 
metastatic cancer cells and their localisation post-injection in vivo. As such, novel cell 
labelling systems such as paramagnetic and fluorescent liposomes developed in this 
project can be useful in the labelling of and subsequent tracking of a range of cells 
including therapeutically relevant cells.  
 
We were interested in assessing the cell labelling capabilities of liposomes 
formulated with the bimodal lipid Gd.DOTA.Rhoda.DSA 27. For this purpose, based 
on the successful cell uptake results demonstrated through the use of the cationic 
lipid CDAN and the neutral helper lipid DOPE, cationic liposomes were formulated 
with Gd.DOTA.Rhoda.DSA for IGROV-1 cell labelling. Cationic liposomes consisting 
of CDAN/DOPE/Gd.DOTA.Rhoda.DSA: 50/45/5 mol % (Gd liposome formulation 12), 
were formulated in water and their size and pH checked and adjusted. The initiative 
here was to use a liposome formulation that bore very close resemblance to the 
successful transfection agent Trojene®, and as such the choice for CDAN and 
DOPE, both constituents of Trojene®. These lipids were also used at similar molar 
ratios.  
 
A 5 mol % composition of Gd.DOTA.Rhoda.DSA 27 was used in these liposomes for 
preliminary cell labelling experiments since this ratio would ensure an adequate and 
non-excessive amount of rhodamine fluorescence in the cells. IGROV-1 cells were 
used here too since xenograft tumours from this cell line was previously developed 
and as such their subsequent use will lead to comparable data. Approximately 5 x 105 
IGROV-1 cells were grown and labelled with Gd liposome formulation 12; the cells 
were incubated with the liposomes (150 μL, 1.2 mg mL-1, 1.976 μM of Gd) for 8 
hours. After the completion of the uptake period, the cells were washed, trypsinised 
and then spun into cell pellets and imaged at 4.7 T whilst covered in PBS. 
Interestingly, the labelled cells looked bright pink under normal light and this was 
corroborated with the MR images obtained of the same cell samples. Figure 76 
presents these findings, where the labelled cells look pink in comparison to 
unlabelled control cells and the T1-weighted image of the same cell samples reveals 
a bright cell pellet.   
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Figure 76. a: Photograph of cells labelled with cationic Gd.DOTA.Rhoda.DSA liposomes, b: 
T1-weighted image of the cells, vials to the left contain labelled cells and the vials to the right 
are unlabelled cells alone.  
 
The pink appearance of the IGROV-1 cells is due to either uptake or association of 
the bimodal liposomes with the cells, and these data are co-validated with MRI 
findings which revealed a bright cell pellet mass (Figure 76, b). In order to assess the 
intracellular uptake of the bimodal gadolinium liposome formulation 12, microscopy 
experiments were carried out using this formulation. IGROV-1 cells (2.5 x 105) were 
grown on cover slips for fluorescence microscopy experiments and were incubated 
with Gd liposome formulation 12 for 8 h. Post-uptake period the cells were washed 
and fixed. Fluorescence microscopy of the fixed IGROV-1 cells revealed uptake of 
these liposomes to be intracellular, ubiquitous and dispersed through out the 
cytoplasm (Figure 77).  
 
 
 
Figure 77. Fluorescence microscopy of IGROV-1 cells labelled with the bimodal cationic 
liposome formulation 12 (image on the left-side is x 20 and the image on the right is x 40 
magnification).  
 
The successful in vitro cell labelling of IGROV-1 cells and visualisation by both MRI 
and fluorescence microscopy revealed Gd.DOTA.Rhoda.DSA 27 to be an effective 
bimodal cell labelling vehicle and qualitative results were obtained that co-validated 
the presence of the liposomes within cells by both MRI and fluorescence microscopy.  
a 
b 
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5.2 In Vivo Solid Tumour Imaging with Gd.DOTA.Rhoda.DSA 
PEGylated Liposomes 
 
Successful tumour imaging is valuable in the assessment of a range of 
characteristics of solid tumours, whereby, tumour type, level of aggressiveness, 
location and response to therapy can be both visualised and quantitated with the use 
of appropriate probes. A range of bimodal probes have been applied to the imaging 
of tumours.282,283 Based on the successful tumour imaging results using the first 
generation Gd.DOTA.DSA lipid, we were interested in evaluating the use of the novel 
second generation bimodal Gd.DOTA.Rhoda.DSA for tumour imaging of IGROV-1 
xenografts in vivo. Nude Balb/c mice were inoculated with IGROV-1 cells where two 
weeks post administration the tumours had reached an appropriate size for imaging 
experiments. In order to make a direct comparison with the previously formulated 
PEGylated gadolinium liposome 10, the exact same formulation was also used, with 
Gd.DOTA.Rhoda.DSA in place of Gd.DOTA.DSA. This gave liposome formulation 13; 
Gd.DOTA.Rhoda.DSA/DOPC/Chol/DSPE_PEG2000: 30/33/30/7 mol % (formulated at 
15 mg mL-1 of total lipid content). Baseline MR images were obtained pre-injection, of 
the tumour bearing mice, after which a 150 μL solution of PEGylated gadolinium 
liposome 13 (containing 0.613 μM of Gd) was injected via the tail vein and the mice 
imaged at 2, 14 and 24 h post-injection at 4.7 T. A further interesting observation was 
that, upon immediate injection of these liposomes, the mice turned bright pink, initially 
in their extremities and subsequently throughout their body. This effect persisted for 
approximately 30 min, and demonstrates the rapid blood circulation of the liposomes 
prior to clearance and/or extravasations.  
 
 
 
 
 
 
 
 
 
 
 
Figure 78. Balb/c nude mice; mouse on the left has been injected with Gd.DOTA.Rhoda.DSA 
liposome 13, mouse on the right had no injection.  
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Figure 79. Tumour T1 measurements post injection of Gd.DOTA.Rhoda.DSA liposome 
formulation 13. a: Tumour T1 values at 0, 2, 14 and 24 h post administration of liposomes. b: 
Tumour signal enhancement calculated as percentage of T1 signal enhancement compared to 
baseline (at 4.7 T).  
 
The measured T1 relaxation values from the tumour areas revealed an excellent level 
of tumour signal enhancement of up to ~65 % at 14 h post injection of liposomes 13, 
and this signal enhancement was maintained up to the 24 h end-point (Figure 79, b). 
These results show the effectiveness of PEGylated liposomes formulated with 
Gd.DOTA.Rhoda.DSA for tumour MRI and reveal their tumour signal enhancement 
ability to be superior (even at half the dose used) to PEGylated gadolinium liposomes 
formulated using Gd.DOTA.DSA (formulation 10, see section 3.3). This accelerated 
rate of accumulation in the tumour tissue may be attributed to the effectiveness of 
Gd.DOTA.Rhoda.DSA in becoming “trapped” in tumour tissue, or may be attributed to 
the incorporation of this lipid within tumour cell membranes, given the hydrophilicity of 
the Rhodamine fluorophore moiety. T1-weighted images of axial tumour slices were 
also obtained and revealed the images taken at the 14 h and 24 h time points to be 
brighter than the baseline and 2 h post-injection images (see Figure 80).  
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Figure 80. T1-weighted tumour images of Balb/c mice injected with PEGylated 
Gd.DOTA.Rhoda.DSA liposome formulation 13. a: Baseline scan prior to injection, b: 2 h 
post-injection, c: 14 h post-injection and d: 24 h post injection at 4.7 T.   
 
 
After the 24 h post-administration, the mice were sacrificed and the tumours excised, 
frozen and sectioned for histology. Fluorescence microscopy of the sectioned tumour 
slices revealed a high level of fluorescence signal in the tumour tissue (Figure 81). 
These results validate the MRI results presented in Figure 79 and show the 
ubiquitous presence of the PEGylated liposomes and therefore 
Gd.DOTA.Rhoda.DSA lipid in the tumour tissue.  
 
 
 
Figure 81. Fluorescence microscopy images of sectioned tumours (7 μm thick) post 
Gd.DOTA.Rhoda.DSA liposomes injection. The images on the left are red fluorescent images 
and the images on the right hand side are corresponding bright field images (x 40, bar 
represents 50 μm).  
a b c d 
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The fluorescence pattern observed from the sectioned tumour tissue post liposome 
13 administration appears to be more uniform and spread-out throughout the tumour 
tissue (Figure 81). This pattern is also different to the fluorescence observed post 
injection of liposome formulations 10 and 11, where more hyperintense and localised 
fluorescence signal was observed. Images obtained and presented in Figure 81 may 
support the idea that the Gd.DOTA.Rhoda.DSA lipid is able to incorporate within the 
cancer cell membranes. However, further confocal microscopy studies are necessary 
to elucidate more information on the precise localisation of PEGylated bimodal 
liposomes formulated with the bimodal lipid Gd.DOTA.Rhoda.DSA 27.  
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5.2.1 Chapter Summary 
 
The novel bimodal fluorescent and paramagnetic lipid Gd.DOTA.Rhoda.DSA was 
utilised for the in vitro cell labelling of IGROV-1 human ovarian cells, and was shown 
to be an effective IGROV-1 tumour T1 signal enhancer, producing a 65 % signal 
enhancement of tumour tissue 14 h post injection. This T1 signal enhancement of 
tumour tissue was maintained up to the 24 h experiment end-point.  
 
These findings were co-validated successfully in a bimodal manner using both 
fluorescence microscopy of histological tissue and real-time MRI of tumour bearing 
mice.  
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6 . Work Towards Trimodal 
Gadolinium Lipids 
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6.1 19F MRI Agents 
 
Given that the Larmour frequencies for both 1H and 19F nuclei are close, the imaging 
of agents containing both these nuclei can be achieved on the same MRI scanner. 
Fluorine MRI has recently gained much interest within the field of molecular imaging, 
as so called “hot spot” imaging is made possible with the use of agents such as 
perfluorocarbon emulsions. Since background 19F signal is absent in most body 
tissue apart from teeth, 19F based spectroscopy and/or MRI can provide extremely 
unique signatures. Fluorine signals can be intrinsically quantitated based on 19F 
spectroscopy and can be used to report the actual concentration of particles within a 
given region. This data can then be corroborated with 19F MRI where spatial and 
anatomical information may be obtained.  
 
Fluorine imaging agents are now under investigation for a range of molecular imaging 
applications.284 Fluorine MRI has mostly been carried out with the use of 
perfluorocarbon emulsions where very high numbers of fluorine atoms are present. 
Perfluorocarbon emulsions are colourless and odourless liquids that are denser than 
water and capable of dissolving physiologically important gases such as oxygen and 
carbon dioxide.  
 
Fluorine imaging may be hampered due to the requirement for very high 19F 
concentrations in order to improve image resolution. Perfluorooctanoic acid 
(C7F15COOH) has been encapsulated into liposomes and it was shown that the 
lowest concentration necessary to visualise distribution of this agent in vivo is 
approximately 1 mmol/kg of tissue. 285  
 
Liposomal based 19F MRI has been achieved by Oishi et al. who have developed pH-
sensitive PEGylated nanogels constructed with tethered PEG chains and a 
polyamine gel core containing 19F compounds.286 These agents which act as specific 
smart 19F MRI probes showed remarkable on/off MR signal in response to the 
extracellular pH (6.5) of the tumour environment at very low concentrations of ~ 55 
μM.  This suggests that liposomal based 19F MRI is a possibility, with the potential of 
incorporating thousands of fluorine molecules in a single macromolecular structure.  
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6.1.1 Towards Trimodal 19F Paramagnetic and Fluorescent Lipids 
 
The efficient visualisation of signals from imaging probes used in molecular imaging 
of disease states such as cancer is of great value for the assessment of disease 
gravity and response to treatment. A trimodal probe, capable of producing three 
signatures at the same time can be an attractive tool for the visualisation of difficult in 
vivo aberrant biological processes such as the imaging of metastatic cancer cells 
where a high signal to noise ratio is required and desirable.  
 
To this end, work towards the synthesis of a trimodal imaging probe was undertaken, 
which included the attachment of fluorescent, paramagnetic and fluorine moieties 
onto a single framework.  
 
The trimodal head group shown in Figure 82 was designed with the ultimate aim to 
couple the primary amine to the distal end of a PEG tethered lipid, yielding a trimodal 
PEG lipid for incorporation into liposome formulations. Alternatively this trimodal “war 
head” may be conjugated to a short PEG linker and post-coupled onto the surface of 
suitable liposomes bearing an appropriate functional group for conjugation.  
 
 
 
 
 
Figure 82. A trimodal probe bearing a fluorine moiety for 19F MRI and spectroscopy, a 
Gd.DOTA moiety for contrast agent MRI and a Cy5.5 NIR dye for fluorescence imaging.  
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The forward synthesis towards the trimodal probe 48, involved the initial conversion 
of the tetrakis-trifluorobenzhydrol to the amine compound 52 (Scheme 20). First the 
alcohol was converted into a good leaving group by reaction with methanesulfonyl 
chloride in the presence of triethylamine to give the methanesulfonate ester 50. This 
was then reacted with an excess of sodium azide in DMF to yield the azide product 
51.  
 
 
 
 
 
 
Scheme 20. a) Et3N, MsCl, CH2Cl2, rt, 12 h, 60%, b) NaN3, DMF, 80 ºC, 12 h, 49%, c) PPh3: 
H2O, THF, 70 ºC, 12 h,  40%, d) DMAP, HPTU, DMF, 40 ºC, 12 h, 60%. 
 
 
Azide 51 was then reduced to amine 52 utilising the Staudinger Reduction conditions. 
Using this mild reduction, azides may be converted to amines as an alternative to the 
use of hydrogenation. The mechanism for this reaction is given in Figure 83. Here, 
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triphenylphosphine initially reacts with the azide in order to generate a phosphazide 
which subsequently loses N2 to give an iminophosphorane. Aqueous work up of this 
intermediate leads to the amine and the stable phosphine oxide.  
 
 
 
 
 
 
Figure 83. Mechanism for the Staudinger Reduction of an azide to an amine. 
 
 
The orthogonally protected tetrakis-trifluorobenzamide 54 was obtained by reaction of 
the carboxylic acid linker 53 with the primary amine of 52 under typical amide bond 
synthesis conditions, using the carboxylic acid activators HBTU and DMAP. It was 
also noted that reaction yields for the series of transformations shown in Scheme 20 
could not be improved upon further. This may be due to the steric hindrance of the 
bulky trifluorobenzyl groups flanking the various methylene bonded functional groups.  
 
Further reactions towards the synthesis of 48 are shown in Schemes 21 and 22. The 
Fmoc protection of 55 may be removed by reaction with 20 % piperidine, yielding 
compound 56. The coupling of the CBz and Boc protected lysine linker in dry DCM 
should yield 57 in good yields. Here, a facile Boc deprotection in acidic conditions 
would give 58 (Scheme 21).  
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Scheme 21. Proposed scheme towards the synthesis of tri-protected precursor 58. 
 
 
Compound 58 can be reacted with the commercially available DOTA.NHS ester to 
give the DOTA precursor 59. Treatment with 2% hydrazine results in the removal of 
the ivDde protecting group rendering the primary amine product 60 which can be 
reacted with a NIR Cy5.5 NHS ester to give 61 (Scheme 22). Ensuing Gd 
complexation, CBz deprotection, and PEG lipid conjugation provides 48 which can be 
used in a range of coupling reactions.  
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Scheme 22. Proposed scheme towards the synthesis of trimodal head group 48. 
 
 
Using trimodal head group 48, Gd enhanced MRI, 19F spectroscopy, 19F MRI and in 
vivo fluorescence imaging may be achieved. It is expected that the relaxivity of 
liposomes coupled onto PEG linked 48 will be high, due to the hydrophilic nature of 
PEG and also due to the added macromolecular effect as a result of post-coupling of 
48 to liposomes surfaces.  
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7 . Conclusions and Future Directions 
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7.1 Conclusion 
 
Two novel gadolinium lipidic probes were designed and synthesised. Initially a 
unimodal paramagnetic lipid Gd.DOTA.DSA was synthesised and its MRI signal 
enhancement measured. At the clinically relevant concentration of 0.5 mM in 
aqueous solutions, this lipid was found to compare favourably with the most 
commonly used clinical contrast agent Magnevist®. The relaxivity of this lipid once 
incorporated into liposomes was also assessed and was found to be comparable to 
similar paramagnetic liposomal systems at 4.7 T, and 8 fold higher than the relaxivity 
of the free lipid in solution.  
 
Bimodal cationic liposomes (both fluorescent and paramagnetic) were formulated 
with Gd.DOTA.DSA and the molar ratio of this lipid in these liposomes was optimised 
so that an ideal non-toxic formulation could be identified, capable of maximum Gd 
delivery into cells. Using HeLa cells, it was shown that between 21-35 % of the 
gadolinium liposomes were taken up into cells which translated to a 65% signal 
enhancement of labelled cells, compared to non-labelled cells. The toxicity of these 
optimised gadolinium liposomes was assessed to be < 10% of overall cell death. 
Confocal microscopy post cell labelling using HeLa cells, revealed uptake of these 
liposomes to be intracellular and dispersed throughout the cytoplasm. The 
bifunctionality of these liposomes was also shown with the successful encapsulation 
of plasmid DNA encoding for luciferase. This transfection result looked promising and 
was comparable to expression levels obtained with a commercial transfection agent. 
These gadolinium liposomes show promise as both cell labelling and transfection 
agents and may be developed further.  
 
A limitation here has been the testing of gadolinium liposomes formulated with 
Gd.DOTA.DSA only on a single HeLa human ovarian cell line. Future work could 
involve the further optimisation of the cell labelling liposome formulations towards a 
more “universal” formulation, capable of uptake into a range of cell lines.  
 
The novel Gd.DOTA.DSA lipid was also used to formulate PEGylated liposomes for 
in vivo tumour imaging. Physical characteristics of these liposomes were extensively 
studied, whereby their serum aggregation, zeta potential and size were assessed. 
The inclusion of a fluorescent lipid in the liposome formulation produced bimodal 
liposomes which were then used to image xenografts in mice. Due to the EPR effect 
of tumour tissue, the successful accumulation of these nanoparticles was shown and 
  192
effective tumour signal enhancement post-injection was observed. These liposomes 
were shown to have excellent in vivo circulation properties, whereby due to their 
~100 nm size, they were able to clear the liver and circulate in the blood for over 12 
h, gradually accumulating in the tumour tissue through leaky vasculature. The tumour 
signal measurements were taken 24 h post-injection of the liposomes and shortly 
before the mice were sacrificed; these promising tumour signal enhancement data 
suggest the need for longer imaging windows, where a longitudinal imaging of the 
tumours post-injection of up to 3-7 days would be appropriate. In addition, further 
experiments could include comparisons with control clinically used contrast agents 
such as Magnevist® or Dotarem®, as well as established tumour imaging agents.  
 
In order to improve the specificity of PEGylated liposomes formulated with 
Gd.DOTA.DSA, use was made of a targeting ligand in the form of the folate molecule, 
which is the natural ligand for folate receptors. This ligand was incorporated into the 
liposome formulation at 3 mol %. Since these folate receptors are highly over-
expressed on cancer cells, the effect of signal enhancement post-administration of 
these targeted liposomes in tumour bearing mice was investigated. It was shown that 
just within 2 h post injection of the folate-targeted gadolinium liposomes, a 65% 
enhancement in tumour T1 was observed compared to signal achieved with non-
targeted liposomes alone (only ~ 13%). This very promising result suggested that 
folate targeting accelerates the rate of tumour accumulation of these liposomes and 
the persistence of T1 signal up to the 24 h end-time point suggests that there may be 
a tumour accumulation equilibrium effect present, whereby accumulated particles are 
retained and occupy available accumulation sites. Tumour signal enhancement of 
both targeted and non-targeted gadolinium liposome formulations plateaus between 
60-70% at 24 h post injection. This may be due to the Gd saturation level for the 
IGROV-1 xenografts. Further studies using the folate PEG tethered ligand could 
involve the optimisation of ligand to liposome ratio, since it has been shown that 
liposomal targeting ligands may actually be most effective in vivo when used at < 1 
mol% of overall liposome formulation.  
 
A second bimodal fluorescent and paramagnetic lipid, Gd.DOTA.Rhoda.DSA was 
also synthesised and was used to successfully label IGROV-1 cells in vitro and image 
tumours in vivo. Tumour results post injection of PEGylated liposomes formed with 
this lipid revealed these liposomes to be extremely effective at reducing tumour T1 
signal, with a 65% signal enhancement observed at 14 h post injection. In addition, 
these liposomes were injected at half the concentration injected for the non-targeted 
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liposomes formulated using Gd.DOTA.DSA. This suggests that the Rhodamine 
moiety of Gd.DOTA.Rhoda.DSA may be aiding the accumulation of liposomes in the 
tumour tissue, and could be as result of tumour cell membrane incorporation of 
Gd.DOTA.Rhoda.DSA.  
 
Future work using this lipid could involve the assessment of liposome biodistribution 
of liposomes made with this lipid by optical in vivo imaging methods. For this, the 
conjugation of a NIR dye (see Figure 82) in place of the rhodamine moiety would be 
appropriate.  
 
 
 
 
 
Figure 84. A NIR dye; Cy5.5 with superior fluorescence properties (λex: 673 and λem: 692) 
 
 
A major limitation of optical methods is the low tissue penetration of light and as such, 
the current bimodal Gd.DOTA.Rhoda.DSA lipid could only be of value in histology. 
However, the use of the Cy5.5 NIR dye in place of the rhodamine fluorophore can 
increase the depth of fluorescence signal observed and would be an improvement on 
the design of these bimodal fluorescent and paramagnetic lipids.  
 
Work towards the synthesis of a trimodal imaging probe was also initiated. This probe 
is expected to lead to an excellent multimodal imaging strategy whereby three types 
of signal may be observed as a result of probe localisation; 1H MRI contrast 
enhancement and 19F MRI/MRS can be achieved, as well as a fluorescent signature 
from the fluorophore. Future directions for this project could involve the completion of 
synthesis of this timodal probe, and its subsequent post-coupling to the surface of 
similar in vivo liposomes used for tumour imaging so far. These trimodal liposomes 
will posses a high degree of sensitivity due to the NIR probe and facilitate 
fluorescence imaging paving the path for fluorescence molecular tomography as well.
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8 . Experimental 
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8.1 General Information 
 
8.1.1 Materials 
 
N1-cholesteryloxycarbonyl-3,7-diaza-1,9-diaminonane (CDAN), 1,2-Dioleoyl-sn-
glycero-3-phosphoethanolamine (DOPE), phosphatidylethaolamine-lissamine 
rhodamine B (DOPE-Rhodamine), Cholesterol, 1,2-Dioleoyl-sn-Glycero-3-
Phosphocholine (DOPC) and 1,2-Distearoyl-sn-Glycero-3-Phosphoethanolamine-N-
Methoxy(Polyethylene glycol)-2000 (DSPE-PEG2000) were purchased from Avanti 
Polar Lipids Inc. (Alabaster, AL, USA). All other chemicals were of analytical grade or 
the best grade available and purchased from Sigma-Aldrich (UK) or Macrocyclics 
(USA). 
 
8.1.2 General Procedures 
 
1H NMR spectra were recorded on a 400 MHz Bruker Advance 400 spectrometer.  
Chemical shifts are reported in parts per million (ppm) downfield from TMS, using 
residual chloroform (7.27 ppm) as an integral standard. Data are supported as 
follows: chemical shift, s = singlet, br = broad singlet, d = doublet, t = triplet, q = 
quartet, m = multiplet, coupling constants J are given in hertz (Hz). 13C NMR spectra 
were recorded on a 400 MHz Bruker Advance 400 spectrometer. Chemical shifts are 
reported in parts per million (ppm) downfield from TMS, using the middle resonance 
of CDCl3 (77.0 ppm) as an integral standard. Infrared (IR) spectra were recorded on a 
JASCO FT/IR-620 infra-red spectrophotometer; absorption’s are recorded in 
wavenumbers (νmax in cm-1). Analytical HPLC was conducted on a Hitachi-LaChrom 
L-7150 pump system equipped with a Polymer Laboratories PL-ELS 1000 
evaporative light scattering detector. HPLC gradient mixes assigned as follows: 
gradient mix A = H2O/0.1%TFA; mix B = MeCN/0.1%TFA; mix C = MeOH. Mass 
spectra were performed using VG-070B, Joel SX-102 or Bruker Esquire 3000 ESI 
instruments. Melting points were determined on a Stuart Scientific SMP3 apparatus 
and are reported without correction. Reactions with air sensitive material were carried 
out by standard syringe techniques. CH2Cl2 was distilled over P2O5. Thin layer 
chromatographic (TLC) analyses were performed on Merck 0.2 mm aluminium-
backed silica gel 60 F254 plates and components were visualised by illumination with 
UV light or by staining with potassium permanganate, acidic ammonium molybdate 
(IV), iodine, ninhydrin, Rhodamine B, dilute aqueous sulphuric acid or bromocresol 
green, where appropriate a Pharmacia LKB – Ultrospec III (deuterium lamp at 300 
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nm) was used to visualise the UV absorbance. Flash column chromatography was 
performed using Merck 0.040 to 0.063 mm, 230 to 400 mesh silica gel.  
UV spectroscopy was conducted on a Pharmacia Biotech UItrospec 4000 
spectrometer at defined wavelengths. Fluorescence measurements were carried out 
on a Shimadzu RF-5301 PC spectrofluorophotometer. Zeta potentials were recorded 
on a Nanoseries Nano-ZS zetasizer (Malvern instruments). Microscopy experiments 
were conducted on an Olympus or Nickon Eclipse E600 microscope and confocal 
microscopy was carried out with an upright Leica instrument. FACS analysis was 
conducted on a Becton Dickinson FACSCalibur machine. All MRI experiments were 
conducted on a 4.7 T Magnex magnet (Oxford, UK) Varian Unity Inova console (Palo 
Alto, CA, USA).  
 
All procedures on animals were conducted in accordance with UK Home Office 
regulations and the Guidance for the Operation of Animals (Scientific Procedures) Act 
(1986). 
 
8.1.3 Chemical Synthesis 
 
8.1.4 Synthesis of Gd.DOTA.DSA 
 
2-(4,7,10-Tris(2-tert-butyloxycarbonylmethyl)-1,4,7,10-tetra-azacyclododecan-
1yl)acetic acid, 3. 
 
 
 
 
 
2-Chlorotrityl chloride resin (916.7 mg, 1.265 mmol) was added to a solid phase 
synthesis vessel and swelled by the addition of CH2Cl2 (40 mL) and the vessel 
agitated for 30 min (0.8 mmol.g-1 loading). Bromoacetic acid (1.758 g, 12.65 mmol, 10 
eq.) and iPr2NEt (1.107 mL, 6.325 mmol, 5 eq.) were added to the resin and the 
vessel was agitated on a motor shaker overnight at room temperature. MeOH (1000 
eq.) was added as a capping reagent and the reaction agitated for a further 10 min; 
the solution was filtered and the resin was washed by alternating between; CH2Cl2 
and iPrOH (× 3) and MeOH (× 2) and finally dried. Cyclen (2.179 g, 12.65 mmol, 10 
eq.) was dissolved in CH2Cl2 (40 mL) and added to the vessel containing the 
bromoacetyl resin, the reaction was agitated for 4 h. The solvent was filtered and the 
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resin washed alternating between; CH2Cl2 and iPrOH (× 3), CH2Cl2 and MeOH (× 3), 
distilled H2O (× 2) and finally CH2Cl2 and iPrOH (× 3). The chloroanil test was 
positive. The resin was then washed with DMF (× 2) and dried. tert-Butyl 
bromoacetate (3.064 mL, 18.975 mmols, 5 eq. per free amine), NEt3 (1.587 mL, 
11.389 mmol, 3 eq. per free amine) were dissolved in DMF (40 mL) and added to the 
cyclen functionalised resin. The reaction was left shaking for a further 12 h. The 
solvent was removed by filtration and the resin was washed with iPrOH and distilled 
H2O (× 3), CH2Cl2 and iPrOH (× 3), MeOH (× 2), toluene (× 2) and finally diethylether 
(× 2). The chloroanil test was negative. The resin was transferred to a round-
bottomed flask and stirred in a solution of CH2Cl2: trifluroethanol 2: 1 (v/v) for a further 
2 h at room temperature and subsequently filtered and washed with CH2Cl2 (× 3), the 
filtrate was collected and reduced in vacuo to give a yellow oil. The compound was 
purified by flash column chromatography (eluted with (CH2Cl2: MeOH: H2O: 34.5: 9: 
1): CH2Cl2 3:7, v/v) to yield a crystalline pale yellow solid (361.79 mg, 51%, mp = 88-
93 ºC), Rf [CH2Cl2: MeOH: H2O: 34.5: 9: 1 v/v] 0.48. 1H NMR (400 MHz, d6-DMSO, 
400K) δH (ppm) 3.14 (8H, s, br, 4 × CH2COOC(CH3)3), 2.58 (16H, s, br, 4 × 
NCH2CH2N), 1.46 (27H, s, C(CH3)3 × 3). 13C NMR (400 MHz, d6-DMSO, 400K) δC 
(ppm) 174.92 (COOH), 172.30 (COOt-Bu), 82.35 (C(CH3)3 × 2), 82.02 (C(CH3)3), 
56.70 (CH2COOH), 56.11 (CH2COOt-Bu), 55.74 (CH2COOt-Bu), 50.96 (CH2 × 2), 
50.22 (CH2 × 2), 28.15 (C(CH3)3, FTIR: νmax (nujol)/cm-1 3735.53, 2726.56, 2366.78, 
1731.76, 1262.32. HPLC tR = 16.0 min, column C-4 peptide, gradient mix: 0.0 min 
[100% A], 15-25.0 min [100% B], 25.1-45.0 min [100% C], 45.1-55.0 min [100% A]; 
flow: 1 mL/min. HRMS (FAB+) calculated for C28H52N4O8 m/z 572.3785, found 
573.386 (M + H)+. 
 
 
N, N-Distearylamidomethylcarbamic acid tert-butyl ester, 18. 
 
 
 
 
 
Boc-glycine (310 mg, 1.77 mmol) and dioctadecylamine (923.96 mg, 1.77 mmol) 
were dissolved in dry chloroform (30 ml). HBTU (804.12 mg, 2.12 mmol) and DMAP 
(648.72 mg, 5.31 mmol) were added to the solution and the reaction was stirred at 
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room temperature under N2 for 12 h. The solvents were removed in vacuo. The 
mixture was dissolved in CH2Cl2 (50 mL) and extracted with H2O (3 × 50 mL). The 
combined aqueous extracts were back extracted with 2: 1 CH2Cl2: MeOH (2 × 50 
mL), the solvents reduced and re-dissolved in diethyl ether and a subsequent 
extraction with 7% citric acid and H2O was performed; the organic layer was washed 
with brine, collected and filtered through celite and finally dried over MgSO4. The 
diethyl ether was evaporated in vacuo to yield a pure white solid (1.164g, 97% yield, 
mp = 82-85 ºC). Rf [CH2Cl2: MeOH: H2O: 34.5: 9: 1 v/v] 0.56. 1H NMR (400 MHz, 
CDCl3) δH (ppm) 5.50 (1H, s, br, amide NH), 3.99 (2H, s, br, NHCH2), 3.35-3.25 (2H, 
d, br, OCNCH2), 3.17-3.07 (2H, d, br, OCNCH2), 1.44 (9H, s, C(CH3)3), 1.61-1.44 
(13H, m, C(CH3)3 and OCN(CH2CH2)), 1.25 (60H, s, CH2’s alkyl chain), 0.872 (6H, s, 
br, CH3 x 2). 13C NMR (400 MHz, CDCl3) δC (ppm) 167.6 (CON(CH2)17), 156.0 
(C(CH3)3COCO), 79.0 (C(CH3)3), 46.9 (N(CH2CH2)9), 46.1 (N(CH2CH2)9), 42.2 
(NHCH2CO), 31.9-26.9 (CH2 x 30), 22.7 (N(CH2CH2)9), 14.1 (C(CH3)3). FTIR: νmax 
(nujol)/cm-1 2360.56, 1723.85, 1650.78, 1580.63, 1377.25. HPLC: tR = 36.08 min, 
column C-4 peptide, gradient mix: 0.0 min [100% A], 15-25.0 min [100% B], 25.1-45.0 
min [100% C], 45.1-55.0 min [100% A]; flow: 1 mL/min. HRMS (FAB+) calculated for 
C43H86N2O3 m/z 678.6638, found 679.6953 (M + H)+. 
 
 
N,N-Distearylamidomethylamine (DSA), 4. 
 
 
 
 
 
The protected amine 18 was dissolved in anhydrous CH2Cl2 (5 mL), to which was 
added trifluoroacetic acid (3 mL). The reaction was stirred under an atmosphere of N2 
for 2 h. The solvents were removed in vacuo and the product dried under vacuum to 
obtain a white powder (158 mg, 94% yield, mp = 59-64 ºC). Rf [Hexane: Ethyl 
acetate: 9:1 v/v] 0.44. 1H NMR (400 MHz, CDCl3) δH (ppm) 3.85 (2H, s, OCCH2NH2), 
3.32 (2H, t, J 7.2 Hz, OCNCH2CH2), 3.13 (2H, t, J 7.2 Hz, OCNCH2CH2), 2.39 (2H, s, 
very br, NH2), 1.61-1.55 (4H, m, OCNCH2CH2), 1.26 (60H, s, chain CH2’s), 0.86 (6H, 
t, J 6.8, CH3 × 2). 13C NMR (400 MHz, CDCl3) δC (ppm) 168.8 (CO), 43.7 (OCNCH2), 
41.9 (OCNCH2), 35.6 (CH3CH2CH2), 33.4 (alkyl chain CH2’s), 32.3, 31.1 
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(NCH2CH2CH2), 22.7-14.1 (alkyl chain CH2’s). FTIR: νmax (nujol)/cm-1 1681, 1534, 
1313, 1206, 1174. HPLC: tR = 31.46 min, column C-4 peptide, gradient mix: 0.0 min 
[100% A], 15-25.0 min [100% B], 25.1-45.0 min [100% C], 45.1-55.0 min [100% A]; 
flow: 1 mL/min. HRMS (FAB+) calculated for C38H78N2O m/z 578.6114, found 
579.6199 (M+ H)+. 
 
 
2-{4,7-Bis-tert-butyloxycarbonylmethyl-10-[(N,N-distearyl-amidomethyl-N`-
amidomethyl]-1,4,7,10-tetraazacyclododec-1-yl}-acetic acid tert-butyl ester, 5. 
 
 
 
 
 
N,N-distearylamidomethylamine (DSA), 4 (4.837 mg 0.0084 mmol)  tert-
butyloxycarbonyl DOTA acid (3) (4.35 mg, 0.0076 mmol) and were added to a dry 
round-bottomed flask followed by the addition of dry CHCl3 (8 mL). HBTU (3.46 mg, 
0.0091 mmol) and DMAP (2.785 mg, 0.022 mmol) were also added, and the reaction 
was stirred at 40 oC for 6 h until TLC indicated completion. The solvents were 
removed in vacuo, and the crude mixture was purified by flash column 
chromatography (eluted with (CH2Cl2: MeOH: H2O: 34.5: 9: 1): CH2Cl2 1:9 → 1:1, v/v) 
to yield a yellowish oil (7.58 mg, 88% yield). Rf [CH2Cl2: MeOH: NH3 34.5: 9: 1 v/v] 
0.84. 1H NMR (400 MHz, CDCl3, 318K) δH (ppm) 3.98 (2H, s, OCCH2NCH2), 3.31 
(2H, t, J 7.6 Hz, OCNCH2CH2), 3.15 (8H, s, br, 4 × CH2COOC(CH3)3), 3.13 (2H, t, J 
7.6 Hz, OCNCH2CH2), 2.58 (16H, s, br, 4 × NCH2CH2N), 2.35 (2H, s, very br, 
CH2NH), 1.67-1.59 (4H, m, OCNCH2CH2), 1.46 -1.44(27H, d of s, J 6.0, C(CH3)3 × 
3),1.25 (60H, s, chain CH2’s), 0.90 (6H, t, J 6.8, CH3 x 2). 13C NMR (400 MHz, CDCl3) 
δC (ppm) 172.9 (C(CH3)3OCO), 171.3 (NCH2CONH), 166.8 (CONCH2(CH2)16), 81.7 
(C(CH3)3), 81.5 (C(CH3)3), 55.8 (C(CH3)3OCOCH2N), 53.4 (NCH2CH2N), 47.1 (NCH2), 
41.1 (NHCH2CON), 32.0 (NCH2CH2CH2CH2), 29.7-27.1 (C(CH3)3 and chain CH2’s), 
22.7 (CH2CH3), 14.6 (CH2CH3). FTIR: νmax (nujol)/cm-1 3054.52, 2306.23, 1265.85, 
896.66. HPLC: tR = 27.71 min, column C-4 peptide, gradient mix: 0.0 min [100% A], 
15-25.0 min [100% B], 25.1-45.0 min [100% C], 45.1-55.0 min [100% A]; flow: 1 
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mL/min. HRMS (FAB+) calculated for C66H128N6O8 m/z 1132.9794, found 1155.9669 
(M + Na)+. 
 
 
2-{4,7-Bis-carboxymethyl-10-[(N,N-distearylamidomethyl-N`-amidomethyl]-1,4,7,10-
tetra-azacyclododec-1-yl}-acetic acid (DOTA.DSA), 6.  
 
 
 
 
 
tert-Butyl protected DOTA.DSA (5) was dissolved in a 1:1 mixture of c.HCl/1,4-
dioxane and the reaction stirred for 2 h. The solvents were removed in vacuo, the 
mixture suspended in water and freeze-dried to yield a white powder of DOTA.DSA 
(50 mg, 68% yield, decomposition = 235-245 ºC). Rf [CH2Cl2: MeOH: H2O: 34.5: 9: 1 
v/v] 0.61. 1H NMR (400 MHz, CDCl3: MeOD: AcOD: 3: 1, 300K) δH (ppm) 10.55 (3H, 
s, br, 3 × COOH), 5.30 (1H, s, br, CH2NHCOO), 3.65 (6H, m, 3 × NCH2COOH), 3.22 
(6H, m, 2 × NCH2CH2, 1 × NCH2CONH), 2.58 (16H, s, br, 4 × NCH2CH2N), 2.29 (2H,  
s, br , CH2NH), 1.67-1.59 (4H, m, OCNCH2CH2), 1.46 -1.44(27H, d of s, J 6.0, 
C(CH3)3 × 3),1.25 (60H, s, chain CH2’s), 0.90 (6H, t, J 6.8, CH3 x 2). FTIR: νmax 
(nujol)/cm-1 3750.56, 2726.56, 1889.87, 1793.63, 1681.21, 1534.22. HPLC: tR = 34.16 
min, column C-4 peptide, gradient mix: 0.0 min [100% A], 15-25.0 min [100% B], 
25.1-45.0 min [100% C], 45.1-55.0 min [100% A]; flow: 1 mL/min. HRMS (FAB+) 
calculated for C54H104N6O8 m/z 964.7916, found 987.7833 (M + Na)+. 
 
 
Gadolinium (III) 2-{4,7-bis-carboxymethyl-10-[(N, N-distearylamidomethyl-N`-amido-
methyl]-1,4,7,10-tetra-azacyclododec-1-yl}-acetic acid (Gd.DOTA.DSA), 2.  
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A stoichiometric amount of GdCl3.6H2O (28.118 mg, 0.075 mmol) was added to 
DOTA.DSA (6) (73 mg, 0.0757 mmol), and the reaction was stirred in distilled H2O 
(20 mL) at 90 ºC overnight (pH dropped to 3.5 upon Gd addition). The water was 
freeze-dried to yield a white powder (83.9 mg, 99% yield, decomp. = 345-348 ºC). Rf 
[CH2Cl2: MeOH: H2O: 34.5: 9: 1 v/v] 0.55. The xylenol orange test indicated no 
detectable free Gd3+ ions. FTIR: νmax (nujol)/cm-1 3750.23, 2234.78, 1991.59, 
1889.89, 1793.44, 1681.90.77. HPLC: tR = 36.22 min, column C-4 peptide, gradient 
mix: 0.0 min [100% A], 15-25.0 min [100% B], 25.1-45.0 min [100% C], 45.1-55.0 min 
[100% A]; flow: 1 mL/min. MS (ESI+) calculated for C54H101GdN6O8 m/z 1119.67, 
found 1120.10 (M + H)+. 
 
 
8.1.5 Synthesis of Gd.DTPA.BSA 
 
 
[N,N-Bis-stearylamidomethyl-N`-amidomethyl]-diethylenetriamine-tetra-acetic acid 
(DTPA.BSA), 22.287  
 
 
 
 
 
A solution of octadecylamine (301.86 mg, 1.2 mmol) dissolved in chloroform (30 mL) 
was added to a solution of DTPA bisanhydride (200 mg, 0.560 mmol) previously 
dissolved in DMF (40 mL). The reaction was stirred at 40 ºC for 2 h. The white 
precipitate formed was collected by filtration and washed with acetone and dried 
under vacuum overnight. The white solid was stirred in water at 80 ºC for 3 h to 
dissolve any excess DTPA. The insoluble residue was filtered and dried under 
vacuum overnight. The white solid was then washed with boiling chloroform and 
stirred in chloroform for 2 h, and then filtered and dried (198 mg, 40% yield, mp = 
168-173  ºC, Lit. mp = 168 ºC).287 Rf [CH2Cl2: MeOH: H2O: 34.5: 9: 1 v/v] 0.50. 1H 
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NMR (400 MHz, CF3-COOD at δ = 11.30 ppm) δH (ppm) 4.55 (8H, d, J 5.2, 
HOOCCH2N),  4.09 (6H, t, NCH2CH2N × 2 and HOOCCH2N), 3.69 (4H, t, J 4.8 and J 
19.6, NCH2CH2N × 2), 3.34 (4H, t, J 7.2, NHCH2 × 2), 1.57 (4H, d, J 6.0, NHCH2CH2 
x 2), 1.27 (60H, d, 30 × CH2 alkyl chain), 0.83 (6H, t, J 7.2, CH2CH3 × 2). 13C NMR 
(400 MHz, CF3-COOD at δ = 116.6 and 164.2 ppm) δC (ppm) 170.2 (CH2COOH), 
166.1 (NCH2CONHCH2CH2-), 58.5 (HOOCCH2), 57.2-55.0 (NCH2CONH), 51.8 
(NCH2CH2N(CH2COOH)CH2CH2N), 42.5 (NHCH2CH2), 32.8 (NHCH2CH2), 30.5-30.2 
(chain CH2’s), 27.4 (NHCH2CH2CH2), 23.1, 14.1 (-CH3). FTIR: νmax (nujol)/cm-1 
3675.06, 2272.91, 1991.37, 1869.23, 1771.48, 1684.66. HPLC; tR = 34.23 min, 
column C-4 peptide: gradient mix: 0.0 min [100% A], 15-25.0 min [100% B], 25.1-45.0 
min [100% C], 45.1-55.0 [100% A]; flow: 1 mL/min. HRMS (FAB+) calculated for 
C50H97N5O8 m/z 895.7337, found 896.7423 (M + H)+. 
 
  
Gd (III) [N, N-bis-stearylamidomethyl-N`-amidomethyl]-diethylenetriamine tetra-acetic 
acid (Gd.DTPA.BSA), 19. 
 
 
 
 
 
A stoichiometric amount of Gd.Cl3.6H2O (45 mg, 0.0502 mmol) was added to 
BSA.DTPA 22 (18.67 mg, 0.0502 mmol) and the reaction was stirred in distilled H2O 
(20 mL) at 90 ºC for 3 h (pH dropped to 3.5). The water was freeze-dried to yield a 
white powder (48 mg, 91% yield, decomp. = 350 ºC). Rf [CH2Cl2: MeOH: H2O: 34.5: 
9: 1 v/v] 0.43. The xylenol orange test indicated no detectable free Gd3+ ions. FTIR: 
νmax (nujol)/cm-1 3779.8, 3674.69, 2271.73, 1868.68, 1771.3, 1683.55. HPLC; tR = 
34.60 min, column C-4 peptide, gradient mix: 0.0 min [100% A], 15-25.0 min [100% 
B], 25.1-45.0 min [100% C]; 45.1-55.0 min [100% A]; flow: 1 mL/min. MS (ESI+) 
calculated for C50H94GdN5O8 m/z 1050.56, found 1051.10 (M + H)+. 
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8.1.6 Synthesis of Gd.DOTA.Rhoda.DSA 
 
 
6-Benzyloxycarbonylamino-2-(tert-butoxycarbonylamido) hexa-amido-N,N-
dioctadecylacetamide, 34. 
 
 
 
 
 
The boc-Lys-(CBz)-succinimide ester (5.0 g, 10.471 mmol) and N,N-
distearylamidomethylamine (DSA), 4 (6.96 g, 12.041 mmol) were added to an air 
evacuated flask and dissolved in anhydrous CH2Cl2  (200 mL). The solution was 
briefly stirred, followed by the slow addition of Et3N (4.38 mL, 31.413 mmol, 3 eq.). 
The reaction was stirred for a further 5 h at 40 oC until TLC indicated completion. The 
reaction was stopped and the organic layer washed with water (× 3, 50 mL) and the 
aqueous layer back extracted with 2:1 CH2Cl2: MeOH (× 3, 50 mL). The combined 
organic layers were subsequently washed with 7% citric acid (× 3, 50 mL) and the 
aqueous layer extracted further with CH2Cl2 (× 3, 50 mL).  The final combined organic 
layers were collected and dried over MgSO4, filtered and reduced in vacuo to yield a 
hygroscopic white solid (9.05 g, 92%). Rf [CH2Cl2: MeOH: H2O: 34.5: 9: 1 v/v] 0.56. 
1H NMR (400 MHz, CDCl3) δH (ppm) 7.35 (m, 6H, J 8.8 aromatic and Boc-NH), 6.99 
(t, 1H, CBz-NH), 5.08 (s, 1H, PhCH2-), 4.85 (s, 1H, Boc-NHCH-), 4.03 (d, 1H, 
CH2NHCOCH(NH-Boc)CH2-), 3.31 (m, 2H, CBz-NHCH2-), 3.19 (m, 4H N(CH2)2), 1.81 
(s, br, 2H, CHCH2-), 1.52 (m, 6H, N(CH2CH2)2 and -CH2CH2NHCBz), 1.43 (s, 9H, -
OC(CH3)3), 1.26 (s, 60H, chain CH2’s), 0.88 (t, 6H, (CH3CH2CH2)2). 13C NMR (400 
MHz, CDCl3) δC (ppm) 172.13 (-NHCOCH(NHBoc)), 167.28 (-NCOCH2NH), 156.82 
(PhCH2OCO), 155.87 (-OCOt-Bu), 136.98 (-C1 aromatic), 128.79 (-C3, C5 aromatic), 
128.42 (-C2, C6 aromatic), 128.34 (-C4 aromatic), 80.30 (C(CH3)3), 66.90 (PhCH2), 
54.65 (Boc-NHCH-), 47.62 (-N(CH2)2), 41.46 (CBz-NHCH2-), 40.87 
(CH2NHCOCH(NH-Boc)CH2-), 32.23 ((CH3CH2CH2-)2), 29.88 (12 chain CH2’s), 29.66 
(-C(CH3)3), 29.03 (-CH2CH2NHCBz), 27.32 (N(CH2CH2)2), 22.99 ((CH3CH2-)2), 22.80 
(-CH2CH2CH2NHCBz), 14.41 ((CH3CH2-)2). FTIR (nujol) νmax: 3322.75, 1721.16, 
1643.05, 1246.75, 1171.54 (cm-1). HPLC; tR = 36.28 min, column C-4 peptide, 
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gradient mix: 0.0 min [100% A], 15-25.0 min [100% B], 25.1-45.0 min [100% C], 45.1-
55.0 min [100% A]; flow: 1 mL/min. HRMS (FAB+) calculated for C57H104N4O6 m/z 
940.7956, found 941.8031 (M + H)+. 
 
 
 
6-Benzyloxycarbonylamino-2-(amino) hexa-amido-N,N-dioctadecylacetamide, 33. 
 
 
 
 
 
The Boc protected lipid 34 (288.0 mg, 0.306 mmol) was added to a round-bottom 
flask and to this was added a 1:1 TFA: CH2Cl2 (20 mL, v/v) solution. The reaction was 
stirred at room temperature for 2 h until TLC indicated reaction completion. The 
solvents were removed in vacuo and the product freeze-dried from water to yield a 
white hygroscopic solid (257.09 mg, quantitative, mp = 47-50 ºC). Rf [(CH2Cl2: MeOH: 
H2O: 34.5: 9: 1): CH2Cl2: 1:1 v/v] 0.39. 1H NMR (400 MHz, CDCl3) δH (ppm) 8.2 (s, br, 
2H, NH2), 7.35 (m, 5H, J 15.2 aromatic) 5.07 (s, 1H, PhCH2-), 4.18 (d, 1H, -
NCOCH2NHCO), 3.87 (d, 1H, -NCOCH2NHCO), 3.26 (s, br, 1H, -CHNH2), 3.15 (m, 
4H N(CH2)2), 1.92 (s, br, 2H, NH2CHCH2-), 1.48 (m, 8H, (CH2CH2)2N-, -
CH2CH2NHCBz and -CH2CH2CH2NHCBz), 1.27 (s, 60H, chain CH2’s), 0.89 (t, 6H, J 
13.6 (CH3CH2CH2)2). 13C NMR (400 MHz, CDCl3) δC (ppm) 169.26 (-NHCOCHNH2), 
167.51 (-NCOCH2NH), 157.20 (PhCH2OCO), 136.99 (-C1 aromatic), 128.78 (-C3, C5 
aromatic), 128.30 (-C2, C6 aromatic), 128.26 (-C4 aromatic), 80.30 (C(CH3)3), 66.95 
(PhCH2), 54.01 (NH2CH-), 47.56 (-N(CH2)2), 41.45 (CBz-NHCH2-), 40.30 
(CH2NHCOCHNH2), 32.24 ((CH3CH2CH2-)2), 31.10 (12 chain CH2’s), 29.89 (-
C(CH3)3), 28.97 (-CH2CH2NHCBz), 27.37 (-N(CH2CH2)2), 23.00 ((CH3CH2-)2), 21.71 (-
CH2CH2CH2NHCBz), 14.42 ((CH3CH2-)2). FTIR (nujol) νmax: 3848.26, 1676.8, 
1203.36, 722.21 (cm-1). HPLC; tR = 27.98 min, column C-4 peptide, gradient mix: 0.0 
min [100% A], 15-25.0 min [100% B], 25.1-45.0 min [100% C], 45.1-55.0 min [100% 
A]; flow: 1 mL/min. HRMS (FAB+) calculated for C52H96N4O4 m/z 840.7432, found 
841.7529 (M + H)+. 
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6-Benzyloxycarbonylamino-2-(amido-{1,4,7,10-tetra azacyclododec-1-yl}-acetic acid) 
hexa-amido-N,N-dioctadecylacetamide, 31. 
 
 
 
 
 
Amine 33 (84.44 mg, 0.100 mmol) and DOTA-NHS ester (100 mg, 0.120 mmol) were 
added to an air evaporated flask fitted with a reflux condenser. Anhydrous CH2Cl2 (20 
mL) was added and the reaction stirred briefly at room temperature. To this was 
added Et3N (41.81 μL, 0.300 mmol, 3 eq.) and the reaction stirred at 45 ºC under 
reflux for an overnight period. The solvent was evaporated in vacuo to yield a white 
hygroscopic solid (64.98 mg, 53%). Rf [CH2Cl2: MeOH: H2O: 34.5: 9: 1 v/v] 0.26. 1H 
NMR (400 MHz, CDCl3) δH (ppm) 7.44 (m, 5H, benzene ring), 5.24 (s, 2H, 
HNCOOCH2-), 4.42 (s, 1H, CH), 4.21 (m, 2H, NCOCH2NH), 3.41 (m, 6H, 3 x 
HOOCCH2N), 3.24 (m, 4H, 2 x NCH2CH2), 3.11 (m, 2H, HNCOCH2N), 3.05 (m, 2H, 
OOCNHCH2), 1.85 (s, 2H, CHCH2), 1.65 (m, 6H, 2 x NCH2CH2- and 
OOCNHCH2CH2), 1.43 (s, 60H, chain CH2’s), 1.01 (t, 6H, 2 x CH3) (ppm) 13C NMR 
(400 MHz, CDCl3) δC (ppm)  175.42, (COOH), 175.14 (-HNCOCH), 174.85 (-
CHNHCOCH2), 172.59 (-HNCOCH2), 157.42 (HNCOO), 136.59 (COOCH2C=C), 
128.38 (aromatic), 127.93 (aromatic), 127.80 (aromatic), 66.49 (COOCH2), 51.03-
50.58 (DOTA CH2’s), 48.88 (N(CH2CH2-)2), 47.81 (-NCOCH2NH), 46.18 (-
OOCNHCH2), 31.79 (-CHCH2CH2), 29.56 (-N(CH2CH2)2), 29.51-26.90 (chain CH2’s), 
22.50 (-CHCH2CH2), 21.00 ((CH3CH2)2),14.9 (CH3 x 2)  (ppm). FTIR (nujol) νmax: 
3741.23, 3681.44, 3621.66, 2360.44, 2333.45, 1953.54, 1835.9, 1743.33, 1691.27, 
1646.91, 1513.85, 1481.06 (cm-1). HPLC; tR = 29.33 min, column C-4 peptide, 
gradient mix: 0.0 min [100% A], 15-25.0 min [100% B], 25.1-45.0 min [100% C], 45.1-
55.00 min [100% A]; flow: 1 mL/min. MS (ESI) calculated for C68H122N8O11 m/z 
1226.9233, found 1227.80 (M + H)+. 
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6-Benzyloxycarbonylamino-2-(amido-Gd(III) {1,4,7,10-tetra azacyclododec-1-yl}-
acetic acid) hexa-amido-N,N-dioctadecylacetamide, 40. 
 
 
 
 
 
DOTA lipid 31 (61.69mg, 0.0503 mmol) was added to a round-bottom flask and 
stirred in pure distilled water (80 mL). To this was added a stoichiometric amount of 
Gd.Cl3.6H2O (18.7 mg, 0.0503 mmol) and the reaction stirred at 90 ºC for 12 h. The 
water was freeze-dried to yield a white solid (69.46 mg, quantitative, decomp. = > 300 
ºC). Rf [CH2Cl2: MeOH: 1:1 v/v] 0.60. FTIR (nujol) νmax: 3748.94, 2952.48, 2854.13, 
2360.44, 2017.18, 1992.11, 1967.04, 1918.82, 1843.61, 1793.47, 1747.19, 1650.77, 
1558.2, 1508.06, 1396.21, 1261.22, 1043.3, 669.179 (cm-1). HPLC; tR = 34.38 min, 
column C-4 peptide, gradient mix: 0.0 min [100% A], 15-25.0 min [100% B], 25.1-45.0 
min [100% C], 45.1-55.00 min [100% A]; flow 1: mL/min. MS (ESI) calculated for 
C68H119GdN8O11 m/z 1381.82, found 1381.00 (M + H)+. 
 
6-Amino-2-(amido-Gd(III) {1,4,7,10-tetra azacyclododec-1-yl}-acetic acid) hexa-
amido-N,N-dioctadecylacetamide, 36. 
 
 
 
 
 
The CBz protected gadolinium lipid 40 (93.7 mg, 0.068 mmol) was added to a two 
necked round-bottom flask equipped with a reflux condenser and stirrer bar. To this 
was added a 2:1 MeOH: H2O solution (30 mL, v/v) followed by the addition of 1,4-
cyclohexadiene (200 μL, 2.13 mmol). The reaction was stirred and 10% Pd-C (10 mg) 
was added, whilst ensuring the catalyst was fully dispersed under the surface of the 
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solution. The air was displaced with H2 gas and the reaction stirred at 60 ºC under 
reflux and a stream of H2 gas for 3 h. The reaction was stopped and the solution 
filtered through celite. The solvents were removed in vacuo and the product freeze-
dried from cyclohexane to yield an off white hygroscopic solid (73.8 mg, 87%). Rf 
[CH2Cl2: MeOH: H2O: 65: 25: 4 v/v] 0.29. FTIR (nujol) νmax: 3673.73, 2360.44, 
1943.89, 1918.82, 1889.9, 1793.47, 1698.98, 1558.2, 1340.28, 1068.37, 669.18 (cm-
1). HPLC; tR = 34.22 min, column C-4 peptide, gradient mix: 0.0 min [100% A], 15-
25.0 min [100% B], 25.1-45.0 min [100% C], 45.1-55.0 min [100% A]; flow: 1 mL/min. 
MS (ESI) calculated for C60H113GdN8O9 m/z 1247.79, found 1248.90 (M + H)+. 
 
 
6-Rhodamine-isothiocyanamide-2-(amido-Gd(III) {1,4,7,10-tetra azacyclododec-1-yl}-
acetic acid) hexa-amido-N,N-dioctadecylacetamide, 38. 
 
 
 
 
 
Rhodamine B isothiocyanate 37 (11.78 mg, 0.0209 mmol) and the deprotected amine 
36 were dissolved in a 1:1 solution of CH2Cl2: MeOH (10 mL, v/v). To this was added 
Et3N base (8.73 μL, 0.0627 mmol, 3 eq.) slowly and the reaction was stirred at 0 ºC, 
and allowed to warm to room temperature overnight. The crude mixture was purified 
by preparative TLC (CH2Cl2: MeOH: H2O: 34.5: 9: 1 v/v), the product isolated and 
freeze-dried from cyclohexane to yield a bright pink solid (10.4 mg, 29%, 
decomposition = 269-274 ºC). Rf [CH2Cl2: MeOH: H2O: 34.5: 9: 1, v/v] 0.10. FTIR 
(nujol) νmax: 3748.94, 2854.13, 2339.23, 1889.9, 1793.47, 1716.34, 1698.98, 
1558.20, 1340.28, 1070.30, 1045.23, 669.17 (cm-1). HPLC; tR = 33.76 min, column C-
4 peptide, gradient mix: 0.0 min [100% A], 15-25.0 min [100% B], 25.1-45.0 min 
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[100% C], 45.1-55.0 [100% A]; flow: 1 mL/min. λex: 545 nm and λem: 565 nm in MeOH 
MS (ESI+) calculated for C89H143GdN11O12S+ m/z 1747.99, found 1747.10 (M + H). 
 
 
6-FITC-isothiocyanamide-2-(amido-Gd(III) {1,4,7,10-tetra azacyclododec-1-yl}-acetic 
acid) hexa-amido-N,N-dioctadecylacetamide, 44. 
 
 
 
 
 
Fluorescein isothiocyanate 43 (27.63 mg, 0.022 mmol) and the deprotected amine 36 
were dissolved in anhydrous CH2Cl2 (10 mL, v/v). Then Et3N base (89.20 μL, 0.022 
mmol, 3 eq.) was slowly added and the reaction stirred at 0 ºC and allowed to warm 
to room temperature overnight. The crude mixture was purified by preparative TLC 
(CH2Cl2: MeOH: AcOH: 87: 12: 1 v/v), the product was isolated and freeze-dried from 
cyclohexane to yield a bright orange solid (10.27 mg, 30%, decomposition = 320-330 
ºC). Rf [CH2Cl2: MeOH: AcOH: 87: 12: 1, v/v] 0.09. FTIR (nujol) νmax: 2923.56, 
2360.44, 1698.98, 1457.92 (cm-1). HPLC; tR = 33.91 min, column C-4 peptide, 
gradient mix: 0.0 min [100% A], 15-25.0 min [100% B], 25.1-45.0 min [100% C], 45.1-
55.0 min [100% A]; flow 1 mL/min. λex: 497 nm and λem: 535 nm in MeOH. MS (ESI+) 
calculated for C81H124GdN9O14S m/z 1636.82, found 1659.20 (M + Na)+. 
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6-amino-2-(amido {1,4,7,10-tetra azacyclododec-1-yl}-acetic acid) hexa-amido-N,N-
dioctadecylacetamide, 30. 
 
 
 
 
 
The CBz protected lipid 31 (100 mg, 0.0724 mmol) was added to a two necked 
round-bottom flask equipped with a reflux condenser and stirrer bar. To this was 
added a 2:1 MeOH: H2O solution (40 mL, v/v) followed by the addition of 1,4-
cyclohexadiene (212.3 μL, 2.27 mmol). The reaction was stirred and 10% Pd-C (10 
mg) was added, whilst ensuring the catalyst was fully dispersed in solution. The air 
was displaced with H2 gas and the reaction stirred at 60 ºC under reflux and a stream 
of H2 gas for 12 h. The reaction was stopped and the solution filtered through celite. 
The solvents were removed in vacuo and the product lyophilised from cyclohexane to 
yield a white fluffy powder (67.0 mg, 85%). Rf [CH2Cl2: MeOH: H2O: 34.5: 9: 1] 0.12. 
1H NMR (400 MHz, CDCl3) δH (ppm)  8.3 (s, 2H, 2 x NH), 4.55 (s, 1H, CH), 4.23 (m, 
2H, NCOCH2NH), 3.44 (m, 6H, 3 x HOOCCH2N), 3.34 (m, 4H, 2 x NCH2CH2), 3.29 
(m, 2H, HNCOCH2N), 3.08 (m, 2H, OOCNHCH2), 1.80 (s, 2H, CHCH2), 1.67 (m, 6H, 
2 x NCH2CH2- and OOCNHCH2CH2), 1.38 (s, 60H, chain CH2’s), 0.87 (t, 6H, 2 x CH3)    
(ppm) 13C NMR (400 MHz, CDCl3) δC (ppm)  177.0, (COOH), 176.14 (-HNCOCH), 
173.85 (-CHNHCOCH2), 52.0 (DOTA CH2’s), 30.22 (-CHCH2CH2), 27.94 (chain 
CH2’s), 22.50 (-CHCH2CH2), 20.90 ((CH3CH2)2),11.73 (CH3 x 2)  (ppm) FTIR (nujol) 
νmax: 2360.44, 1698.98, 1650.28, 1558.20, 1540.85 (cm-1). HPLC; tR = 36.20 min, 
column C-4 peptide, gradient mix: 0.0 min [100% A], 15-25.0 min [100% B], 25.1-45.0 
min [100% C], 45.1-55.00 min [100% A]; flow: 1 mL/min. HRMS (ESI+) calculated for 
C60H116N8O9 m/z 1092.8865, found 1093.8951 (M + H)+. 
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6-Rhodamine-sulfunoamide-2-(amido-{1,4,7,10-tetra azacyclododec-1-yl}-acetic acid) 
hexa-amido-N,N-dioctadecylacetamide, 28. 
 
 
 
 
 
Amine 30 (143.1 mg, 0.131 mmol) and Lissamine Rhodamine B sulfonyl chloride 47 
(75.63 mg, 0.131 mmol) were added to an air evacuated flask to which was added 
anhydrous CH2Cl2 (100 mL). Then Et3N (1% of solvent, v/v) was added slowly and 
the reaction stirred under an atmosphere of N2 at room temperature for 12 h. The 
solvent was removed in vacuo and the crude product purified by flash coloumn 
chromatography (eluted with (CH2Cl2: MeOH: H2O: 34.5: 9: 1): CH2Cl2: 9:1 v/v). The 
solvents were removed in vacuo and the product was freeze-dried from cyclohexane 
to yield a fluffy purple solid (175.6 mg, 82%, decomposition = 255-260 ºC). Rf 
[CH2Cl2: MeOH: H2O: 34.5: 9: 1 v/v] 0.31. 1H NMR (400 MHz, MeOD: CDCl3: AcOD: 
3: 1: 1) δH (ppm)  9.10 (s, 1H, -NCOCH2NHCOCH), 8.50 (d, 1H, -CHNHCO), 8.13 (s, 
1H, -NHSO2), 7.85 (d, 1H, aromatic), 7.74 (d, 1H, J 17.6, aromatic), 7.58 (dd, 1H, J 
29.2, aromatic), 7.42 (s, 1H, aromatic), 7.34 (t, 1H, J 17.6, aromatic), 4.06 (d, 1H, -
NCOCH2NHCO), 3.96 (m, 18H, -CH2NCO, 3 x HOOCCH2, -HNCOCH2N, -
CH2NHSO3, and 2 x PhNCH2CH3), 3.43 (m, 16H, macrocycle CH2’s), 1.18 (s, 36H, 
chain CH2’s, -CHCH2CH2, =NCH2CH3), 1.10 (s, 6H, 2 x –NCH2CH3), 0.71 (t, 6H, 
chain: 2 x -CH2CH3) (ppm). 13C NMR (400 MHz, CDCl3) δC (ppm)  174.24 (-COOH), 
157.97 (-NHCOCH2-), 157.57 (-NHCOCH2DOTA), 155.68 (CON(CH2)2-), 144.54 
(C=COC=C), 132.62 (CH2’s, DOTA), 130.10 (aromatic), 127.31 (aromatic), 125.72 
(aromatic), 114.13 (aromatic), 113.56 (aromatic), 95.58 (aromatic), 46.62 (-
N(CH2CH2)2-), 45.53 (-NCH2CH3), 31.70 (-NHCOCHCH2-), 29.44 (Chain CH2’s), 
29.11 (Chain CH2’s), 22.39 (2(CH3CH2CH2-)), 13.33 (CH3CH2N=), 11.74 
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(CH3CH2NC=) (ppm) FTIR (nujol) νmax: 3853.08, 3748.94, 3629.37, 2854.13, 
2360.44, 2339.23, 1992.11, 1868.68, 1747.19, 1716.34, 1683.55, 1590.99, 1419.35, 
1274.72, 1180.22, 1072.23, 1043.30, 719.32, 669.18 (cm-1). HPLC; tR = 36.20 min, 
column C-4 peptide, gradient mix: 0.0 min [100% A], 15-25.0 min [100% B], 25.1-45.0 
min [100% C], 45.1-55.00 min [100% A]; flow: 1 mL/min. HRMS (ESI+) calculated for 
C87H144N10O15S2 m/z 1633.0254, found 1634.2624 (M + H)+. 
 
 
6-Rhodamine-sulfunoamide-2-(amido-Gd(III) {1,4,7,10-tetra azacyclododec-1-yl}-
acetic acid) hexa-amido-N,N-dioctadecylacetamide, 27. 
 
 
 
 
 
The fluorescent lipid 28 (20.02 mg, 0.0539 mmol) was added to a round-bottom flask 
and stirred in pure distilled water (80 mL). To this was added a stoichiometric amount 
of Gd.Cl3.6H2O (88 mg, 0.0539 mmol) and the reaction stirred at 90 ºC for 12 h. The 
water was freeze-dried to yield a dark purple solid (93 mg, 96%, decomposition. = 
327-330 ºC). Rf [CH2Cl2: MeOH: H2O: 34.5: 9: 1 v/v] 0.20. FTIR (nujol) νmax: 
3748.94, 3673.73, 2854.13, 2339.23, 1920.75, 1868.68, 1772.26, 1683.55, 1573.63, 
1419.35, 1396.21, 1274.72, 1178.29, 1072.23 (cm-1). HPLC; tR = 34.19 min, column 
C-4 peptide, gradient mix: 0.0 min [100% A], 15-25.0 min [100% B], 25.1-45.0 min 
[100% C], 45.1-55.00 min [100% A]; flow 1: mL/min. λex: 545 nm and λem: 568 nm in 
MeOH MS (ESI+) calculated for C87H141GdN10O15S2 m/z 1787.926, found 1809.50 (M 
+ Na)+. 
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8.1.7 Towards the Synthesis of Trimodal Gadolinium Lipids 
 
 
Bis(3,5-bis(trifluoromethyl)phenyl)methyl methanesulfonate, 50. 
 
 
 
 
 
Methanesulfonyl chloride (340 μL, 7.384 mmol) and 3,3’,5,5’-tetrakis 
(trifluoromethyl)benzhydrol 49 (2.0 g, 4.384 mmol) were added to a flask equipped 
with a stirrer bar. Anhydrous CH2Cl2 (24 mL) was also added followed by Et3N (1.22 
mL, 8.768, 2 eq.) and the reaction stirred at room temperature for 12 h. The solvent 
was removed in vacuo and the mixture dissolved in CH2Cl2 (20 mL) and then 
extracted with 0.1M HCl (2 x 10 mL), NaHCO3 (2 x 10 mL) and finally washed with 
brine (2 x 10 mL). The organic layer was dried over MgSO4, filtered and then reduced 
in vacuo to yield a creamy yellow solid (1.41 g, 60%, mp = 100-106 ºC). Rf [EtOAc: 
Hexane: 1: 9 v/v] 0.22. 1H NMR (400 MHz, CDCl3) δH (ppm) 7.94 (s, 2H, H4 and H4’), 
7.90 (s, 1H, H7), 7.83 (d, 4H, J 9.6, H1, H6 and H1’, H6’), 3.03 (s, 3H, CH3). 13C NMR 
(400 MHz, CDCl3) δC (ppm) 139.64 (C1 and C1’), 133.16 (C3, C5 and C3’, C5’), 127.79 
(C2, C6 and C2’, C6’), 124.74 (CF3 x 4), 121.47 (C4 and C4’), 80.06 (C7), 39.48 (-SCH3) 
(ppm). FTIR (nujol) νmax: 3743.15, 3066.26, 2856.06, 2356.59, 1830.12, 1697.05, 
1635.34, 1517.70, 1280.50, 1143.58, 908.308, 850.454, 790.67, 669.18 (cm-1). 
HRMS (ESI+) calculated for C18H10F12O3S m/z 518.021, found 553.521 (M + Cl)+. 
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Bis(3,5-bis(trifluoromethyl)phenyl)methyl azide, 51. 
 
 
 
 
 
The mesylated compound 50 (1.53 g, 2.869 mmol) and sodium azide (1.87 g, 28.690 
mmol) were added to an oven dried flask and dissolved in DMF (10 mL). The reaction 
was stirred at 80 ºC for an overnight period. The solvent was removed in vacuo and 
the product purified with flash coloumn chromatography (eluted with EtOAc: Hexane: 
1: 19 v/v) to give a yellow oil (681.0 mg, 49%). Rf [EtOAc: Hexane: 1: 9 v/v] 0.45. 1H 
NMR (400 MHz, CDCl3) δH (ppm) 8.27 (s, 1H, H4 and H4’), 8.23 (s, 2H, H2 and H6, H2’ 
and H6’) (ppm). 13C NMR (400 MHz, CDCl3) δC (ppm) 137.63 (-C1 and –C1’), 132.65 (-
C3, -C5 and –C3’, -C5’), 129.88 (-C2, -C6 and –C2’, -C6’), 126.92 (4 x -CF3), 121.29 (-C4 
and –C4’) (ppm). FTIR (nujol) νmax: 3741.23, 2856.06, 2360.44, 1876.68, 1857.11, 
1837.83, 1731.76, 1687.41, 1548.56, 1280.50, 1135.87, 904.45, 842.74, 757.88, 
671.11 (cm-1). HRMS (ESI-) calculated for C17H7F12N3- m/z 481.0454, found 504.0378 
(M + Na)-. 
 
 
Bis(3,5-bis(trifluoromethyl)phenyl)methyl amine, 52. 
 
 
 
 
 
Azide 51 (1.07 g, 2.222 mmol) and triphenylphosphine (1.17 g, 4.444 mmol) were 
added to a flask followed by DMF (10 mL) and the reaction stirred at room 
temperature for an hour. Distilled H2O (6 mL) was then added and the reaction stirred 
  214
further for 12 h at 70 ºC. The solvents were then reduced in vacuo and the crude 
mixture purified by flash coloumn chromatography (eluted with EtOAc: Hexane: 1:19 
v/v) to give a white solid (400 mg, 40%, mp = 140-143 ºC). Rf [EtOAc: Hexane: 1: 19 
v/v] 0.10. 1H NMR (400 MHz, CDCl3) δH (ppm) 7.73 (s, 1H, H4 and H4’, J 40.0 ),  7.33 
(s, 2H, H2 and H6, H2’ and H6’, J 51.2) 2.20 (s, 2H, NH2) (ppm). 13C NMR (400 MHz, 
CDCl3) δC (ppm) 137.63 (-C1 and –C1’), 132.46 (-C5, –C3 and –C5’, -C3’), 131.14 (-C2, -
C6 and –C2’, -C6’), 124.00 (-C4 and –C4’), 62.13 (-C7) (ppm). FTIR (nujol) νmax: 
3741.23, 2857.99, 2360.44, 1876.40, 1857.11, 1731.76, 1702.84, 1650.77, 1548.56, 
1525.42, 1513.85, 1378.85, 1058.73 (cm-1). HRMS (ESI+) calculated for C17H9F12N 
m/z 454.0543, found 454.2927 (M + H)+. 
 
9H-fluoren-9-yl-methyl 1-(bis(3,5-bis(trifluoromethyl)phenyl)methylamino)-6-(1-(4,4-
dimethyl-2,6-dioxocyclohexylidene)-3-methylbutylamino)-1-oxohexan-2-yl-carbamate 
54. 
 
 
 
 
 
The primary amine 52 and Fmoc-lys(ivDde)-OH 53 were added to an oven dried flask 
equipped with a stirrer bar. Anhydrous DMF (10 mL) was also added and the reaction 
stirred. HBTU and DMAP were added to the reaction and the reaction stirred at 40 ºC 
for 48 h. The solvent was removed in vacuo and the mixture dissolved in CH2Cl2 (30 
mL) and subjected to firstly, an acidic work up with 7% citric acid (x 2, 20 mL) and 
then the organic layer was washed with NaHCO3 (x 2, 20 mL) and finally washed 
with brine (x 2, 20 mL). The organic layer was dried over MgSO4, filtered and purified 
by flash coloumn chromatography (eluted with EtOAc: Hexane: 1: 4 v/v) and reduced 
in vacuo to yield a bright yellow oil (533.20 mg, 60%). Rf [EtOAc: Hexane: 3: 7 v/v] 
0.53. 1H NMR (400 MHz, CDCl3) δH (ppm) 7.94 (s, 2H, H4 and H4’), 7.90 (s, 1H, H7), 
7.83 (d, 4H, J 9.6, H1, H6 and H1’, H6’), 3.03 (s, 3H, CH3). 13C NMR (400 MHz, CDCl3) 
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δC (ppm) 139.64 (C1 and C1’), 133.16 (C3, C5 and C3’, C5’), 127.79 (C2, C6 and C2’, 
C6’), 124.74 (CF3 x 4), 121.47 (C4 and C4’), 80.06 (C7), 39.48 (-SCH3) (ppm). FTIR 
(nujol) νmax: 3741.41, 2857.99, 2360.44, 1876.40, 1733.69, 1700.91, 1689.34, 
1650.77, 1548.56, 1525.42, 1056.80 (cm-1). HPLC; tR =  min, column C-4 peptide, 
gradient mix: 0.0 min [100% A], 15-25.0 min [100% B], 25.1-45.0 min [100% C], 45.1-
55.00 min [100% A]; flow: 1 mL/min. HRMS (ESI+) calculated for C51H49F12N3O5m/z 
1011.3481, found 1075.7091 (M + Zn)+. 
 
8.1.8 Xylenol Orange Test 
 
The presence of free gadolinium ions in Gd incorporated compounds was determined 
by measuring the absorbance at 573 nm of a mixture of xylenol orange solution (990 
μL, 0.5 mM in sodium acetate buffer (0.1 M, pH 5.2) and test solution (in 1:1 MeOH: 
CH2Cl2) containing the Gd compound (10 μL). Extinction coefficient  ε = 20, 700 L 
mol-1 cm-1 whereby [Free Gd] = A573/ε. 
 
8.1.9 Chloroanil Test 
 
To 1-5 mg of resin was added one drop of 2% acetaldehyde in DMF (v/v) followed by 
one drop of 2% p-chloranil in DMF (w/v). The sample was allowed to stand at room 
temperature for 5 min. Blue stained beads indicate presence of secondary amines. 
 
8.1.10 MRI Analysis of Gd.DOTA.DSA and Gd.DTPA.BSA 
 
For T1 analysis, Gd.DOTA.DSA 2, Gd.DTPA.BSA 19, and controls of the metal free 
compound, and Magnevist (Schering AG, Germany) were added to water to give a 
final concentration of 0.5 mM. The solutions (200 μL) were placed in eppendorf tubes 
and T1 relaxation values measured on a 4.7T Varian MR scanner at ambient 
temperature. For relaxivity measurements; gadolinium liposome formulations were 
prepared in order to obtain five different gadolinium concentrations between 0.20 to 
0.66 μM in 200 µL of distilled water and the molar relaxivity r1 (mM-1 s-1) determined 
(see 8.1.11 for liposome preparation method). T1 values were obtained using 
saturation recovery experiments performed with a standard spin-echo sequence and 
a 2 mm single slice acquisition (TR = 50, 100, 200, 300, 500, 700, 1200, 3000, 5000, 
7000 ms, TE = 15 ms), number of signal averages; 2, FOV; 70 × 70 mm2, collected 
into a matrix of 256 × 128.  
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8.1.11 Liposome Preparations 
 
All lipids were stored as stock solutions in anhydrous organic solvents (CHCl3, MeOH 
or a mixture of both), at – 20 ºC under argon. Liposomes were made with a range of 
defined molar ratios of individual lipids to give a predetermined total lipid 
concentration of 1.2 mg mL-1 in water for in vitro and 10, 15 or 30 mg mL-1 in HEPES 
(20 mM, NaCl 135 mM, pH 6.5) for in vivo experiments. Fluorescent liposomes 
always contained 0.5 mol% and 1 mol % DOPE-Rhodamine (Avanti Polar Lipids inc. 
USA) for in vitro and in vivo experiments respectively (IM injected liposomes 
contained no fluorescent lipid). Appropriate volumes of each lipid stock were placed 
in a round bottom flask (typically 5 mL) containing distilled CHCl3 (500 µL) and stirred 
to ensure thorough mixing of the lipids. The solvent was slowly removed in vacuo to 
ensure production of an even lipid film. The film was re-hydrated with water or buffer 
at a defined volume. The resulting solution was sonicated for 5-8 min for in vitro 
formulations and 30 min (at 30 oC) for in vivo formulations in order to form gadolinium 
liposomes of appropriate size. The pH of the liposomal suspension was checked by 
pH Boy (Camlab Ltd., UK), and if appropriate adjusted to neutral by addition of 
aqueous solutions of NaOH (0.99 M) and HCl (0.99 M). For each preparation, the 
size of liposomes was measured by photon correlation spectroscopy (PCS) to ensure 
a size distribution of on average, below 250 nm for in vitro experiments and 100 nm 
for in vivo experiments.  
 
8.1.12 In Vitro Fluorescent Cell Uptake Assay with Gd.DOTA.DSA Liposomes 
 
At 24 h prior to gadolinium liposome uptake experiments, adherent HeLa cells were 
grown in Dulbecco’s-Modified Eagle culture medium (DMEM) with 10% Fetal calf 
serum (FCS) and 1% penicillin-streptomycin (Sigma-Aldrich), in a 48-well plate 
(80,000 cells per well, 250 µL of complete medium) and in a wet (37 ºC) 10% CO2 / 
90% air atmosphere. The cells were grown until 80% confluent. The media was then 
removed and replaced with fresh media (same volume as previous). Bimodal 
gadolinium liposomes (see Table 4) containing 0.5 mol % DOPE-Rhodamine were 
prepared (see 8.1.11 for preparation method) then added at three different doses (6, 
12, and 18 μg) to the wells, swirled to ensure even dispersion and then incubated in a 
wet (37 ºC) 10 % CO2 / 90% air atmosphere for either 4, 6, 8 or 10 h. The amount of 
Gd per liposome sample added to each well was as follows; for the 6 µg gadolinium 
liposome dose, liposomes 1 and 2 contained; 0.358 µg , liposomes 3 and 4; 0.449 
µg, liposomes 5 and 6; 0.554 µg and liposomes 7 and 8; contained 610.32 μg of Gd. 
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For the 12 µg gadolinium liposome dose, liposomes 1 and 2 contained; 0.716 μg, 
liposomes 3 and 4; 0.898 μg, liposomes 5 and 6; 1.108 mg, liposomes 7 and 8; 1.220 
mg of Gd. Finally, for the 18 μg gadolinium liposome dose, liposomes 1 and 2 
contained; 1.074 mg, liposomes 3 and 4; 1.347 mg, liposomes 5 and 6; 1.662 mg and 
liposomes 7 and 8; 1.831 mg of Gd.  After liposome uptake the cells were washed 
with PBS (2 x 200 μL) and then treated with lysis buffer (100 μL per well). Cell lysate 
(80 μL) was diluted with MeOH (50 μL) and CHCl3 (300 μL). The resulting solution 
was vigorously vortexed and then allowed to separate into 2 phases (organic and 
aqueous). The organic layer was isolated and its fluorescence was recorded on a RF-
5301PC Shimadzu spectrofluorophotometer (λex 545 nm, λem 585 nm). As a positive 
control: control gadolinium liposomes (6, 12 or 18 μg) were added to the lysate of 
untreated cells, to provide a 100% liposome uptake result. The amount of cellular 
protein was quantified with a bicinchoninic acid base protein (BCA) assay (Pierce, 
Rockford, IL, USA).  
 
8.1.13 MTT Cell Viability Assay with Gd.DOTA.DSA Liposomes 
 
Twenty four hours prior to the MTT assay, adherent HeLa cells were grown in DMEM 
with 10% FCS and 1% penicillin-streptomycin (Sigma-Aldrich), in 48-well (4 x 104 
cells per well, 250 µL of complete medium) plates and in a wet (37 ºC) 10% CO2 / 
90% air atmosphere. The cells were grown until 80% confluent and the media was 
then removed and replaced with fresh media (same volume as previous). Gadolinium 
liposome formulations 1, 2 and 7 (see Table 4) were added to each well at three 
doses (6, 12 and 18 µg/well, see 8.1.11  for exact Gd content per liposome dose), 
and the cells were incubated in a wet (37 ºC) 10 % CO2 / 90% air atmosphere for 
either 4, 6, 8, and 10 hours. In addition, at the end of each incubation period the cells 
were washed with PBS and then incubated for a further 24 h period. A cell 
proliferation kit (MTT, Roche) assay was used to assess the cells viability post 
liposome exposure. Briefly, after each uptake period, the media was removed and the 
cells washed with PBS (1 × 0.5 mL). Then fresh DMEM media (with FCS and 
streptomycin) was added to the cells (250 μL), followed by addition of the yellow MTT 
reagent (15 μL) and subsequent incubation for 2 h. The appearance of purple spots 
and patches was visible at this stage. The media was removed and Formazan 
solubilising solution was added (~ 100 μL) and the plates were incubated in a wet (37 
ºC) 10 % CO2 / 90% air atmosphere overnight. The lysates were then transferred to 
96 welled plates and the absorbance of each well and therefore the amount of purple 
Formazan was measured at 550 nm with a microplate reader.  
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8.1.14 Lactate Dehydrogenase Toxicity Assay (LDH) with Gd.DOTA.DSA 
Liposomes 
 
Twenty four hours prior to the LDH assay, adherent HeLa cells were grown in DMEM 
with 10% FCS and 1% penicillin-streptomycin (Sigma-Aldrich), in 48-well (4 x 104 
cells per well, 250 µL of complete medium) plates and in a wet (37 ºC) 10% CO2 / 
90% air atmosphere. The cells were grown until 80% confluent and the media was 
then removed and replaced with fresh media (same volume as previous). Gadolinium 
liposome formulations 1, 2 and 7 (see Table 4) were added to each well at three 
doses (6, 12 and 18 µg/well, see 8.1.11 for exact Gd content per liposome dose), and 
the cells were incubated in a wet (37 ºC) 10 % CO2 / 90% air atmosphere for either 4, 
6, 8, and 10 hours. In addition, at the end of each incubation period the cells were 
washed with PBS and then incubated for a further 24 h period. The LDH assay was 
carried out using the CytoTox 96® Non-Radioactive Cytotoxicity Assay (Promega, 
USA). In brief, the supernatant from the cells was transferred to 96-well plates (150 
μL) and this was spun down in a centrifuge (2 000 rpm for 10 min), the remaining 
media was removed from the cells and they were washed with PBS, and lysis buffer 
was added to the wells, and the plate incubated at 37 ºC for 30 min. The supernatant 
from the spun cells was transferred to a 96-well plate (50 μL) and cell lysates were 
also added to the other half of this plate (50 μL). The LDH substrate mix was added 
to these wells (50 μL) and the plate incubated in darkness for 30 min. The reaction 
was stopped with the addition of acetic acid (50 μL) and the wells measured for their 
fluorescence at 490 nm on a microplate reader. The cell death from cytotoxicity of the 
added gadolinium liposomes was calculated as follows: % cell death from cytotoxicity 
= (% LDH released from these cells) – (% LDH released from control cells).  
 
8.1.15 MRI Analysis of Cells Labelled with Gd.DOTA.DSA Liposomes 
 
Twenty four hours prior to liposome uptake, adherent HeLa cells were grown in 
DMEM with 10% FCS and 1% penicillin-streptomycin (Sigma-Aldrich), in a 25 cm3 
culture flask (5 x 105 cells per well, 5 mL of growth medium) and in a wet (37 ºC) 10% 
CO2 / 90% air atmosphere. The cells were grown until 80% confluent and the media 
was then removed and replaced with fresh media. Gadolinium liposomes were 
prepared (see section 8.1.11) and then added to each flask, swirled to ensure even 
dispersion and then incubated in a wet (37 ºC) 10 % CO2 / 90% air atmosphere for 8 
h (125 μL of 1.2 mg mL-1 liposome solution containing 8.95 µg Gd (0.057 μM), the 
optimal dose was scaled up ~ 12.5 fold from the dose used for the in vitro 
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fluorescence assay to label approximately 1 x 106 cells in culture, since the HeLa cell 
population was expected to double over 24 h). After liposome uptake the cells were 
washed with PBS (2 × 2 mL) and then treated with trypsin-EDTA (500 μL trypsin, 
1mM EDTA) for 2 min at 37 ºC. DMEM (complete, 3 mL) was added to neutralise the 
trypsin. The cells were washed with PBS and then centrifuged in PBS buffer (1 mL), 
the solution was decanted and the cells reconstituted in PBS by vortexing and spun 
(1500 rpm for 5 min) into pellets in eppendorf tubes filled with 200 μL PBS. The tubes 
were imaged whilst placed in a plastic sample holder, and T1 values were measured 
on a 4.7T Varian MR Scanner. T1 values were obtained from saturation recovery 
experiments performed with a standard spin-echo sequence and a 10 mm single slice 
acquisition in the sagittal plane (TR = 50, 100, 200, 300, 500, 700, 1200, 3000, 5000, 
7000 ms, TE = 15 ms), 4 signal averages, FOV; 100 × 100 mm2, collected into a 
matrix of 256 × 128. As negative controls; cells treated with liposomes containing no 
Gd (substituted for by using the Gd free lipid DOTA.DSA), untreated cells and an 
eppendorf containing PBS buffer were also imaged. 
 
8.1.16 Fluorescence Microscopy of Cells Labelled with Gd.DOTA.DSA 
Liposomes 
 
Twenty four hours prior to gadolinium liposome uptake, adherent HeLa cells were 
grown in DMEM with 10% FCS and 1% penicillin-streptomycin (Sigma-Aldrich), in a 
6-well plate (1.25 x 105 cells per well, 3 mL of complete medium) fitted with plastic 
microscopy slides, in a wet (37 ºC) 10% CO2 / 90% air atmosphere. The cells were 
grown until 80% confluent and the media was then removed and replaced with fresh 
media (same volume as previous). Fluorescent gadolinium liposomes (formulation 1, 
Table 4, prepared as described in 8.1.11), 37.5 µg per well, were then added to 
appropriate wells, swirled to ensure even dispersion and then incubated in a wet (37 
ºC) 10 % CO2 / 90% air atmosphere for 8 h (31.25 μL of 1.2 mg mL-1 liposomes 
containing 2.24 µg of Gd (0.014 μmol) was added, based on scaling up of the optimal 
dose from the in vitro fluorescence assay, although this dose was doubled in order to 
account for the doubling HeLa cell population within 24 h). After liposome uptake the 
media was removed and the cells were washed with PBS (× 2), heparin (× 1 (20 
mg/mL), in order to remove unbound liposomes from cell surface), PBS (× 2), 
paraformaldehyde (PFA, × 1 (20 min at 37 °C)), PBS (× 2), glycine (× 1 (20 mM, 20 
min at 37 °C)), and finally PBS (× 2). The slides were removed from the wells and 
fixed. Microscopy images were obtained on an Olympus 251 scope, and confocal 
images were obtained using an upright Leica instrument. 
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8.1.17 Plasmid DNA Transfection with Gadolinium Lipoplexes formed with 
Gd.DOTA.DSA 
 
Gadolinium lipoplexes were prepared as per the Trojene® transfection protocol 
(Avanti Polar Lipids Inc. USA). At 24 h prior to transfection, adherent HeLa cells were 
grown in DMEM media supplemented with 10% FCS and 1% penicillin-streptomycin 
(Sigma-Aldrich), in 24-well (6 x 104 cells per well, 300 μL of complete medium) plates 
and in a wet (37 ºC) 10% CO2 / 90% air atmosphere. The cells were grown until 80% 
confluent. The media was then removed and replaced with fresh media. Gadolinium 
lipoplexes, Gd Free lipoplexes (made using the DOTA.DSA lipid), and the Trojene 
lipoplex mixtures were made by the addition of a 12:1 liposome: DNA w/w ratio of 
DNA to the preformed liposomes made as described previously (see 8.1.11, liposome 
concentration; 1.2 mg mL-1, dose; 12:1 μg of liposome to DNA), and were added to 
each well, swirled to ensure even distribution, and then incubated in a wet (37 ºC) 10 
% CO2 / 90% air atmosphere for 4 h. The media was removed, and the cells washed 
with PBS and then fresh media was added (300 μL). The cells were then incubated 
for a further 24 h. Before the luciferase assay was carried out, the cells were washed 
with PBS and harvested with lysis buffer (100 μL).  
 
Luciferase Reporter Assay 
Luciferase gene expression was measured with the Luciferase Assay System 
purchased from Promega. Light output readings were done on a Berthold Lumal LB 
9507 luminometer. Transfection efficiency, measured in relative light units (RLU) was 
normalised to the total mass of cellular protein using a bicinchoninic acid base protein 
(BCA) assay (Pierce, Rockford, IL, USA).  
 
8.1.18 Inductively Coupled Plasma – Atomic Emission Spectrometry Analysis 
of Cell Lysates Post-incubation with Gd.DOTA.DSA Liposomes 
 
At 24 h prior to gadolinium liposome uptake experiments, adherent HeLa cells were 
grown in DMEM with 10% FCS and 1% penicillin-streptomycin (Sigma-Aldrich), in a 
48-well plate (80,000 cells per well, 250 µL of complete medium) and in a wet (37 ºC) 
10% CO2 / 90% air atmosphere. The cells were grown until 80% confluent. The 
media was then removed and replaced with fresh media (same volume as previous). 
Gadolinium liposome 1 (see Table 4) was then added at the optimised dose of 12μg 
to each well, swirled to ensure even dispersion and then incubated in a wet (37 ºC) 
10 % CO2 / 90% air atmosphere for 8 h. After liposome uptake the cells were washed 
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with PBS (2 x 200 μL) and then treated with lysis buffer (200 μL per well). Samples 
containing 100% of the gadolinium liposome dose (diluted in water to a total volume 
of 200 μL) and the cell lysates (200 μL) were submitted for ICP-AES measurements 
of 157Gd content. Briefly; 150 μL of each sample was pipetted and diluted to 3.75 ml 
with 2% nitric acid to give a total dilution of 1 in 25 and then analysed on a Varian 
VIST PRO instrument. All data were corrected for these dilutions and the values; a 
blank 2% nitric acid sample was also analysed.  
 
8.1.19 Preliminary Intramuscular Injections of Gd.DOTA.DSA Liposomes 
 
High concentration DOTAP and Gd.DOTA.DSA liposomes (50: 50 mol %, 10 mg mL-
1) were prepared (see 8.1.11 for preparation method) in HEPES buffer (20 mM, NaCl 
135 mM, pH 6.5). Control liposomes were also prepared in a similar manner, with the 
Gd free DOTA.DSA lipid. Each sample (30 μL) was then injected into the hind leg 
muscle of C57BL/6 mice previously anaesthetised with an isoflurane/O2 mix. The 
mice were then imaged at 5 min, 24 h and 7 days post injection at 4.7 T in the axial 
plane (spin echo sequence: TR = 400 ms, TE = 30 ms, FOV = 45 x 45 cm2, 
averages: 4, matrix size: 256 x 128, slice thickness: 2.0 mm, and 4 slices). T1 
measurements of the injected dose were carried out by imaging eppendorfs 
containing the gadolinium liposomes and the control Gd free liposomes at 4.7 T in the 
coronal plane (spin-echo sequence: TR = 50, 100, 200, 300, 500, 700, 1200, 3000, 
5000, 7000 ms, TE = 15 ms), 4 signal averages, FOV; 100 × 100 mm2, collected into 
a matrix of 256 × 128, slice thickness: 10.0 mm, and 1 slice).  
 
8.1.20 Serum Aggregation Analysis of PEGylated Gadolinium Liposomes 
Formulated with Gd.DOTA.DSA  
 
Liposomes were prepared as previously described (see section 8.1.11 and Table 6 
for formulations) and added (50 μL) to a 1:1 mixture of FCS/HEPES (20 mM, NaCl, 
135 mM, pH 6.5) buffer (total volume: 200 μL). Their initial size prior to incubation 
was measured using photon correlation spectroscopy. The liposomes were then 
incubated at 37 °C and their size and poly dispersity index measured every 60 min 
over 10 h. Control liposomes contained the DOTA.DSA lipid in place of 
Gd.DOTA.DSA (see Table 7). 
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8.1.21 Zeta Potential Measurements of PEGylated Gadolinium Liposomes 
Formulated with Gd.DOTA.DSA  
 
PEGylated gadolinium liposome formulation 10 prepared as per section 8.1.11, was 
added to a plastic electrode cuvette (1 mL, total liposome concentration: 1.2 mg mL-1) 
and the electrophoretic mobility was calculated. The electrophoretic mobility is 
obtained by performing an electrophoresis experiment on the sample and measuring 
the velocity of the particles using Laser Doppler velocimetry (measurements carried 
out at 25 °C, on a Zetasizer Nanoseries, Nano-ZS).  
 
8.1.22 Cryo-TEM of PEGylated Gd.DOTA.DSA Liposomes 
 
Gadolinium liposome formulation 10 was prepared as per section 8.1.11 in water 
(total lipid concentration of 1.2 mg mL-1) and sonicated for 30 min to ensure a size 
distribution of ~ 100 nm. The liposomes were then dropped onto the surface of 
copper grids, and excess liquid was blotted using filter paper in an environment 
chamber with a relative humidity of 100% at 297K. The liposomes were frozen in 
liquid ethane and the vitrified specimens were stored under liquid nitrogen and placed 
in the TEM (temperature was maintained at -184 ºC). Images were obtained using a 
Philips CM200 microscope operating at 200 kV. 
 
8.1.23 Relaxivity Measurement of PEGylated Gd.DOTA.DSA Liposomes 
 
PEGylated gadolinium liposomes were prepared as previously described (see section 
8.1.11 and Table 8 for formulations, at a total liposome concentration of 3 mg mL-1) in 
HEPES (20 mM, NaCl, 135 mM, pH 6.5) buffer. These liposomes were prepared in 
order to obtain five different gadolinium concentrations ranging between 0.089 to 
0.384 µmol. The liposome solutions were placed in small eppendorf tubes (200 μL), 
imaged at 4.7 T in the coronal plane, T1 values obtained, and the molar relaxivity r1 
(mM-1 s-1) determined. T1 values were acquired using saturation recovery experiments 
performed with a standard spin-echo sequence and a 2 mm single slice acquisition 
(TR = 50, 100, 200, 300, 500, 700, 1200, 3000, 5000, 7000 ms, TE = 15 ms), number 
of signal averages; 2, FOV; 70 × 70 mm2, collected into a matrix of 256 × 128. 
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8.1.24 Mouse Tumour Model 
 
IGROV-1 cells (5 x 106 /1 mL PBS) were implanted into the flanks of 6-8 weeks old 
Balb/c nude mice for generation of subcutaneous tumours. After ~2 weeks (estimated 
tumor weights 40-50 mg) the mice were anaesthetized with an isoflurane/O2 mix and 
placed into a quadrature 1H volume coil and positioned into the magnet. Baseline 
scans were obtained and then the mice were injected intravenously via lateral tail 
vein with either a 200 µL liposome solution (HEPES (20 mM, NaCl 135 mM, pH 6.5)) 
and imaged at 4.7 T (spin echo sequence: TR = 400-2800 ms, TE = 10 ms, FOV = 45 
x 45 cm2, averages: 1, matrix size: 256 × 128 thickness: 2.0 mm, and 20 slices). 
Liposomes were prepared containing a total of 9.87 µM of Gd for the PEGylated 
liposome formulation 10, and 4.84 μM of Gd for the folate targeted PEGylated 
liposome formulation 11. The total amount of Gd concentration in PEGylated 
liposome formulation 13 was 2.44 μM. The injected mice were imaged at 3, 16 and 
24 h post injection when liposome formulation 10 was injected; they were imaged at 
2, 16 and 24 h post injection when liposome formulation 11 was injected and finally 2, 
14 and 24 h post injection when liposome formulation 13 was used.  
All procedures on animals were conducted in accordance with UK Home Office 
regulations and the Guidance for the Operation of Animals (Scientific Procedures) Act 
(1986). 
 
 
8.1.25 Laser Ablation – Inductively Coupled Mass Spectrometry (LA-ICP MS) of 
Tumour Sections Post-administration of Gd.DOTA.DSA Liposomes 
 
Tumour sections were mounted on glass slides and no additional sample preparation 
was carried out. A 266nm Nd:YAG laser system (NewWave, Cambridgeshire) was 
used in conjunction with an ICP-MS (HP4500, Agilent Technologies, UK) for the 
analysis of all tissue samples. A 20um laser beam diameter was utilised with a scan 
speed of 25 um/s. 
 
8.1.26 Immunohistochemistry and FACS Analysis of Folate Receptor 
Expression 
 
Microscopy immunohistochemistry of folate receptor expression 
At 24 h prior to microscopy experiment, adherent IGROV-1, OVCAR-3 and LS174T 
cells were grown on cover slips in folic-acid free RPMI media with 10% FCS and 1% 
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penicillin-streptomycin (Sigma-Aldrich), in a 6-well plates (125, 000 cells per well, 3 
mL of complete medium) and in a wet (37 ºC) 10% CO2 / 90% air atmosphere. The 
cells were grown until 80% confluent. The media was then removed and the cells 
washed with PBS. Non-specific cell binding was blocked by incubating the cells in 8% 
BSA/PBS (1 mL) for 1 h at 4 ºC. The primary antibody (MAb Mov18/ZEL, Axxora, UK) 
selective for the α-FR was then added to each well (5 μg/mL in 3% BSA/PBS (total 
volume 1 mL)) and the cells incubated at 4 °C for 1 h (for each cell line one well 
contained no antibody). The cells were washed with PBS (2 x 1 mL), and the 2° 
antibody (Goat anti-body IgG, FITC conjugated, Santa Cruz Biotechnology, USA) 
was then added to the cells (1: 1000 dilution, in 3% BSA/PBS (total volume 1 mL)) 
and the cells were incubated at 4 °C for a further hour. The wells were then washed 
with PBS (3 x 1 mL) and the slides fixed using an anti-fade mounting medium 
(Promega).  
 
FACS analysis of folate receptor expression 
At 48 h prior to FACS experiment, adherent IGROV-1, OVCAR-3, HeLa and SKBR-3 
cells were grown in RPMI media (folic-acid free) with 10% FCS and 1% penicillin-
streptomycin (Sigma-Aldrich). Cells were grown in 25 cm3 culture flasks (5 x 105 cells 
per well, 5 mL of growth medium) and in a wet (37 ºC) 10% CO2 / 90% air 
atmosphere. The cells were grown until 80% confluent. The media was then removed 
and the cells washed with PBS. The cells were then treated with trypsin-EDTA (500 
μL trypsin, 1mM EDTA) for 2 min at 37 ºC, then transferred to 25 mL falcon tubes and 
centrifuged (1500 rpm for 5 min). The PBS was removed and the cells were washed 
furthermore with PBS and centrifuged (1500 rpm for 5 min). The cells were then 
incubated in 10% FCS, 1% NaN3 solution (1 mL) for 1 h at 4 ºC. The cells were spun 
down (1500 rpm for 5 min) and washed with PBS (1 mL) and this was repeated twice 
more. The primary antibody (MAb Mov18/ZEL) selective for the α-FR was then added 
to each falcon (5 μg/mL in 3% BSA/PBS (total volume 1 mL)) and the cells incubated 
at 4 °C for 1 h (for each cell line one well contained no antibody). The cells were 
centrifuged (1500 rpm for 5 min) and washed with PBS (3 x 1 mL, followed by 
centrifugation), and the 2° antibody (Goat anti-body IgG, FITC conjugated) was then 
added to the cells (1: 1000 dilution, in 3% BSA/PBS (total volume 1 mL)) and the 
cells were incubated at 4 °C for a further hour. The wells were then washed with PBS 
(3 x 1 mL) and centrifuged (400 rpm for 5 min). The cells were then diluted in 10% 
FCS/PBS 1% NaN3 (1 mL) and analysed for their FITC fluorescence on a flow 
cytometer.  
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8.1.27 MRI Analysis of Gd.DOTA.Rhoda.DSA 
 
 
For T1 analysis, Gd.DOTA.Rhoda.DSA 27, DOTA.Rhoda.DSA 28 and Gd.DOTA were 
added to water to give a final concentration of 0.5 mM. The solutions (200 μL) were 
placed in eppendorf tubes and T1 relaxation values measured on a 4.7T Varian MR 
scanner at ambient temperature. For relaxivity measurements; gadolinium liposome 
formulations were prepared in order to obtain five different gadolinium concentrations 
between 0.285 and 0.084 μM in 200 µL of distilled water and the molar relaxivity r1 
(mM-1 s-1) determined (see 8.1.11 for liposome preparation method). T1 values were 
obtained using saturation recovery experiments performed with a standard spin-echo 
sequence and a 2 mm single slice acquisition (TR = 50, 100, 200, 300, 500, 700, 
1200, 3000, 5000, 7000 ms, TE = 15 ms), number of signal averages; 2, FOV; 70 × 
70 mm2, collected into a matrix of 256 × 128.  
 
8.1.28 IGROV-1 Cell Labelling with Gd.DOTA.Rhoda.DSA Liposomes 
 
Cationic liposomes were formulated in water as per the liposome preparation method 
described in 8.1.11 using CDAN/DOPE/Gd.DOTA.Rhoda.DSA: 50/45/5 mol% (total 
lipid concentration of 1.2 mg mL-1). The pH of these liposomes was adjusted to ~ 7 
and their size assessed using PCS and was found to be on average ~ 250 nm.  
At 24 h prior to cell labelling experiments, adherent IGROV-1 cells (5 x 105 in 6-
welled plate) were grown on cover slips in DMEM media supplemented with 10% 
FCS and 1% penicillin-streptomycin (Sigma-Aldrich). Cells were grown until 80% 
confluent. The media was then removed and the cells washed with PBS. Gadolinium 
liposome formulation 12 was then added to the cells (150 μL, at 1.976 μM of Gd/well) 
and allowed to incubate with the cells for 8 h. Post uptake the cells were washed with 
PBS and fixed as described in 8.1.16.  
 
8.1.29 MRI Visualisation of IGROV-1 Cells Labelled with Gd.DOTA.Rhoda.DSA 
Liposome Formulation 12 
 
Twenty four hours prior to liposome uptake, adherent IGROV-1 cells were grown in 
DMEM with 10% FCS and 1% penicillin-streptomycin (Sigma-Aldrich), in a 25 cm3 
culture flask (5 x 105 cells per well, 5 mL of growth medium) and in a wet (37 ºC) 10% 
CO2 / 90% air atmosphere. The cells were grown until 80% confluent and the media 
was then removed and replaced with fresh media. Gadolinium liposomes were 
prepared (see section 8.1.11) and then added to each flask, swirled to ensure even 
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dispersion and incubated in a wet (37 ºC) 10 % CO2 / 90% air atmosphere for 8 h 
(150 μL, at 1.976 μmol of Gd/well). After liposome uptake the cells were washed with 
PBS (2 × 2 mL) and then treated with trypsin-EDTA (500 μL trypsin, 1mM EDTA) for 
2 min at 37 ºC. DMEM (complete, 3 mL) was added to neutralise the trypsin. The 
cells were washed with PBS and then centrifuged in PBS buffer (1 mL), the solution 
was decanted and the cells reconstituted in PBS by vortexing and spun (1500 rpm for 
5 min) into pellets in eppendorf tubes filled with 200 μL PBS. The tubes were imaged 
whilst placed in a plastic sample holder, and T1 values were measured on a 4.7T 
Varian MR Scanner. T1 values were obtained from saturation recovery experiments 
performed with a standard spin-echo sequence and a 10 mm single slice acquisition 
in the sagittal plane (TR = 50, 100, ms, TE = 15 ms), 4 signal averages, FOV; 100 × 
100 mm2, collected into a matrix of 256 × 128.  
 
 
8.1.30 Histology Experiments 
 
Following MRI, the animals were sacrificed and the tumours, livers and kidneys were 
excised, frozen in liquid nitrogen, embedded in OCT (VWR) embedding fluid and 
either 10 or 7 μm thick sections cut, mounted on slides and studied for fluorescence 
microscopy.  
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